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The object of this Investigation was to define the nature of 
the immune responses of mice that had been given a sublethal pulmonary 
infection with Bordetella pertussis - an infection which shares many 
features with whooping cough in man. Both serum antibodies and local, 
secretory antibodies were studied^the latter being sampled as tracheo­
bronchial washings (TBW). A particular focus of interest was in those 
responses that were directed against biologically active components of 
B, pertussis and in those responses involved in passive protective 
activity against intracerebral and sublethal intranasal challenge with 
1ive B, pertussis.
Preparatory to this, it was necessary to define the time 
characteristics of the sublethal pulmonary infection in HAM 1/CR mice
given B. pertussis strain 18-323, After instilling a dose of approx
5 7 810 bacteria via the nose, peak viable counts of 10 -10 c.f.u. per
I
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lung mass occurred, around day 15, after which the count quickly 
decreased. However B. pertussis was occasionally isolated from mouse 
lungs as late as 31 or 35 days post-instillation. The peak pathological 
response occurred around day 18, a few days after the c,f,u, peak. 
Subsequently there was a plateau where pathological changes varied 
little.
As a measure of the inflananatory response within the lungs 
during the sublethal pulmonary infection, lysozyme levels were assayed ;p
in pooled TBW and were maximum at day 15 post-ins filiation. This 
coincided with the peak colony count in the lungs.
Antibody levels in pooled sera and TBW which were taken from 
groups of normal and infected mice were assayed in parallel with the 
U,S, Standard Antipertussis serum. Among the B, pertussis antibodies
serum
in this reference\were agglutinins, precipitins, antibodies to fila­
mentous haemagglutinin (F-HA), lipopolysaccharide (LPS) and histamine 
sensitizing factor (HSF); however no antibodies to heat labile toxin
ill
challenge. In both cases, the serum was tested as a mixture with the
respectively day 48 and 34 after infection. Conversely, a strong
(HLT) were detected. This serum was protective against sublethal 
intranasal challenge and also, at a lower titre against intracerebral
'i:?:Bo pertussis challenge, Sublethal intranasal passive protective 
activity was measured by the ability to prevent or reduce both
B. pertussis isolation from lungs on lung culture and pathological 
changes in lungs after infection.
Immune responses to certain components of B, pertussis appeared 
strongly in serum but were absent from TBW, These serum antibodies 
included precipitins, agglutinins to B. pertussis X-mode (reciprocal
*titre of 64) and C-raode (reciprocal titre of 8) and anti-F-HA (reciprocal 
titre of 32), The agglutinin and anti-F-HA responses peaked
anti-LPS response (reciprocal titre of 64) was detected in TBW but not 
in serum despite the fact that serum had a 50-times higher concentration
of protein than TBW, No anti-HLT was detected in TBW and sera at any 
time, but the inherent neutralizability of the toxin preparation was 
demonstrated with a rabbit hyperimmune serum against HLT-toxoid which 
served as a positive control. Antibodies to HSF were likewise not 
detected in mouse convalescent sera or TBW even up to 61 days after 
challenge (when the longest experiments were ended). However the 
convalescent mice themselves showed some degree of resistance to 
histamine-sensitization, compared with age-matched controls, when
'injected with low doses of pertussis vaccine and then challenged
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with histamine. These same mice also showed some degree of resistance 
to leucocytes is-induction by vaccine. Thus the mice convalescent from 
the sublethal pulmonary infection had probably developed antibodies to 
pertussigen.
Pooled normal and acute-phase (15 day) sera containedneciptocaL
Bo pertussis agglutinins with both having aAtitre of 8, and anti-F-HA 
fe.clpt'ocsL reciproc&Lwith both having aAtitre of 2, TheAagglutinin titre of individualreciprocal
normal and acute phase sera were investigated and both sera had}titres
the reciprocal
ranging from 2-32,. There was no.booster effect onAagglutinin titre
in acute phase sera which would be expected if the normal agglutinins
were due to previous encounters with Bordetella antigens. Individualreciprocal
day 61 mouse convalescent sera had^agglutinin titres ranging from 32 
to 256,
When given as a mixture with a sublethal pulmonary challenge, 
pooled convalescent sera and TBW had easily demonstrahLs,Sublethal ; 
inferanbâal. passive protective activity. The activity appeared on or 
after 34 days post-instillation and increased 10 fold by day 61 in both 
sera and TBW to give respective ml  ^of approx 39,000 and 900,
The activity ratio of sera to TBW of 33:1 is slightly less than the 
protein ratio for these samples (50:1), Neither pooled convalescent 
sera nor TBW were protective against intracerebral challenge with 
100 LD^q of B, pertussis - a dose of bacteria approximately equal in 
c.f.u. to that used for a sublethal intranasal (SLIN) challenge,
Sublethal intranasal passive protective activity was.removed 
from pooled convalescent sera by absorption with Phase I B, pertussis 
but not Phase IV organisms. Phase I absorption also removed 
agglutinins. When the pooled convalescent sera or TBW were given
intranasaLly up to and including 48 hours before challenge, they 
exhibited passive protective activity. This suggested that a part of
the passive protective activity might be due to antibodies of the IgE 
class.
Further investigation of immunoglobulin (Ig) class(es) responsible 
for SLIN passive protective activity showed that removal of IgG 
reduced this activity in pooled convalescent sera and to a greater 
extent in pooled convalescent TBW, Removal of IgM had no effect.
Removal of IgA and IgE also reduced SLIN..passive protective activity of 
pooled convalescent sera and TBW, It therefore appeared that the 
intranasally passive-protective antibodies in both sera and TBW 
belonged to the IgG, IgA and IgE classes, with the first mentioned 
being the most important in TBW,
These results are seen as increasing the value of the murine 
sublethal pulmonary infection as a model of pertussis in man. They 
highlight the desirability of examining the respiratory tract and 
pharyngeal secretions (e.g. nasal washing, saliva) of convalescent 
humans for the antibody activities detected in mouse tracheobronchial 
washings,
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HAI haemagglutination inhibition
HLT heat labile toxin
HSF histamine sensitizing factor
lAP islet activating protein
IC intracerebral
IN intranasal
i.p. intraperitoneal
i.v. intravenous
■■LAT late appearing toxicity
lipopolysaccharide Î
PA protective antigen
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SECTION I BORDETELLA PERTUSSIS    ■  —  ' ' ■
I
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1,1 General introduction
According to Linnetnan (1979) the first account of whooping
cough was given by Guillaume de Baillou in 1640 who reported an
.epidemic which had occurred in Paris in 1578 and gave details of a 
patient in a fit of paroxysmal coughing. However the characteristic 
inspiratory whoop of pertussis was not mentioned.
Bordet and Gengou first examined the organism microscopically 
in 1900. Later (1906) they cultured it, from the sputum of infected 
children, on solid medium containing glycerinated-potato. extract and 
50% (v/v) whole human or rabbit blood. They named it "Le microbe de
la coqueluche". MacDonald and MacDonald (1933) confirmed that
Bordetella pertussis is the causative agent of whooping cough by 
inoculating their four children with 140 viable organisms of a culture 
isolated from a case of the disease. Two of the children were 
previously immunized and did not develop the disease while the two 
unprotected children had a full-blown attack of whooping cough,
Marino-Lopez (1952) proposed the generic name Bordetella for 
the three organisms which had previously been referred to as 
Haemophilus pertussis. Bacillus parapertussis and Brucella bronchiseptica. 
This was accepted in the 7th and 8th Edition of Bergey's Manual of 
Determinative Bacteriology (M, Pittman 1957 and 1974),
Lautrop (1960) proposed the names pertussis and parapertussis
fbr the infections initiated by B. pertussis and B. parapertussis
respectively. Parapertussis is a milder disease and tends to have a 
lower incidence of occurrence, B. bronchiseptica infection has
occasionally been reported in man (MRG Report, 1956; Lautrop, 1960) 
although it is primarily an infection of animals. Lautrop (1960) 
proposed that "whooping cough" was the clinical syndrome caused in 
man by any one of the above three species.
1.2 Morphological and cultural characteristics of B. pertussis .
B. pertussis is a small Gram -ve coccobacillus, 0.2-0,3 pm by 
0,5-1.0 pm, Pleomorphisra occurs in older cultures and when the 
organism is undergoing phase variation. The organism is non-motile 
and non-sporing. Capsules have been reported in young cultures.
The organism is aerobic and grows best at 35°C (Pittman, 1970),
Bordet-Gengou (B,G.) and charcoal agar are the main solid 
media used to grow B, pertussis and it is believed that the blood and 
charcoal in the respective media are required to absorb:growth inhibitors 
such as fatty acids (Pollock, 1947). Despite being a fastidious 
organism, B. pertussis has simple growth requirements. Its source 
of carbon and nitrogen are L-glutamate, proline or aspartate.
Cysteine is the only amino acid which can provide the organism with 
its organic source of sulphur. However glutathione, a tripeptide, 
can also do this. Nicotinic acid or nicotinamide fulfill the sole 
vitamin requirement (Jebb and Tomlinson, 1955),
1.3 Antigenic Variation
A striking feature of B. pertussis is its ability to undergo 
cultural and serological variation. Two main types of variation 
have been recorded.
(a) Phase variation which occurs after.a series of mutations 
and resultsiin an irreversible loss of a variety of cell properties.
(b) Phenotypic modulations which occur after changes in 
cultural conditions and are freely reversible,
1.3ol Phase variation
Leslie and Gardner (1931) found that during repeated subculture 
4 distinct serological and cultural forms of B. pertussis could be 
isolated. They categorised them as Phase I, II, III and'IV, Phase I 
strains were virulent and homogeneous in their agglutination 
properties, while Phase IV were avirulent, did not agglutinate with 
Phase I antisera and grew on nutrient agar.
It has since been observed that the loss of virulence and 
changes in growth requirements happen in a random fashion rather than 
the stepwise process proposed by Leslie and Gardner (Standfast, 1951; 
Field and Parker, 1979). Parker has proposed the terms "fresh isolate" 
"intermediate strain" and "degraded strain" to replace the Phase system 
of Leslie and Gardner. The biological activities associated with 
fresh isolates (Phase I in Table 1) are lost in a random fashion and 
intermediate strains have various combinations of these properties,
1.3,2 Phenotypic variation
There are two main types of phenotypic variation recorded
(i) Antigenic modulation
(ii) Nicotinic acid modulation,
(i) Antigenic modulation
This was first described by Lacey (1951 and 1960) who reported 
that the various changes in cultural conditions led to phenotypic 
changes which were due to "reversible and continuously environmentally 
dependant in metabolism", Lacey (1960) described 3 modes : X, I and
Ç mode, X (xanthic) mode referred to the yellowish ochre hue in the :
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Table 1 : Comparison of properties of Phase I and Phase IV
B, pertussis
Property Phase I Phase IV Reference
Protective antigen (PA) - 1, 2, 4
Virulence + “ 10
Histamine-sensitizing 
factor (HSF) + - 2, 3, 4
Lymphocytosis promoting factor (LPF) + - 4
28K, 30K, 88K and 98K 
envelope polypeptides + - 5, 6
Cytochrome d - 629 + “ 6
Adenylate cyclase activity + - 7, 8, 9
Agglutinogens + - 10
Heat-labile Toxin (HLT) + - 4
1 Kasuga ^  £l (1954) 6 Dobrogosz ^  (1979)
2 Aprile,(1972) 7 Parton and Durham (1978)
3 Kind (1953) 8 Hewlett £t al (1979)
4 Field and Parker (1979) 9 Endoh eit al (1980)
5 Parton and Wardlaw (1975) 10 Leslie and Gardner (1931)
+ - present; absent
growth of B« pertussis on a B.C. plate; the I-mode is an intermediate 
mode formed within a narrow range of conditions and G (cyanic) mode 
described the greyish-blue appearance of B. pertussis grown on B.G, 
with MgSO^ added.
The following changes in cultural condition may bring about 
antigenic modulation;
(i) ionic composition of the medium, e.g. MgSO^ in place
■j
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of NaCl
(ii) growth at low temperatures^ e.g. 25°C in place of 35°C
(iii) miscellaneous factors such as fatty acids, tellurite 
and old blood,
C-mode cells lack a variety of factors associated with X-mode
cells. These are protective antigen (PA), histamine sensitizing
.factor (HSF) (Wardlaw et al, 1976); lymphocytosis promoting factor
■(LPF) (Idigbe, 1979); the adjuvant(s) for reaginic antibody and
■hyperacute experimental allergic encephalomyelitis (EAE)(Wardlaw et al
1979); adenylate cyclase (Parton and Durham, 1978); and heat labile 
toxin (Livey et al, 1978), G-raode cells also lack the 28K, 30K,
88K and 98K bands from the outer membrane (Idigbe, 1979) as determined 
by SDS polyacrylamide gel electrophoresis (PAGE),
(ii) Nicotinic acid modulation
Culture media used for growth of B. pertussis phase I Or X-mode 
typically contains about 1 |igml  ^nicotinic acid, Pusztai and Joo 
(1967) found that modulation occurred if the concentration of nicotinic
Ïacid was increased to 500 figml The change was reversible byfurther culture in medium containing 1 [igml  ^nicotinic acid.
Of the 7 strains tested by these Hungarian workers, all lost
PA and HSF, and 5 did not agglutinate with Phase I specific antisera. 
None of the strains lost the ability to produce HLT, . unlike G-mode 
cells. There is another significant difference between nicotinic 
acid and antigenic modulation, viz in the former there is a much 
reduced level of the main agglutinogen but with no altered specificity 
whereas in the latter there is a new G-mode antigen which replaces 
the X-mode antigen.
Like C-mode cells, nicotinic acid modulated cells lack adenylate 
cyclase (McPheat, 1980) and the 28K and 30K cell envelope polypeptides 
(Wardlaw ^  al, 1976),
1,4 Biologically active components of B, pertussis
Many biological activities have been shown to be associated 
with B, pertussis; HLT, endotoxin (LPS), agglutinogen, haemagglutinin 
(HA), adenylate cyclase and the factor designated pertussigen, Munoz
and Bergman (1977) proposed the term pertussigen as the single entity
■4Î,responsible for a wide variety of responses which have each been 
attributed to the following independent factors; PA, HSF, LPF, late
:appearing toxicity (LAT), Islet activating protein (lAP) and heat
labile adjuvant. However the term has not been universally accepted
and Pittman (1979) in particular has proposed the term "pertussis
toxin", >■, M
The various biological activities will now^ be considered Individually
1,4.1 Heat Labile Toxin
Bordet and Gengou (1909) first extracted heat labile toxin (HLT).i
from B,. pertussis. Given intraperitoneally, their preparation killed 
guinea-pigs and subcutaneously it produced haemorrhagic oedema leading
within 48 hours to necrosis. Wood (1940) found in mice intraperiton- 
eally injected with culture filtrate, small colourless spleens, 
shrunken livers and peritonitis, Munoz (1963) and Cowell ejt ^  (1979) 
showed the HLT to be located in the cytoplasm.
The toxin's role in the pathogenicity of the disease is 
uncertain. Standfast (1951) found no relationship between the ability 
of B, pertussis to infect by the intranasal (IN) or the intracerebral 
(IC) routes and HLT production. Vaccines which are deficient in HLT 
are actively protective (Munoz and Bergman, 1977), Antibodies to HLT are
not found in hman.oonvalesosnt sera (Evans and /Maitland 1939) • ' /j^ oweyer Evans
(1944) found that antibodies to a crude preparation of toxin did 
protect mice against a sublethal challenge when the antiserum was
imixed with the bacteria before IN administration. The toxin 
preparation was crude and therefore the protective antibodies may not 
necessarily have been directed against HLT, Asada (1953) observed 
similar pathophysiological changes in guinea pigs given crude HLT as 
has been observed in the lungs of children who had died from pertussis 
(Mallory and Horner, 1912),
1,4,2 Lipopolysaccharide
Fisher (1955) proposed that the protective antigen in the
‘mouse lethal intranasal (LIN) test was lipopolysaccharide (LPS), since 
heating a vaccine at lOO^Cdid not destroy protective ability, Dolby 
(1965) found that the antigen against which the bactericidal action of 
serum was directed (in the presence of complement and lysozyme) was LPS, 
However Ackers and Dofby (1972) noted that the LPS did not induce 
mouse protective activity against the IC challenge with B, pertussis.
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The gross chemical structure of this LPS is similar to that of 
other gram -ve bacteria except that 2 different polysaccharides and 
lipids appear to be present (Chaby ^  al, 1979), B, pertussis LPS 
possesses all the typical biological activities associated with gram -ve 
endotoxins (Chaby et al, 1979),
1*4.3 Pertussigen
Highly purified preparations of pertussigen exhibit the 
following activities: Histamine sensitisatior^, lymphocytosis promotion,
islet activation, heat-labile adjuvancy and mouse-protective activity 
against an IC infection (Munoz and Bergman, 1977). When purified 
pertussigen was heated at 80°C for h h all these activities were 
destroyed (Munoz and Bergman, 1977).
Parker and Morse (1973), Krzanowski et ad (1976); Ortez (1977) 
and Lee (1977) all found that pertussigen alters the responsiveness of 
different cells to adrenergic and other agents, as well as upsetting 
cAMP metabolism. Recently, Katada and Ui (1982a and b) and Katada 
et al (1982) on the molecular action of lAP on C6 glioma cells indicated 
that lAP (pertussigen) causes ADP-ribosylation of a membrane protein, 
which in turn increases receptor-mediated and GTP-induced activation 
of adenylated cyclase. This.mechanism is similar to cholera toxin 
although it appears that each causes ADP-ribosylation of different 
membrane proteins. This work has yet to be confirmed, Wardlaw and 
Parton (1982) suggested pertussigen interacts with these cell types 
through sialoprotein receptors,
Most of the published work on this component does not use the 
name pertussigen but refers to the substance by its pathophysiological 
activity.
(i) Histamine sensitizing factor
Parfentjev and GoodLine (1948) first described histamine 
sensitivity induced by pertussis vaccine in mice, Fishel ejt ^1 (1962) 
reported that p-adrenergic receptor antagonists were capable of 
producing similar changes induced by pertussis vaccine, ie histamine 
sensitivity, hypoglycaemia and refractoriness to the hyperglycaemia 
induced by epinephrine. These, authors suggested that pertussis 
vaccine induces p-adrenoceptor blockade. The basis of this altered 
responsiveness to epinephrine is not yet understood and results 
inconsistent with the p-blockade theory (Gulbenkian e^ al, 1968) have 
been reported, Lehrer (1979) found that HSF decreased in stability 
and antigenicity when it was purified. He reported that high doses 
of HSF sensitized mice within 4-8 h and low doses required 72-96 h.
This could not be explained by possible delay in the low doses finding 
their receptors, since antisera given after HSF could not neutralise 
the sensitivity,
(ii) Leucocyte promoting factor
Frohlich in 1897 (cited by Morse, 1965) first noted leucocytosis 
in pertussis cases, Morse (1965) demonstrated B. pertussis vaccine 
induced in mice a hyperleucocytesis with predominating lymphocytosis. 
This appears to be due to redistribution of cells from the lymphatic 
tissue to the circulation. The lymphocytes seem unable to migrate 
out of the circulation at the appropriate site. It is not knownif 
this is due to some alteration of the capillaries or the cell surface 
of the lymphocytes, Idigbe (1979) found the responsiveness of mice to 
the lymphocytosis effect of pertussis vaccine was 4-fold increased if 
the vaccine was administered intravenously instead of intraperitoneally. I
i'
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(iii) Lymphocytosis promoting factor haemagglutinin (LPF-HA)
Arai and Sato (1976) first isolated this spherical (6 nm in 
diameter) component and found it also had relatively low haemagglutin- 
ating activity. The haemagglutinating activity is sensitive to 
sialoproteins (Irons and.MacLenncm, 1979), It was first found to 
develop low IC protection (Morse and,Morse, 1976; Arai and Sato, 1976; 
Irons and MacLennon, 1979). However it has.since been found to 
produce active protection by this route (Munoz and Bergman, 1977 and 
1979), Antisera to this protein protects against sublethal intranasal 
(SLIN) infection (Sato £t al, 1981),
(iv) Islet activating protein
Sumi and Ui (1975) found pertussis vaccine given by the intra­
peritoneal route to rats induced an enhanced hyperinsulinaeraia response 
to.insulin secretagogues. Whereas epinephrine in normal rats inhibits 
glucose induced hyperinsulinaemia, this is reversed in pertussis 
sensitized rats and a hyperinsulinaemia response occurred. Islet 
activating protein (lAP) was then isolated from B, pertussis culture 
supernate (Yajima jet al, 1978) and shown to produce the same changes 
in both the intact rat and the perfused pancreas as whole-cell 
vaccine.
1.4.4 Agglutinogens
Bordet and Sleeswyk (1910) demonstrated that B. pertussis 
stimulated agglutinins in animals. Much later Andersen (1953a) 
showed that strains were not homogeneous in their serotype, Eldering 
et al (1957) designated the three most common agglutinogens as 1, 2
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and 3 and since then eight agglutinogens have been demonstrated. 
Agglutinogen 1 is common to all strains, SpKbaroplasts free of 
agglutinogen 1-6 produce an effective vaccine against IC challenge 
(Ross and Munoz, 1971; Dolby and Bronne Shanbury, 1975), However 
Preston (1966) has criticised the mouse protection test as a suitable 
measure of vaccine potency and proposed the agglutinogens as 
protective antigens in man,
1,4,5 Filamentous haemagglutinin
Keogh et ^  (1947) first isolated haemagglutinin (HA) from 
pertussis and suggested it as a protective antigen in experimental 
murine Infections, Masry*s (1952) preparations of HA-were antigenic 
but did not protect mice against IN or IC infection, Sato ^  ^
(1974) isolated a purified HA which protected mice against challenge 
and also promoted lymphocytosis. On further purification two 
distinct haemagglutinins were isolated with different properties, filament­
ous haemagglutinin .(Fî-HA):j and LPF-HA (Arai and Sato, 1976; Ito'rse and 
Morse, 1976)
According to Arai and Sato (1976) the former component is a 
protein, has high haemagglutinating activity, consists of 2 x 40 nm 
filaments of molecular weight 130,000, Irons and MacLenncm (1979) 
found its activity to be sensitive to cholesterol. It possesses no 
lymphocytosis promoting activity. Arai and Sato (1976), Morse and 
Morse (1976) and Irons and MacLenncin (1979) found it developed active 
protection against the IC infection. Antiserum to this F-HA also 
passively protects against a SLIN infection (Sato et al^ , 1981),
However on further purification this component was protective actively 
and passively only against a SLIN infection (U,S, Workshop), Sato
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et al (1979) reported the interaction of specific anti F-HA with pili- 
like structures of Bo pertussis<> It was widely believed that F-HA 
was derived from pili and often the term fimbria1 haemagglutinin has 
been used. However, Ashworth ^  al (1982) recently indicated that 
pili did not label with anti F-HA, but instead with antibody towards a 
serotype-specific agglutinogen 2,
1.4.6 Adenylate cyclase
Phase I B, pertussis have high levels of extracytoplasmic 
adenylate cyclase, a location peculiar to pertussis and not shown by 
mammalian or other microbial cells (Hewlett _et £l (1979), Phase IV 
and C-mode B, pertussis have negligible levels of the enzyme,
Wardlaw and Par ton (1979) proposed that the enzyme was involved in the 
expression of biological properties known to Phase I organisms but 
not present in Phase IV or C-mode,
1.4.7 Others
A number of other active substances of B, pertussis have been
I
3
described which are less well characterised. These include a 
haemolysin, a neurotoxin, a polymorphonuclear, leucocyte-inhibiting 
factor, a factor which affects macrophage function (Wardlaw and 
Parton, 1983) and a tracheal cytotoxin (Goldman et al, 1982), This 
tracheal cytotoxin recently described by Goldman ^  al (1982) which 
causes ciliostasis ija vitro may also have a prime role in lodgment.
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SECTION II B„ PERTUSSIS INFECTIONS OF M M
2,1 Pertussis - The disease
Pertussis is an acute localized disease of the respiratory
tract for which man is the only natural host (Pittman, 1970), Sub-
clinical or clinically unrecognized infections do occur but there is
no evidence that chronic carriers are significant in the transmission
of infection. The disease is spread primarily by droplets expelled
from the respiratory tract (Linneman, 1979), Pertussis is highly
communicableo The disease has four distinct stages and the average
length of the illness is around 60-70 days (Pittman, 1970),
The first stage is the incubation period which lasts between
7-14 days (Court, 1953), its length varying with the infecting dose
(Olson, 1975), The onset of symptoms begins in the catarrhal stage
with sneezing, anorexia, a little fever and ends with an increasinglyêtalsevere cough. This stage also lasts between 7-14 days (Court^ 1953), 
The disease is highly contagious at this stage with attack rates of 
80-90% in unvaccinated children exposed at home (MRC, 1951), The 
paroxysmal stage follows and persists for 2-6 weeks or longer; fever
is usually absent from this stage (Dayal et al, 1969). The severe-----
bouts of coughing or paroxysms, which occur without warning during 
this stage, may be as frequent as 10-21 per day and may be accompanied
.if
by the classical whoop which is caused by a long inspiration of air.
Vomiting may also follow these paroxysms (Linneman, 1979) and 
lymphocytosis and hypoglycaemia are usually present at this stagq.
Most of the complications of pertussis are by products of the paroxysmal 
coughing and its associated lung damage and cerebral anoxia. Death
s
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may occur at this stage (Olson, 1975)„
The symptoms associated with the paroxysmal stage begin to 
subside gradually as the disease enters the convalescent stage.
However it may take up to 6 months for paroxysms to cease (Olson, 197 5), 
Pulmonary and neurological sequelae may be present as a result of the 
disease. Pulmonary sequelae have a low frequency and take the form 
of bronchitis and pneumonia (White, Finberg and Tramer, 1964), Neuro­
logical sequelae have a much higher incidence (Olson, 1975), In a 
follow-up report of 35 children over a 14 year period 9 children showed 
evidence of more prolonged intellectual and emotional difficulties 
(Byers and Rizzo,(1950), The remaining 26 apparently recovered 
without suffering any ill effects. Six of the nine children had 
permanent handicaps with 4 showing encephalopathy,
Farber and Vawt€r (1961) and Olson (1975) have reported 
adenovirus isolation from clinically diagnosed cases of whooping cough. 
These viruses may cause paroxysmal coughing but not the inspiratory 
whoop or lymphocytosis which characterise the pertussis syndrome 
(Linneman, 1979),
Pertussis is found worldwide but has a higher incidence in 
countries with lower socio-economic conditions such as overcrowding 
(World Health Statistics Report, 1977), Epidemics of pertussis occur 
in cycles of 3-4 years (J,C,V,I«, 1977),
2,2 Laboratory findings 
Pathology
Autopsy of a child who had died of pertussis showed organisms 
on and between the cilia of the epithelium on the tracheobronchial
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tree (Mallory and Hornor, 1912), Infected epithelial cells had been
shed and cilia reduced to stubs. Organisms had not penetrated into
the epithelial cells. Polymorphs, lymphocytes and plasma cells were 
 ^ all present and bacteria were observed within the phagocytic cell, i
Olson (1975) suggested that the organism would find amino acids as t
its carbon source in the mucus of these regions.
Collier et ^  (1977) showed that tracheal organ cultures with i
ciliated epithelial cells attracted B, pertussis which attached to 
the cilia and microvilli. The bacteria did not attistch to nonrciliated 
cells, Ciliostasis followed after attachment. Standfast (1958) 
suggested that heat labile toxin paralysed the cilia and thus prevented 
the organism from being washed away by mucus. Matsuyama (1977) found 
Phase I but not Phase III attached to the lung but both caused 
ciliostasis suggesting attachment is the important step in establishing 
infection, Sato e^ ah (1979) proposed that pili attach the organism 
to the ciliated epithelium but direct evidence of this was not forth­
coming (Matsuyama, 1977).
Although B, pertussis remains localized in the lung, pathological 
changes have also been observed in the central nervous system (Dolgopol,
1941), fO'ederaa and haemorrhages were present and were consistent with 
anoxia and venous pressure,
2,2,2 Bacteriology
■B. pertussis is rarely isolated from the host after the second 
week of the paroxysmal stage (Linneman, 1979), The isolation rate 
after the third week of infection is ar.Ound 507, (Brooks et al, 1942),
Collection of specimens by the pernasal swab method (Cruikshank, 1944)
and direct plating of specimens onto B.G, medium gives the best chance
,
'
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of recovery (Parker and Linneman, 1980), Rapid diagnosis by 
fluorescent antibody technique has the disadvantage of giving false posit­
ives (Chalvardjian,. 1966),. Treatment of a case with antibiotics 
decreases the chance of a positive culture but has little effect on 
the clinical symptoms unless started within 8 days of symptom 
appearing (MRC Report, 1953), Bass e_t al (1969) found erythromycin 
was the most effective, when administered before the paroxysmal 
stage, at reducing the length and severity of the illness. Hyperimmune 
human serum like antibiotic therapy, is said to be effective in 
eradicating organisms from the host but ineffective in reducing the 
severity of infection unless administered before the onset of the 
paroxysmal stage (Bass et al, 1969). However there has been no 
controlled trial of pertussis immune serum,
2, 2,3 White blood cell count
Kaufman and Bruyn (1960) found 57% of hospitalized patients
had a white blood cell count greater than 20,000 rara"^  with admissions
-3 -3showing a range between 8,000 mm to 140,000 ram . They found the
average count in complicated cases to be greater than that of
uncomplicated cases. However the variability was so great that
'complications could not be predicted by this means* L a g e r g r i (1963)
found leucocytesis less frequent in patients below 6 months of age.
In the cases showing leucocytosis, 63%. of these exhibited 
lymphocytosis (Lagergreh , 1963), Lymphocytes comprise 50-75% of the 
total white cell count (Kaufman and Bruyn, 1960), The cells are for 
the most part normal-appearing mature, small T and B lymphocytes in 
equal proportions (Tsukimoto and Lampkin,, 1976), Treatment of patients
ï:;
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with antibiotics produced a rapid decline in white blood cell count 
within 24 hours (Kaufman and Bruyn, 1960).
Eosinophilia was observed by Biro (1960), Klimt (1961) and 
Olson 2Ë ^  (1964), The latter found this phenomenon, to be more 
pronounced in convalescence and defined the syndrome as acute 
infectious lymphocytosis. However Reed ejt _al (1970) were unable to 
confirm it,
2,2,4 Biochemistry and pharmacology
Regan and Tolstoouhov (1936) described the disturbances 
induced by whooping cough in blood chemistry. Inorganic phosphorus 
and pH were diminished usually by the end of the catarrhal stage and 
significantly, diminished during the first weeks of paroxysms. Carbon 
dioxide combining power remained normal but due to inadequate 
respiration particularly after the onset of paroxysms GO^ accumulated 
in the blood to cause an increased concentration of carbonic acid.
Calcium concentration shows slight instability. Blood sugar was at 
the lower limits of the normal range and became hypoglycaeraic at the 
end of the paroxysmal stage. This drop in blood glucose could not 
be explained by reduction in food intake since the children ate normally. 
Uric acid was present, at increased levels.
Other metabolic disturbances have been observed, Badr-El Din 
£t ^  (1976) found that attenuation of epinephrine induced hyperglycaemia 
persisted for at least 50 days in children with whooping cough,
Sanya1 (1960) examined 30 children in the typical stage of whoop in the 
age group 1-10 'years, for sensitivity existing to histamine, 5-hydroxy- 
tryptamine and 48/80, a histamine liberator. It.was shown that nearly
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all were maximally sensitive to histamine and slightly sensitive to 
5“hydroxytryptamine as measured by the area of erythema around the 
lint soaked in an aqueous solution of the testing substance. The 
48/80 did not cause any reaction.
2.3 Resistance to infection
2.3.1 Natural Immunity
There appears to be no passive transfer of protective anti 
B. pertussis antibodies from mother to foetus (Lorber, 1975; Preston;.etqai,
1974), The infant below one year of age and especially below 6 
months of age, is very susceptible. Despite this, it may not be
practicable to start immunisation much before 3 months of age because
of poor immune response (J.C.V,!,, 1981),
In regard to duration of immunity after infection, Mannerstedt 
(1934) found 29 cases of adult infections and three infections in 
children between the ages of five and 15 years all of whom had previously 
had whooping cough. However second attacks are rare and are usually 
not diagnosed (Pittman, 1970),
The nature of the immunity that develops after. infection has 
been little studied, Pittman (1979) proposed that local secretory 
immune responses gave a short-term immunity by preventing attachment 
of the organisms to the ciliated epithelium. More durable immunity,
lasting for a few years, might be due to serum antibodies against 
pertussis toxin (pertussigen),
2.3.2 Vaccination
Madsen (1925, 1933) studied pertussis vaccine efficacy during
I
i
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two epidemics in the Faroe Islands, He found vaccination significantly 
reduced the severity of the disease and if completed before the onset 
of an epidemic, the rate of infection was reduced from 98% to 75%.
More encouraging results were found in subsequent vaccine trials. In
these the criteria for cultural conditions which are required to give 
Phase I virulent organisms (Leslie and Gardner, 1931) were used for 
vaccine production, Kendrick and Eldering (1939), in a controlled 
study, found 35% vaccinated children exposed to infection in the home 
contracted pertussis compared with 89% pf unvaccinated children.
The initial controlled studies of the Medical Research Council
(1951) revealed a reduction in home exposure attack rate (H.E.A.R.) 
averaging around 70%in vaccinated children and also a reduction in the 
severity of illness. Many vaccines were tested in this and the 
subsequent MRC field trials reported, in ,1956 and 1959, Not all 
vaccines produced a worthwhile reduction in the H.E.A.R. These later 
two trials established an inverse correlation between H.E.A.R, and 
vaccine potency in the intracerebral mouse protection test (Kendrick 
et al, 1947), The World Health Organisation (WHO) subsequently 
recommended this test as the standard assay of pertussis vaccine 
protective potency (W.H.O. 1964; 197 ), Pertussis vaccine, combined 
with diphtheria and later also with tetanus toxoids, was introduced in 
the United Kingdom on a national scale in 1957 (figure 1),
In a report by the Public Health Laboratory Service 
Working Party (1969) on the efficacy of whooping-cough vaccines, it 
was subsequently shown that vaccination at that time was not significantly 
reducing the attack rate. Preston (1963) had already shown a shift 
in the serotype of organisms causing infections, ie from serotype 1,
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Figure 1, Whooping cough in England and Wales from 1945-1980
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2, 3 to serotype 1, 3* Perkins (1969) found British vaccines contained 
only one-half the international standard dose of 4 A mineral
adjuvant, aluminium hydroxide, was incorporated as this was found to 
provoke a greater immune response than the plain preparations previously 
in use as well as reducing the toxicity of the vaccine (Burland e_t al, 
1968)o A major consideration in the routine vaccination of children 
is that it induces herd immunity which in turn minimises the risk of 
infection in the very young infant not yet immunized (Stuart-Harris, 
1979).
Adverse reactions to pertussis vaccines have been well 
documented. The earlier worker (Madsen, 1933) recorded two deaths 
after pertussis vaccine, Byers and Moll (1948). found in 15 vaccine 
associated reaction cases admitted to hospital, all but one showed 
evidence of impairment to the nervous system. An examination of the 
family histories showed a high incidence of neurological abnormalities.
In the midr70*s there was much publicity to the adverse neuro­
logical reactions to pertussis vaccine by the Association of Parents 
of Vaccine-Damaged Children and by Kulenkampff ^  ^  (1974), This led 
to a decline in acceptance rate in the United Kingdom by about 407, 
(Stuart-Harris, 1979),
Subsequently a study by the Joint Committee on Vaccination and 
Immunization on adverse reaction in hospitalised children under 3 years 
of age was published in 1981, It concluded that permanent damage as a 
result of pertussis iiranunization was a rare event - around 1 in 310,000 
immunizations, and that attribution of a cause in individual cases was 
precarious.
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2,3o3 Passive immunization
Debre (1923) found that serum from patients who had been 
infected for four weeks had some immediate protective ability for 
intimately-exposed children to whom it was given during the incubation 
period of pertussis. McGuinness e_t ^  (1944) reviewed the use of 
human hyperimmune serum. They reported that it dramatically reduced 
the mortality rate if given in adequate dosage compared to patients 
given no sera. There was also therapeutic value for exposed children 
but here the dose was increased.
Ames (1953), Kaufman and Bruyn (19,' ) and Bass eh al (1969)
found hyperimmune globulin treatment did not alter the course of the 
disease unless treatment began b'a-jcre.the catarrhal stage compared to 
patients given no sera. Only in a few cases was the length of the 
paroxysmal stage reduced,
2,4 Nature of the immune response after infection
Many parameters of the immune response after a B. pertussis 
infection have been investigated with a view to relating severity of 
disease to one or more immunological tests,
Kendrick. ^  ^  (1937) found blood from B. pertussis 
infected children had an increased degree of phagocytosis as well as
an increased number of phagocytic cells taking part. This response
'
was B, pertussis specific. This was demonstrated by incubation of
9 -1blood with 20 x 10 B. pertussis ml . A drop, 5 mm in diameter, of
antigen-blood mixture was placed on a slide, dried and stained. Twenty
five polymorphonuclear cells were examined and B. pertussis contained
within were counted.
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The polymorphonuclear cells of blood from uninfected children 
contained no or very few B. pertussis organisms, whereas in infected 
children's sera increasing numbers of polymorphs contained many 
organisms as the disease progressed. The maximum opsonocytophagic 
response occurred at eight weeks after the onset of infection and 
remained elevated for the next four months. However there was no 
definite relationship between opsonocytophagic response and the 
severity of the disease in the 28 children examined.
Winter (1953) examined the development of antibacterial 
agglutinins, antihaeraagglutinins and protective antibodies as measured 
by the LIN mouse protection test. 62% of patients developed 
B. pertussis agglutinins but only 14% developed antihaemagglutinins,
'ISera tested during the acute stage of the infection had either no
5^0protective activity or a PD^ p, ml  ^between 5-10 against a LIN murine
-1infection. However during convalescence the PDj-^ ral showed a 4 to 
10-fold increase to 11-30, The maximum titre occurred between the 
5th to 8th week of disease protective antibody was present in all 
sera tested and its development parallelled the course of recovery.
Dolby and Stephens (1973) were unable to relate the immunity 
of the infected child to titres of either agglutinin or bactericidal 
antibody. The proportion of children with both these antibodies 
were higher in bloods taken between 2-6 months after appearance of 
symptoms than in bloods taken between 1-2 months. Older children 
of 1 to 6 years who did develop agglutinins did so within 1 month of 
infection, whereas infants below 1 year of age produced agglutinin 
only after months. However the frequent absence of both bactericidal 
and agglutinin antibody response was noted. All sera examined had 
antihaeraagglutinins in bloods taken after 2 weeks to 4% months from
24
onset of symptomso The protective ability of sera of infected 
children bled 1-12 weeks after infection measured in mice against a 
small lethal brain infection was present in 66% of the cases.
The distribution of agglutinins, bactericidal antibodies and 
antihaemagglutinins in serum IgG and IgM was examined. Infants below 
one year of age had a higher antihaemagglutinin titre in the 19S 
globulins' than 7S globulins. In older children the titre was similar 
for both 7S and 19S, Levels of agglutinins and bactericidal titres 
in both 7S and 198 was similar in children of all ages,
Bradstreet ^  ^  (1972) proposed that the complement fixation
and immunofluorescence tests were the best routine serological tests 
for pertussis, particularly in the 6 months or over age group. 
Ninety-five percent of patients had raised antibody titre in paired 
sera during infection,
Aftandelians and Connor (1973) using the Ouchterlony technique 
to examine the development of precipitins, found that such antibodies 
to sonicated B« pertussis developed in 86% of paired, sera from pertussis
cases. In contrast agglutinins developed in only 42% of paired sera,
2,5 Nature of the immune response after vaccination
Dolby and Stephens (1973) were unable to relate the immunity 
of the child to the titre of the agglutinin, bactericidal antibody or 
protective ability of sera against a small, lethal brain infection, 
Aftandelians and Connor (1973) found precipitin lines to B, pertussis 
sonicate by the Ouchterlony technique in only 36% of samples from 
vaccinated children. Bradstreet £t ^  (1972) found complement fixing 
antibody undetectable 7 months after the last injection of the
25
vaccination programme. Macaulay (1979) found indirect haemagglutin- 
ation, complement fixation and agglutination antibody response 
developed, although not always together, in pertussis vaccinated 
children. Indirect haemagglutination developed more frequently than 
the other two antibodies in paired sera, IgG was the only Ig class 
involved in complement fixation test whereas IgG and IgM were involved 
in indirect haemagglutination (Macaulay, 1981).
SECTION III EXPERIMENTAL MODELS OF B, PERTUSSIS OTHER THAN THE MOUSE
3,1 Animal models
Various experimental animal models other than the mouse have 
been studied for their ability to reproduce the clinical changes and 
laboratory findings associated with the pertussis syndrome. Pertussis 
infections in primates have been most successful (Table 2),
The B. pertussis strain and infecting dose are rarely mentioned 
in the early literature on primate infections with ,pertussis. However 
Huang ^  ^  (1962) infected the Taiwan monkey with 20 x 10^ organisms 
of the 18-323 strain and Stanbridge and Preston (1974) infected the
9marmoset with 50 x 10 organisms strain 41633,
Comparative efficacy of the various methods of administering 
B, pertussis infection to the respiratory tract has not been established 
and intratracheal, IN and spraying into the nose have all been used 
as a mode of infection. However the two most thorough investigations 
by Lin (1958) and Huang £t al^  (1962) both infected the monkey by 
spraying the nose. The number of animals used has generally been 
small (3-11) except with the experimental infection of the Taiwan
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monkey where 42 were used.
Clinical observations of pertussis infections in some of the 
primates indicated a disease pattern closely similar to that in man. 
Interstitial mononuclear pneumonia was found in 8 out of 9 Erythrocebus 
monkeys (Sprunt et al, 193^, Huang aj^  (1962) found that the 
temperature of Taiwan monkeys was normal throughout infection and no 
weight loss occurred. These animals developed a paroxysmal cough.
The paroxysmal cough has also been recorded in other species 
of monkey (Lin, 1958), However, Mallory £t ^  and Stanbridge and 
Preston failed to find it in the Macacus monkey or marmoset respectively. 
The length of time before paroxysmal coughing begins after infection 
ranges from two days to 3 weeks incubation, Inaba (1912) recorded 
vomiting after paroxysms.
The induction of immunity to reinfection in the monkey has 
been demonstrated (Sauer and Hambrecht, 1929; Lin, 1958), Active 
immunization by vaccination was possible in the Taiwan monkey (Huang 
et al, 1962), Passive immunization of this species was also 
successful with sera from convalescent and vaccinated Taiwan monkeys 
(Huang et al, 1962),
Laboratory findings in pertussis-infected primates are also 
similar to pertussis in man. Actual pulmonary multiplication of the 
bacteria has not been demonstrated, but colonization persisted until 
the 46th day (Lin, 1958; Stanbridge and Preston, 1974), Leucocytosis 
(13,000-38,000 mm ^) with predominately lymphocytosis has been 
demonstrated (Sauer and Hambrecht, 1929; Lin, 1958), Lymphocytosis 
alone has also been observed (Sprunt al^ , 1938; Huang et al, 1962), 
The opsonocytophagic index in infected Macacus cvclopsis increased
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(Lin, 1958), The agglutination titre was either low with a 
reciprocal agglutination titre 32 (Huang e_t al, 1962) or only present 
after reinfection (Lin, 1958).
A range of rodents and carnivores have also been studied.
Again only the more recent papers state the infecting dose (Hornibrook 
and Ashburn, 1939; Preston, 1980), The method, of administration 
was either IN or intratracheal,
Klimenko (1908) was unable to infect rabbits whereas Sprunt 
et al (1938) and Preston (1980) were both successful in establishing 
infection in this species, Klimenko (1908) observed infection of 
normal puppies by intimate contact with sneezing and coughing puppies 
(following infection). This result was confirmed by Mallory et al 
(1913) who were also able to reisolate B, pertussis between 15 to 25 
days after infection. These latter authors also infected rabbits and 
observed emaciation after a few days and histological lesions charac­
teristic of pertussis on the tracheobronchial tree, Mallory et aI 
(1913) later acknowledged that their clinical and laboratory finding
could have been due to B, bronchiseptica, etaLjPrestonX(1980) observed that colonization of the rabbit naso-
pharynx persisted for as long as nine to ten months. The serotype of 
the infecting strain changed with time. Catarrh was present but no 
coughing or sneezing was reported. Active immunization was effectivePvsK W a
only if a range of serotypes was present in the vaccine, HornibrookôIyIX 
(1939) found cough-like paroxysms and non-specific interstitial 
bronchopneumonia in rats infected with B. pertussis.
Active immunization of rabbits with either outer membrane 
proteins, F-HA or standard vaccine induced enhanced clearance of 
B, pertussis. However there was no correlation between elimination
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of B. pertussis and serum antibodies to outer membrane proteins, F-HA, 
LPS, LPF or agglutinogen 3, However nasal IgA to F-HA inversely 
correlated with bacterial persistence (Ashworth et al, 1982),
Multiplication of B, pertussis in the lung has not been 
demonstrated in any of the animal models,
3.2 Other models
Chick embryos are susceptible to infection with B. pertussis 
by inoculation of the amniotic fluid (Gallavan and Goodpasture, 1937). 
Infection occurred on the ciliated bronchi and bronchiole, epithelium 
in preference to the trachea and also on the ciliated oesophageal 
epithelium. B. pertussis produced reproducible cell damage in cultures 
of human and cat brain tissue (Felton et al, 1954), The introduction 
of specific antiserum appeared to halt the process of damage produced 
by bacteria where normal serum did not.
Organ culture of Phase I, C-mode and Phase IV B. pertussis on 
hamster trachea has been done by MuseA(1977), C-mode and Phase IV 
organisms were unable to produce ciliostatis over a 48 h period, 
whereas ciliary paralysis had taken place by this time with phase I 
organisms,
SECTION IV B, PERTUSSIS INFECTION OF MICE
There are two sites in which B, pertussis organisms multiply in 
mice; the lungs (Burnet and Timmins, 1937) and the brain (Kendrick 
et al, 1947), Both are localized infections of ciliated epithelium, 
Proom (1947) found that B, pertussis did not multiply in the peritoneal
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cavity or the bloodstream after an i.p. injection of the living 
bacteria. Pertussis in man is a localized infection of the upper 
respiratory tract and the IC infection with thèsE bacteria does not 
occur in the human species. However in the brain of the mouse,
Bo pertussis is isolated from the normal protecting mechanism and the 
bacteria survive and multiply,
4.1 Intracerebral infection
4.1.1 Histological changes
Berenbaum et al^  (1960) investigated two different routes of 
IC infection with strain 18-323, (a) through the foramen magnum and 
(b) through the parietal bone, the route used by Kendrick £t af (1947). 
No difference was found between the two routes except where the 
lesions were made by the needle.
Multiplication of the bacteria was confined to the ciliated 
epithelium and ependyma and although some organisms entered the blood­
stream, they did not multiply out of the cranial cavity. No organisms 
were detected in the lung, spleen and liver throughout the course of 
this infection.
The polymorph reaction which was visible after 24 h in the 
meninges and choroid plexus had tiy day 3 moved into the ventricles. 
Organisms were present in clusters in the supra-optic recess of the 
third ventricle and occasionally on the lateral ventricular choroid 
plexus. Extensive areas of haemorrhages yere present by day 5 and 
by day 6 purulent fluid distended, the ventricles and extensive poly­
morph invasion was evident. Organisms either free or within
' f
iri
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polymorphs were now more apparent in the ventricles than in the 
meninges or choroid plexus. Death followed.
Liver, spleen and adrenal glands had some histological 
changes whereas the lungs, heart, kidneys and pancreas did not. The 
liver had a terminal fatty , change and atrophy of the lymphoid 
follicles of the spleen occurred. The adrenal glands changed markedly. 
Lipid depletion began on Day 5 leaving only small areas of lipid in 
the zone glomerula and innermost cortex. Enzymatic activity of 
succinic dehydrogenase, non-specific esterase and acid phosphatase 
in the adrenal cortex increased. I;g4,1,2 Factors influencing virulence
Standfast (1958) found the LD^q of the IG infection of strain 
18-323 remained constant over a mouse weight range of 12-36 grams in 
an experiment where weight was an indicator of age. He examined the
effect of subculture on the virulence of 5 strains. All maintained
the same virulence by the IC route after 267 subcultures. However 
this virulence was eventually lost, although the number of subcultures 
was not stated. Rough or jphase IV organisms were avirulent.
Standfast also found virulence was not influenced by age of culture 
over a 24 hour to 72 hour range.
4,1,3 Multiplication rate
Berenbaum et al (1960) using strain 18-323 found an initial 
lag phase in the brain lasting 24 h but. by 48 h the organisms were 
rapidly multiplyiiig. Growth tended to level off about Day 5 when 
approx 10^ to 10^ organisms were present in the brain before death.
i
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Standfast and Dolby (1961) examined growth curves of a range
5of infecting doses. As the infecting dose was lowered from 10 to
10^ viable organisms, the critical level at which death occurred also
8 5 7 8 Z»decreased from 10 * to 10 “ organisms respectively. As the infecting «
dose decreased the time taken to reach this critical level increased fl
from 4 to 13 days respectively.
High virulence strains such as 18-323 (Berenbaum ^  al, 1960;
'iDolby and Standfast, 1961) and 2-Atox (Andersen and Bentzon, 1958) 
produce a lethal infection (Adams, 1970), Active multiplication 
continues even after the blood brain barrier becomes permeable. The
organisms then leak out of the brain but are insufficient to cause an
effective antigenic response in the time available (Berenbaum ^  al, |
."iI960),
The majority of fresh isolates of B. pertussis have low IC virulence
^ Low ' ï”
XÀndërsen ihdbBentzonyl958; lida et al, 1962). However ^virulence
strains behave as high virulence strains in the first 24 h of infection
■ ■ ' ■(Adams, 1970), However with low infecting doses the Lbrains became
sterile within 5 days whereas high infecting doses of low virulence 
strains killed the mice by Day 3,
Adams (1970) found the same immediate 90% loss of organisms
Hras Dolby and Standfast (1961) and suggested this was due to washback 
along the needletrack. Complement appeared to have no part in the 
defence of the brain since low virulence strains did not have
enhancement of infection in mice deficient in C5 component. Modu­
lation induced by growth of challenge cultures at 25^G was ruled out
.!
as a possible reason for loss in virulence. An interference phenom- 
enon was observed when a mouse infected with a low virulence strain
I
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was reinfected with a high virulence strain. The mice survived.
Adams (1970) proposed this was due to the infection sites being already 
occupied,
4.1.4 Effect of vaccination
Berenbaum et ^  (1960) examined the histological changes in 
the brains of vaccinated and challenged mice. The cellular reaction 
of day 1 varied little from that in unprotected animals. Polymorphs 
were the predominant cell together with isolated lymphocytes and 
macrophages in the meninges. By day 6 mononuclear cells, mainly 
lymphocytes but also macrophages, accounted for the intense inflammatory 
reaction in the meninges and choroid plexus. Plasma cells were also 
present and actively multiplying. This reaction was still present 
after 2 to 3 weeks and on the 6th week cellular infiltration was still 
apparent,
Berenbaum et sd (1960) also found that the multiplication of
the B. pertussis was similar in vaccinated and unvaccinated mice until
day 3 of infection. Thereafter the infection peak of the vaccinated
5animal occurred on day 4 with around 10 organisms. Subsequently 
the number of organisms declined until day 5 or 6 when the infection
3was reduced to 10 bacteria.
4.1.5 Effect of passive immunisation
Passively protected mice given antisera i,p. from 3 days 
before to 3 days after IC challenge all started to recover 3-4 days 
after infection. Both actively and passive immunization were 
effective only after the blood brain barrier was broken (Berenbaum 
et al, 1960),
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Spasojevxc (1962) and Holt (1972) administered 
antisera and infecting organisms together in a mixture. The same 
antisera to B. pertussis in tissue culture studies prevented adherence 
of the bacteria to human fibroblasts, although these sera would not 
detach previously adherent cells. This ability correlated with the 
passively protective activity of the antisera by the IC/mix route,
4,2 Intranasal infections
4,2,1 Modes of administration
(i) Aerosol spray
Sato et a^ (1980) claim to have uniformly infected mice by
exposing them for 30 min to aerosols generated from bacterial suspensions
of 10^ and 10^ organisms ml The mean bacterial count in the lungs
of these animals infected with the respective 10^ and 10^ suspensions 
4 5was 2,3 X 10 and 1,0 x 10 organisms. Twenty minutes after stopping, 
the mice were removed and placed in animal cages with air filter covers,
(ii) Intratrachea1ly
By making a longitudinal incision over the ventral surface of 
the neck and removing fascia from the trachea^ Bradford (1938) 
inoculated the organisms into the trachea via a small needle on a 
tuberculin syringe. The slit in the skin was healed by a small 
amount of collodion, Te-Punga and Preston (1958) showed that intra­
tracheal inoculation gave more uniform administration of a lethal infect­
ion' than!' IN' • instillation, . Nembutal anaesthesia was used to.i
prevent irregularity in breathing. However since volatile anaesthetics 
had been shown to increase the virulence of the infecting organism
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(Te-Punga and Preston, 1958) the mice were treated with an ether/ 
chloroform mixture 1 to 2 h before the i.p, injection of nembutal.
The intratracheal inoculum was given with a modified calibrated 
pasteur pipette which was slightly curved at the end and tapered with 
a small hole at the tip. The pipette was then passed over the base 
of the tongue and directed into the base of the trachea. Reproducible 
mortality rates were found over a series of lethal doses,
(iii) Intranasally
Burnet and Timmins (1937) anaesthetized mice with an ether/ 
chloroform mixture until rapid, regular breathing was induced. The 
mice were then removed and placed in a fume cupboard. The organisms 
were instilled in a volume of 0,05 ml with the nasal axis in the 
vertical, A major drawback of the procedure was the bubbles which 
formed if -the mouse was not breathing regularly,
4,2,2 Mouse strains and sex
Most of the early papers did not mention the mouse strain 
which was used and merely state “white mice of the laboratory" 
(Andersen, 1952; Fisher, 1955; Dolby et al, 1961), Named mouse 
strains in which a B, pertussis SLIN infection have been established 
are N:NIH(S,W,) (Geller and Pittman, 1973), Anglia (NIH) and HAMl/CR
Pittman ^  (1980) found HAMl/CR mice overall more responsive than 
Anglia NIH as measured by recovery of B, pertussis by lung culture. 
Females of both strains were more susceptible to a lethal infection
(Pittman et.al, 1980) and DDY and ICR (Sato et al, 1980; 1981),
Standfast (1951) examined the virulence of B, pertussis in 3 
mouse strains and found a 3 to 5 fold difference in virulence.
■IS
than males,
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4.2.3 Mouse Age
Mouse age or weight is an important factor in the susceptibility 
to infection by the IN route in contrast to the IC route. Culotta
et al (1938) showed a 93% mortality rate in 10-12 gram mice and a 66% 
mortality rate for 20-25 gram mice for the same infecting dose.
Standfast (1951) confirmed these findings for two mouse strains,
Pittman ah (1980) found age significantly influenced mortality, 
degree and duration of infection. The pathophysiological changes I
associated with infection were more marked and/or of longer duration |
I
in younger than in older mice, Sato ^  al (1980) found that older |
Ianimals of the HAM f/CR strain were iess( susceptible, |
j
4.2.4 Strains of B, pertussis |
IA variety of B, pertussis strains have been used to establish j
IN infection (Table -^), Wide variations in virulence, as measured 
by the of the organisms, were shown for freshly isolated strains
even when the strains were subcultured only once after isolation 
before being used (Standfast, 1951). These freshly isolated strains 
showed a hundred fold difference in virulence. The rate with which i
the virulence of strains degenerated also varied. One strain showed |
a decrease, in virulence of only 3/2 fold and another showed a 300 fold j
decrease over the same number of subcultures. The strains with high j
starting virulence showed a much lower rate of degeneration than the j
lower virulence strains. Enhancement of IN virulence by mouse !
passage was not successful, !' IStandfast (1951) also examined whether the virulence was 
influenced by the viability of infection. The was calculated
40
in terms of total and viable count. Increased percentage viability 
of the infecting dose did not necessarily increase the virulence of 
the infection. Virulence of the fresh isolates was unaffected by 
toxin production and haemagglutinin content. There was no relation­
ship between virulence and when organisms were isolated from the host, 
in relation to the onset of disease or the type of swab used to 
collect specimens (pernasal or postnasal),
4.3 Characteristics of intranasal infections
Intranasal infections are of two general types; lethal and 
sublethal# Individual authors*classification of these doses varies 
(Table 4). The dose used is dependent on susceptibility of mouse 
strain and the virulence of the B. pertussis culture.
4.3.1 Growth of organisms and host mortality
Fisher (1955) found the mean multiplication factor (the
difference between the mean log viable count in the lungs and the log
viable count of the infecting dose) decreased as the infecting.dose 
increased (Table 5). The multiplication factor was negative with 
an infecting dose of 500 x 10^, ie there was a reduction in viable 
counts over the 7 days of infection, Dolby ^  al (1961) found the 
doubling time of viable counts increased as the infecting dose was 
increased, ie the multiplication rate was decreasing. The largest 
infecting dose again showed a decrease in viable count,
Dolby ^  al (1961) found actively immunized mice given a
7 4lethal infection of 10 organisms reduced the viable count to ^ 10
organisms in the lung within 4 days. Passively immunized mice
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Table 5 : Multiplication of;B. pertussis in mouse.lungs
Reference Organism
strain
Infecting
dose
Peak of 
infection 
(Days)
Mean Generation 
Time
Proem (1947) N.M.^ 10x10^ 14 2 days
5x10^ 14 1 day
Cooper (1952) CN134 5x10^ 7-8 N.M.
Andersen (1952) 2 atoxic 10^ 10-24 N.M.
5 atoxic 10^ 10-24
108 10^ 10-17
Dolby et al C2621 10^ 14-21 N.M. '(1961) 14 7,7 hr
10^ 14 19.0 hr
Geller and zPittman (1973) 18-323 2x10 14 N.M.
Sato et al(19807 Tohama 6x10^ 14 N.M.Phase I
N.M. = Not mentioned
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7reduced a lethal infection of 10 organisms to a sublethal level by 
preventing multiplication to the critical number at which death 
would have resulted. Standfast and Dolby (1958) challenged passively 
immunized mice with a sublethal infection and the viable count was 
reduced to zero within 2 days.
The infection peak in sublethally infected mice varied from 
Day 7 (Cooper, 1952) to Day 24 (Andersen, 1952), Dolby et al (1961)found 
the G353 and: C2621 had the respective infection peaks of Dl4 and 
D21, The time of infection peak depended on mouse and strain of 
organism (Table 5),
Pittman (1951) examined the mortality rate over a range of 
infecting doses (Table 4), She showed that a dose of 10 x 10^
3organisms gave 35-40% mortality and 50 x 10 organisms gave 10% mortality. 
The mean time of death was 16,1 days and 23,5 days for the respective 
doses, Dolby et ad (1961) characterised the in vivo growth curves 
over a range of infecting doses for the two strains 02621 and G353,
An infecting dose of ^ 10^ organisms resulted in no mortality.
Above this critical number of organisms a lethal infection occurred 
with 100% mortality. These lethal infections occurred when growth 
was sufficient to reach 10^ organisms before 10-14 days. Standfast
and Dolby (1961) calculated the mean; time of death for the range. 
1/100 LD^Q to 10^ LD^Q of G353 strain moved from 15 days to 1-2 .da]
4,3,2 Pathophysiological changes after infection
(i) Histological
The histological changes occurring in a lethally infected 
mouse have been well documented. Red patches appear all over the
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lung by Day 3 of infection (Bradford, 1938), This colour gradually 
changes to a greyish-pink consolidation (Bradford, 1938; Burnet and 
Timmins, 1937), Acute oedema was found in the trachea and exuding 
from the consolidated areas of a dying mouse. Portions of the lungs 
are airless (Burnet and Timmins, 1937),
Cellular infiltration of mononuclear and polymorph cells 
developed by Day 3 of infections with macrophage infiltration slowly 
replacing the polymorphs, (Bradford, 1938), Organisms were present 
mainly in the bronchioles but also in the bronchi and rarely on the 
trachea. Massive proliferation of the bacilli could be seen in the 
mucus with slight destruction of the cilia and ciliated surface to 
form necrotic areas in the epithelium which also permitted, growth 
(Burnet and Timmins, 1937), Bradford (1938) recovered B, pertussis 
from spleen, heart and bloodstream. This is an unusual result as 
subsequent experience suggested pertussis is a localized infection of 
the lungs (Proom, 1947).
Cheers and Gray (1969) examined the development of histopatho- 
logical changes in mice after a sublethal pulmonary infection with 
B. pertussis. Lung sections showed bacteria in the mucus of 
bronchioles early in infection and in the alveoli by Day 7. Poly­
morphs and macrophages were present in equal proportions on Day 11,
On Day 14 a polymorph invasion led to a massive reduction in 
bacterial numbers in the bronchioles. The polymorphs then disappeared
but macrophages containing bacterial cells persisted to about the
J6th or 7th week.
Muse £t ^  (1977) and Sato et £l (1979) presented electron 
micrographs showing B. pertussis on the ciliated epithelium of a
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guinea pig and mouse lung respectively, Sato observed that some 
organisms are found on non-ciliated epithelium although most were 
associated with ciliated cells,
(ii) Opsonocytophagic
Cooper (1952) examined the opsonocytophagic indices of 
normal and infected mice 8 days after a sublethal infection with 
B, pertussis. The opsonocytophagic index is the ratio of organisms 
within macrophages from a normal mouse and macrophages infected 
mice. The index for normal to infected mice was 1:20,
Cheers and Gray (1969) observed.the change from extracellular 
multiplication of the bacteria after a few days to intracellular 
existence within alveolar macrophages. The latter had increased 
killing power but normal phagocytic capacity. However many bacteria 
survived within the macrophages and this steady state where the 
number of viable organisms did not change was termed the complaisant 
phase.
(iii) Leucocytosis
Bradford (1938) examined leucocytosis in lethally infected
mice over a period of 15 days. There were two control groups
consisting of uninfected mice and mice infected with atypical
B. pertussis. By day 5 B, pertussis infected animals showed
leucocyte counts between 39,000 mm  ^and 220,000 mm Uninfected
"3mice had counts of 20,000 ram and atypically infected animals gave
-3 -3counts of 6,500 mm to 62,000 mm , By day 10 the leucocytosis-i
persisted only in the typical B. pertussis infected mice. Cooper 
(1952) examined the red cell and leucocyte count.of sublethally 
infected animals. The red cell count remained unaffected but the 
leucocyte count showed a five fold increase after 8 days.
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RSato ad (1980) observed a peak WBC count of 1,95 x 10 at 
Day 14 of infection in sublethally infected mice, after which the 
count remained steady, Pittman ^  al (1980) reported peak leucocytosis at 
Day 10 of a lethal infection and Day 20 of a sublethal infection, 
Leucocytosis and hypothermia were highly correlated in lethally infected 
mice as also was the body and spleen weight,
(iv) Histamine sensitisation
Pittman (1951) demonstrated histamine sensitivity after a 
sublethal infection and also determined the onset and duration of this 
sensitisation after 2 infecting doses of 10 x 10^ and 10^ organisms.
The larger infecting dose gave peak sensitivity on day 10 of infection 
persisting to day S'©with 100% mice showing sensitivity. The lowerI
dose gave a slower development of peak sensitivity probably due to 
longer multiplication time required for the infecting dose to reach 
infection peak. Peak sensitisation occurred on day 15 with 70% of 
the mice showing sensitivity. The degree of sensitivity for the 
lower dose was not as great as the larger dose; however both 
infections gave a sensitivity which lasted beyond 50 days,
. Lung culture and lung pathology examination showed a correlation 
between development of sensitivity and development of infection. 
Characteristic lung pathology was found in 83% of sensitised mice and 
64% had positive lung culture. The duration of sensitivity however 
was much greater than persistance of lung infection. The organisms 
were rarely isolated beyond day 30, \diereas sensitivity was demon­
strated on day 50 for 33-50^ of mice,
Geller and Pittman (1973) found the development of histamine 
sensitivity to peak at day 15-20 and to last well beyond day 50 after
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a sublethal infection. Sensitisation was greater after an IN 
infection with live organisms than an IN instillation of dead organisms 
or an intraperitoneal injection of live or dead organisms. The
5i,p* injection of 2,5 x 10 organisms showed a slow developing
sensitivity with a peak at day 20 compared to a peak at day 4 to 5
9for an i.p. injection of 10 organisms, A possible explanation 
would be a different mechanism of sensitisation occurring with the 
different doses.
Pittman ^  al (1980) reported peak sensitivity of day 20 and 
30 for mouse strains HAMl/CR and Anglia NIH respectively. Although 
data were insufficient to make conclusive correlations, it seemed 
that histamine sensitivity was correlated to infectivity, IRI^ concen­
trations and the ratio of spleen to body weight.
' .1
^IRI “ Immuno reactive insulin,
was not demonstrable after 6 weeks.
■:l.
4.3.3 Immunity to. infection
(i) Acquired by infection
Cooper (1952) examined the immunity which developed after a 
SLIN infection by 2 methods: (i) Reinfection with LIN infection
after 4 weeks and (ii) IC challenge after 4 weeks with doses ranging 
from 5 LD^Q to 100 LD^^. Mice reinfected by the IN route had a 93% 
survival rate. Lung cultures were not made. Resistance to IC 
challenge was greatest with low LD^^ and immunity was maximum 4 weeks
'i,after infection with 80% survival rate against 5-9 LD^^ and 58%
'
survival rate against 50-100 LD^q challenge. Immunity to IC challenge
■■n
tîi
T:;
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Andersen (1953b) reinfected mice with a SLIN challenge after 
10 wk„ Lung cultures were usually negative by day 4 in reinfected 
mice. Control mice still had positive lung cultures at day 26 of 
infection. However it was not stated whether the control mice were 
the same age as the reinfected animals. If the control mice were 
younger the comparison would be invalid, and the inability to establish 
infection in the convalescent mice might have been due to the older 
animals having an age-related resistance rather than specific immunity. 
Development of serum agglutinins occurred around day 38, Andersen 
concluded that acquired resistance after infection was due to systemic 
as well as local immunity,
(ii) After vaccination
Burnet and Timmins (1937) showed that mice immunized with live
cultures of B. pertussis had a significantly higher degree of protection
6 6against IN challenges of 10 x 10 or 100 x 10 organisms than mice 
immunized with formalin-treated cells. Neither vaccine was effective 
against a challenge of 1000 x 10^ organisms. No difference in vaccine 
potency was found when administered either by the i,p, or s,c, route, 
Proom (1947) demonstrated that an i.p. challenge of live 
B, pertussis after vaccination was ineffective for assay of vaccine 
potency, B, pertussis does not multiply in the blood or peritoneal 
cavity of mice and death after an i.p, injection of living organisms 
is due to toxaemia. This does not seem to be relevant to pulmonary 
infections, where antibacterial immunity is believed to be the major 
immune response in clearing infections.
Andersen (1953b) compared results of vaccine potency obtained 
by IC and SLIN challenge. Three vaccine doses were examined:
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120 X 10^, 600 X 10^ and 3000 x 10^ organisms. The largest total dose 
gave the greatest survival rate after IC challenge and the quickest 
clearance of infection from lung after SLIN infection. Correlation 
was found between vaccine potency measured by the IC route and SLIN 
route of infection. Administration of vaccine by the i,p, gave 
better protection than the s.c, route,
Fisher (1955) compared the efficacy of protection of 3 
vaccines, boiled and unboiled, as measured by 3 different challenges; 
IC, LIN, SLIN infections, A strong correlation was found when 
vaccine potency was measured by the IC and SLIN routes of infection. 
The protective antigen against both IC and SLIN challenge was found 
to be heat labile (100°C), Survival after LIN challenge showed no 
correlation with the other routes of infection and also the protective 
antigen by this route was heat stable (lOO^C),
Andersen and Bentzon (1958) also compared vaccine potencies 
as measured by the IC and, SLIN challenge procedures. Using the same 
highly mouse virulent strain for both routes of infection similar 
results were obtained. However SLIN challenge results had greater 
variation in protective potency of vaccine when freshly isolated 
strains were used. The mice were infected at 5 weeks and therefore 
were less susceptible to infection than at the normal age for giving 
SLIN infection. Standfast and Dolby (1961) also confirmed a 
correlation between vaccine potency measured by IC and SLIN route of 
infection which did not correlate with the LIN infection.
Intranasal vaccination has been investigated. North and 
Anderson (1942) found it to be more effective than i,p. vaccination 
when mice were challenged with 50 x 10^ infecting dose 7 days after
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vaccination. Intranasal vaccination showed an elevated non specific 
local immunity against organisms with antigenic relationships to 
B» pertussis, ie H, influenza and B. parapertussis. Histological 
examination of lungs of immunised mice Infected with these organisms 
showed a marked cellular infiltration. However this comparison 
between vaccination routes might not have been strictly valid since 
14 days, not 7, is the usual time interval allowed for systemic 
Immunity to develop. Complete development of general immunity would 
not have occurred in the i.p, vaccinated mice.
Cooper (1952) was unable to demonstrate immunity after IN 
vaccination when he infected mice by the IC route over a 5 week 
period. However Andersen (1953) demonstrated general immunity after 
a total IN vaccine dose of 2000 x 10^ organisms in that the mice were 
able to survive an IC challenge. However IN vaccination was more 
dependant on vaccinating dose than i,p, or s.c, vaccination, Dolby 
£t al (1961) found vaccination by the IN route had a PD^^ of 1650 x 10^
-i', Acompared to of 190 x 10 for the i,p, route,
(iii) After passive immunization
North £t ^  (1939) examined the protective value of a range 
of i.p. injected sera against IN infections. Sera from adult 
contacts gave best protection against a LIN infection. Convalescent 
and immunized children's sera were eqpafly effective in lung clearance, 
Evans (1940) found he could remove antibacterial activity from 
rabbit anti-B, pertussis sera and leave anti-HLT, However Anderson 
and North (1943) found no anti-HLT activity in adult contact sera 
which led them to believe that anti-HLT was of little value in IN 
infections. Death after an i,p, injection of H. pertussis was
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prevented by anti-HLT but not by antibacterial serum (Proom, 1947)* 
However an i.p. injection of antibacterial serum prevented a SLIN 
infection. Antitoxin had no effect when given by the i.p. route, 
Evans (1944) demonstrated protective value of intranasally 
introduced antitoxin when mixed with the infecting dose. There was 
a 40% reduction in infected lungs and 100% reduction in mortality.
Thus anti-HLT appeared to be protective when at the site of infection. 
North (1946) concluded that antibacterial sera was almost as 
effective as anti-HLT sera when given intranasally 24 h before IN 
infection.
When, antisera were given 24 h before IN infection, anti­
bacterial sera was of greater protective value than.anti-HLT sera
(Proom, 1947), Phase I and IV sera antibacterial sera and horse■
hyperimmune sera were all shown to protect against IN challenge of 
50 X 10^ organisms, .Immune sera given 14 days after infection
dramatically reduced growth. Within seven days the lung culture of
-most mice was negative. However Proom could only demonstrate
passive protection of antisera against SLIN and not against LIN. infection.
North (1946) demonstrated protective antibodies in mouse 
sera 30-50 days after SLIN infection. Andersen (1953b) found that
Sato et al^  (1981) found that the i.p. injection of anti-LPF 
and anti-F-HA before aerosol challenge protected mice, as evidenced by 
survival and normal rate of body weight gain,
-4,3,4 Nature of immune response
I
the onset of serum agglutinins and protective antibodies to 
reinfection were simultaneous around day 40. However serum
53
agglutinins were not always present in sera that were passively 
protective. Cooper (1952) also found protective antibodies against 
intranasal reinfection by day 28. However both these results may be 
influenced by the age of the mouse at reinfection rather than by a 
state of specific immunity. No passive protective antibodies or 
agglutinins were present on Day 15 (North, 1946; Andersen, 1953b). 
Complement-fixing antibodies were not present on day 8 of infection 
(Cooper, 1952),
Geller and Pittman (1973) examined the classes of immunoglobulins 
present in the tracheobronchial washings (TBW) and sera of SLIN 
infected mice. An increase in B. pertussis specific IgA, IgG, 
and IgG2^ was shown in the TBW, beginning on day 15 and persisting to 
day 50, The serum immunoglobulin did not show such a marked change 
except for IgA which increased on day 30, The appearance and 
gradual increase of Ig in the lung, corresponded to the disappearance 
of organisms between 20 to 30 days. Pittman.(1976) investigated the 
importance of IgA in the clearance of organisms from the lung. She 
found IgA concentrations in convalescent mouse sera increased in 
parallel with the passive protective activity of similar sera to LIN 
murine infections (the latter had been previously demonstrated by 
Winter, 1953).'
OBJECT OF RESEARCH
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Pertussis, or whooping cough is still a very poorly understood 
disease, despite the elapse of over 70 years since Bordet and Gengou 
isolated the causative organism Bordetella pertussis.
In common with many human pathogens, B. pertussis while 
transmissable to laboratory animals, does not set up an infection 
which fully reproduces all the features of the human disease.
Recently there has been reawakened interest in the B. pertussis 
intranasally-infected mouse as providing a useful experimental model 
of pertussis in man. By choice of appropriate infecting doses, mice 
can be given either a lethal or a sublethal pulmonary infection by 
the IN route. It is the sublethal pulmonary infection of the mouse 
which provides the subject for this investigation.
The object of the investigation was to determine the nature 
of the immune response which develops during the course of the murine 
sublethal pulmonary infection and to relate it as far as possible to 
what is known about the human disease.
I
MATERIALS AND METHODS
55
SECTION I ; STRAINS, MEDIA AND CULTURAL PROCEDURES
1.1 Strains
Three Phase I strains and one Phase IV strain of B, pertussis 
were used.
Strain 18-323 Phase I was obtained from two different sources;
(i) Dr, M, Pittman of the Bureau of Biologies, Food and Drug 
Administration, Bethesda, Maryland, U.S.A. This strain is 
referred to as 18-323 (P),
(ii) Dr, F, Sheffield of the National Institute for Biological 
Standardization and Control, Hampstead, London, This strain is 
referred to as 18-323 (S),
Strain 18-334 was a Phase I vaccine strain from the Connaught 
Laboratories Limited, Toronto,
Strain 77/18319 was a Phase I fresh isolate supplied by 
Dr, R, Fallon, Ruchill Hospital, Glasgow,
The Phase IV strain was ;
Strain D30042 from Dr, J,M, Dolby of the Lister Institute 
of Preventive Medicine, Els tree, Herts,
All strains were maintained freeze-dried and also frozen 
after suspension in liquid nitrogen in a fluid containing 1% Casamino 
Acids (CAA) and 10% glycerol,
1.2 Media
The following were used for the cultivation of B. pertussis: 
Bordet-Gengou agar (BG), The agar base was obtained from
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Gibco Bio-cult Diagnostics Ltd., Paisley, Scotland, and after 
rehydrating and autoclaving was mixed at 45^C with defibrinated horse 
blood from the same source to give 17% (v/v) blood.
A modified Cohen and Wheeler medium (Sato and Arai, 1972),
A modified Hornibrook medium (Parton and Wardlaw, 1975).
The composition and preparation of these media are given in 
Appendix 1.
1,3 Growth of cultures
Freeze-dried cultures were reconstituted with 1% (w/v) CAA 
(Appendix 1) and grown on B,G. for 72 h at 35^C in a plastic box 
containing a beaker of water to saturate the atmosphere. Liquid 
nitrogen suspensions were left to thaw at room temperature and grown 
on B,G, for 24 h at 35°C,
1.3.1 Challenge cultures
Liquid nitrogen suspensions were inoculated onto B.C. and 
incubated at 35°C for 24 h. These were then subcultured on B.G, 
and Incubated at 35°C for 24 h,
1.3.2 Batch cultures
One millilitre of 100 opacity units (o.u,) suspension of
B. pertussis 77/18319 was inoculated into Roux bottles, laid flat^
I
ii
-•
'I
■ containing 100 ml modified Cohen and Wheeler medium and incubated
at 37^C for 5 days without shaking. The suspension was then
.centrifuged at 10,000 rpm for 30 min at 4°C to obtain culture 
supernate.
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1.4 Standardisation of bacterial concentrâtion by opacity
The concentration of bacterial suspensions was estimated by 
comparison with the International Opacity Reference Preparation 
supplied by the World Health Organisation International Laboratory 
for Biological Standards (National Institute for Biological Standards 
and Controls, Holly Hill, Hampstead, London), This standard is
defined as having 10 o,u, and consists of a plastic rod mounted in a I
6 X 5/8 test tube. This and the bacterial suspension were matched I
by viewing a printed card through both tubes until the density of I
the bacterial suspension equalled that of the opacity rod (Perkins I
et al, 1973), The dilution factor used to obtain matching of the j
cell suspension with the reference preparation was calculated and I
multiplied by 10 to give the concentration of the undiluted bacterial |
Isuspension in opacity units (o,u.), !
IA concentration of 10 o,u, was found to be equivalent to I
Iapproximately 2,5 x 10 dcolony forming units (c,f,u,) of a 24 h |
Iculture o f  B, pertussis strain 18-323 freshly harvested f r o m  BG, I
I
!
!1.5 Challenge suspensions of B. pertussis strain 18-323 j
I!
Twenty-four hour growth of B. pertussis strain 18-323 was ;
;scraped off B.G, into C,A,A, and matched against the International iI
Opacity Reference Preparation, The matched 10 o.u. suspension II
( 2,5 X  10 c.f.u. ml )^ was diluted by a factor of 1000 in
dilution steps of 10 to give the challenge suspension for administration
to mice. The bacterial concentration was therefore 2,5 x 10
- 1  ' 5c.f.u. ml and each mouse received 0.05 ml or 1,25 x 10 c.f.u.
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The challenge suspension for an intracerebral infection was 
10^ c.f.u. ml  ^and each mouse received 0.03 ml, or 3 x 10^ c.f.u.
The viable count of each challenge suspension was determined 
by making 10 fold dilutions in CAA and spreading 0.05 ml on each of 
2 BG plates which were incubated at 35°C for 5 days, when the colonies 
were counted.
SECTION II ANIMALS AND ANIMAL PROCEDURES
2.1 Mice
Mice were from a randomly-bred closed colony originally 
derived from the HAM 1/CR strain (Charles River, U.K. Ltd., Manston 
Road, Margate, Kent), They were kept in a room at 22^C in a 12 h 
light cycle and maintained with standard pelletted diet on peat litter 
and with water ^  lib,
2.2 Administration of fluids intranasally
The method of Burnet and Timmins (1937) was used for the IN 
infections except that ether alone, rather than an ether/chloroform 
mixture, was used as the anaesthetic. Mice, 3-4 wk old and of either 
sex were placed in groups of up to 5, in a glass jar fitted with an 
ether-soaked pad in the lid. They were kept in the jar until they 
were unconscious and were breathing deeply and at a regular rate.
They were then removed from the jar, held so that the'nose was 
vertical and the challenge fluid administered by placing 2 drops of 
0.025 ml volume from a calibrated dropping pipette (Dynatech, Kloten,
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Switzerland), The drops were usually inhaled rapidly but if the 
breathing was irregular spluttering occurred. After recovering from 
anaesthesia, which took around 2 rain, the mice were then colour coded 
by rubbing blue, red or yellow dye on head, back or rump and put back 
into their cages. The whole process of challenging a batch of mice 
was completed within an hour so that the bacterial suspension did not 
age unduly from beginning to end,
2.3 Administration of challenge suspension intracerebrally
Mice, 3-4 wk old and of either sex, were anaesthetised (as 
in 2,2) and were injected IC with 0.03 ml of challenge suspension 
containing approximately 3 x 10^ cfu B. pertussis 18-323 (P) or (S)
organisms. The challenge was given at right angles to the skull,
through the parietal bone and using a 26 x 5/8 needle and 1 ml 
syringe.
The virulence of the challenge suspension was titrated by 
injecting groups of mice with dilutions 1/10, 1/50 and 1/250 by the 
same technique.
Again the mice were colour coded with similar dyes after 
recovery from the anaesthetic. Intracerebral injections were always 
completed within 90 min of harvesting the cells,
2.4 Collection of serum
.1The mice were anaesthetised individually in an ether jar, 
then secured to an operating board and kept under ether anaesthesia 
with a small beaker containing a cotton wool pad soaked in ether
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held over the head, A 2 ml syringe with a 25 gauge 5/8" needle was 
used to withdraw blood by heart-puncture through the rib cage. The 
volume of blood usually obtained was 1,5 ml. Normally, the bloods 
from a large number of mice were pooled and allowed to clot in a 
universal container, for up to 5 hr at room temperature before 
separating the serum by two successive centrifugations at 3,000 rpm 
for 15 min. The cell free supernatant serum was removed and dispensed 
into 2 ml aliquots and kept at -70^0,
2.5 Collection of tracheobronchial washings (TBW)
After each heart-punctured mouse had died as a result of 
exsanguination, a longitudinal incision was made in the ventral surface 
of the abdomen and the skin and fatty tissue cleared from around the 
trachea. The rib cage was opened to allow the lungs to expand 
freely. The interior of the lungs was then washed out by making a 
small incision in the wind-pipe and flushing in 1 ml of sterile 
saline via a canula made from constricted plastic tubing and attached 
to a 2 ml syringe. After 30 sec, the fluid (usually about 0,75 ml) 
was withdrawn, and pooled in a universal container held on ice. The 
pooled TBW were centrifuged at 10,000 rpm for 30 min, dispensed into 
2 ml aliquots and kept at -70^C, All TBW were millipore filtered 
(0,45 |im) before use In case viable B, pertussis was present,
2.6 Removal of blood for leucocyte count
Mice were anaesthetised (as in 2,2) and bled from the orbital 
plexus with heparinized capillary tubes (Harshaw Chemicals Ltd,,
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Daventry, Northhants, England), The blood sample (40 pi) was 
immediately transferred with a Coulter pipette to plastic vials 
containing 20 ml Isoton II diluent (Coulter Electronics Ltd., 
Harpenden, Herts, England) to give a final blood concentration of 
1:501 (v/v)o
Immediately before counting, six drops of Zap-Oglobin 
(Coulter Electronics Ltd., Harpenden, Herts, England) were added to 
each vial to lyse the red blood cells. The leucocyte were counted 
in a Coulter Counter model FN (Coulter Electronics Ltd., Harpenden, 
Herts, England), Duplicate counts of each diluted blood sample 
were made and the mean of the counts ml  ^was calculated for each 
sample. Mean background counts were subtracted from each mean. To
correct for coincidence losses during counting, mean counts above 
10,000 were adjusted with a coincidence correction chart,
2.7 Histamine sensitisation
Normal mice, convalescent mice and mice given graded doses of 
pertussis vaccine were tested for histamine sensitivity by being 
injected intraperitoneally‘with 3 mg of histamine dihydrochloride 
(Sigma Chemical Co., St, Louis, Mo., U.S.A.) contained in 0,5 ml of 
saline. Survivors were counted 2% h afterwards.
2.8 Autopsy
Mice were killed by dislocation of the neck, dipped in a.!
beaker of disinfectant (hibitane) and pinned out on a board. The 
thorax was opened with sterile scissors and forceps (sterilized by
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dipping in alcohol and flaming) and the lungs inspected for signs of 
consolidation, ie greyish-coloured areas. Healthy lungs were scored 
as 0, doubtful were scored as 1, Definitely infected lungs were 
scored from 2, where there were a few areas of consolidation, 
examples of which are shown on Plate 1, to 4 for complete or almost 
complete consolidation in all lobes of lungs. These gradations are 
illustrated in Figure 2,
A small portion of lung from the smallest of the right hand 
lobes was also taken with sterile scissors and forceps and the cut 
surface smeared onto a BG plate. After 4-5 d of incubation at 35°C, 
"culture scores" were allocated for the resultant B, pertussis growth 
as follows: 0 for no growth; 1 for 1-9 colonies; 2 for 10-99;
3 semi;confluent and 4 confluent (the criteria established by North, 
1946), In both lung pathology and culture scores values greater than 
or equal to 2 were considered to represent a significant departure 
from the normal,
2,9 Subcutaneous inoculation of suckling mice
As an assay of HLT, fluid was injected subcutaneously into the 
back of the neck of 4 day old suckling mice of either sex in 0,05 ml 
volumes using a 1 ml syringe and 25 x 5/8 needle. The mouse was held 
between the thumb and forefinger face down on the bench. Care was 
taken to wear surgical gloves when handling suckling mice to minimise 
any smell of the handler being left which might lead to maternal 
rejection. After injection, the mouse was colour-coded with blue dye 
on the back, rump or left or right leg and returned to the litter as 
soon as the dye had dried.
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Plate 1, Examples of mouse lungs with pathology score 2
-ï'-r
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Figure 2, System pf pathology scores in lungs of B, pertussis 
infected mice. Areas of consolidation are shaded,
SCORE 1 SCORE 2
SCORE 3 SCORE 4
XXX X
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SECTION III BIOCHEMICAL PROCEDURES
3,1 Protein estimation
The composition of the reagents is given in Appendix 2, The
protein concentration of TBW was measured by the method of Herbert,
Phipps and Strange (1971) with bovine serum albumin (BSA) as the
standard,
(i) A, volume of 0,5 ml of. distilled water was pipetted, into 
duplicate, tubes .as reagent blanks,
(ii) Samples were tested at undiluted and 1/5 dilution in 0,5 ml 
volumes in duplicate tubes,
(iii) The BSA standard protein was diluted to give concentrations 
of 500, 400, 300, 200, 100 and 50 pg ml Volumes of 0,5 ml 
of each dilution was pipetted into duplicate tubes,
(iv) All tubes received 0.5 ml 1,0N NaOH, boiled for 5 min, removed 
and allowed to cool,
(v) All tubes received 2.5 ml of Reagent C and vortex mixed,
(vi) After 10 rain incubation at room temperature, 0,5 ml of 
Reagent D was added to each tube and mixed immediately,
(vii) The tubes were then left at room temperature for 30 rain for 
full colour to develop,
(viii) The optical density was measured at 750 nm, each sample being 
measured against the reagent blank,
(ix) A standard curve of ODy^g versus BSA concentrations was plotted 
and the protein concentrations of TBW determined by interpolation 
on to that curve,
I
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3.2 Lysozyme assay
The method was the Lysoplate procedure modified from that 
described by Osserman and LawlOr (1966), Lysoplate preparation is 
given in Appendix 3,
Doubling dilution of hen egg-white (H,EoWo) lysozyme (Sigma,
London) over the range 40 to 0,3125 pg ml  ^were prepared in 0.15M 
phosphate buffered saline pH 6,4 as were doubling dilutions of pooled 
day 15 TBW, Aliquots of each dilution together with buffer controls 
were applied in duplicate to each lysoplate system, incubated at 
20°C for 20 h and the diameters of the resultant zones of clearance 
recorded. This showed that.pooled day 15 TBW gave a response parallel 
to H,E.W, lysozyme over the same dilution range.
Subsequently assays of TBW were made with H,E,W« lysozyme as 
standard,
3.3 Method for concentrating TBW
Pooled TBW from convalescent mice, eg a volume of 40 ml, was 
millipore filtered (Pore size 0,45 pm, Millipore, Millipore S.A., 67120 
Molsheim, France) to remove particulate matter and then placed in 
dialysis tubing (Medicell International, Liverpool Road, London) which 
had been boiled twice in saline and well rinsed. The tubing was 
then put in a plastic box which had Calbiochera Aquacide III (MW c.a.
20,000, C,P, Laboratories Ltd,, Bishops Startford, Herts) as a layer 
on the bottom. The tubing was cqvered with aquacide III and allowed 
to stand for 3 h, when fresh aquacide was layered over. After a 
further 2 h, the aquacide was removed from the outside of the dialysis
: a
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tubing and the tubing washed thoroughly. Typically a 10-fold concen­
tration was achieved.
SECTION IV IMMUNOLOGICAL STANDARDS AND PROCEDURES
4.1 Standard Vaccine
The standard vaccine was a freeze dried preparation of
B. pertussis 18-334 in an ampoule containing 220 o.u, ml, ie 2,2 ml of 
100 O . U . ,  and was prepared in this department by A.C. Wardlaw and 
R, Parton in November 1977. It is referred to as Glasgow Standard 
Pertussis Vaccine,
4.2 Standard Antisera
(i) The U.S. Standard Antipertussis Serum (rabbit concentrated) 
Lot No, 2 supplied by C,R, Manclark (Division of Biologies Standards 
National Institutes of Health, Bethesda, Maryland, U.S.A. was the 
only standard antiserum used in all the immunological assays,
(ii) Rabbit antiserum prepared in this department by Dr, I, 
Livey against toxoided B, pertussis strain 134 supernatant lysate and 
containing 120 antitoxin units ml  ^was also included as a known 
positive ëtandard in the neutralisation of HLT haemorrhagic activity 
in suckling mice. Particulars of this material are given in the 
Ph,D, thesis of I, Livey (1982),
(iii) Rabbit antiserum prepared by J, Hertz ( Hvidovce Hospital, 
Copenhagen,Denmark) raised against X mode 18-334 B, pertussis was 
incorporated in the back gel when determining the precipitin response 
by quantitative iramunoelectrophoresis.
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4.3 Inactivation of IgM and IgE
IgM in pooled convalescent sera and lOx concentrated TBW was ;
inactivated by adding 0,2 ml to 1,6 ml saline and 0,2 ml l.OM mercapto- 
ethanol. The mixture was incubated at room temperature for 1 h. The 
sample mixture was then made to the required dilution and used 
immediately (NowOtney, 1969),
IgE from pooled, convalescent serum at 1/5 dilution in saline 
and lOx concentrated TBW at 1/5 dilution in normal serum was inactivated
4,4,1 Titration of optimum concentrations for immunoglobulin in 
class precipitation from pooled serum and TBW
The titration to find the optimum concentrations of goat 
anti-mouse serum and convalescent samples which would precipitate the 
Ig classes was done by immunodiffusion. The composition of reagents 
is given in Appendix 4, Clean glass slides (10 x 50 mm) were placed 
on a levelling tray and 5 ml of molten 0,757, barbitone agar were
by heating at 56°G for 4 h. The sample was then stored at 4°C until 
needed. This was the method used by Wardlaw ^  aT (1979) to remove 
IgE from sera.
4,4 Removal of IgG and IgA from pooled serum and TBW
The IgG and IgA were removed from convalescent serum and TBW 
by precipitation with the corresponding goat anti-mouse serum, ie 
anti-mouse IgG (heavy and light chains) and anti-mouse IgA (alpha 
chain specific) of Cappel Laboratories, Inc., Cochranville, P,A,, 
19330, U.S.A.
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spread evenly over the slide with a pipette. Wells of 3 ram were 
cut in paired rows with 1 cm between the adjacent wells and 0,5 cm 
from the opposite well.
The range of dilutions in the titrations of reactants and their 
optimal concentrations were as follows,
(i) Goat anti-mouse IgG at 1/5, 1/10 and 1/20 dilutions and pooled 
day 61 convalescent sera at 1/50, 1/100, 1/200 and 1/400 dilutions 
(PLATE 2).
(ii) Goat anti-mouse IgG at 1/5, 1/10 and 1/20 were used and the 
lOx concentrated pooled day 48 convalescent TBW at 1/5, 1/10, 1/20 
and 1/40 dilutions (PLATE 3),
(iii) Similarly goat anti-mouse IgA at dilution 1/5, 1/10 and 1/20 and 
pooled day 61 convalescent serum at 1/5, 1/10, 1/20 and 1/40 dilutions 
(PLATE 4).
(iv) Finally goat anti-mouse IgA at dilutions 1/2, 1/4 and 1/8 
and lOx concentrated pooled day 48 at neat 1/2, 1/5 and 1/10 dilutions 
(PLATE 5),
The four plates were held for 18 h at room temperature, washed, stained
and lines of precipitation recorded, ftp arrow on e&cK pL-Stfi- indLCâtsS th e  
f>re,Qlpitin Line where it  the. were rocxjKL'^  s t t^îmâL diL/tion^ .
4.4,2 Precipitation of IgG and IgA from pooled sera and TBW
Having determined the dilution range within which optimal 
precipitation proportions of goat anti-mouse sera and pooled convales­
cent mouse sera and TBW occurred, the next step was to perform the 
precipitations over a dilution range to determine optimal dilutions 
of the various reactants. This was done by mixing equal volumes 
of reactants (dilutions are given in Table 6) and incubating the
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Plate 2 Determination of the range of concentrations of pooled
day 61 convalescent sera and of goat anti mouse IgG
used to precipitate IgG
Anti IgG Dilutions
C.S. dilutions
Anti IgG dilutions
C.S, dilutions
1 1 1 1 1 15 10 20 5 10 20
0 , 0 . 0 0- . 0 . 0
0 0 0 0 0 0
1/50 1/100
1 1 1 1 1 1
5 10 20 5 10 20
0 . 0 . 0 , 0 . 0 . 0
0 0 0 0 , 0 0
1/200 1/400
a Anti IgG = Goat anti mouse IgG
b C.S, = Pooled day 61 convalescent sera
I
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Plate 3 : Determination of the range of concentrations of lOx
concentrated pooled day 48 convalescent TBW and of
goat anti mouse IgG used to precipitate IgG
Anti IgG^ 1 1 1 ■ 1 1 . 15 10 20 5 10 20
. 0 . 0 . 0 . 0 . 0 . 0
0 0 0 0 0 0
C.TBW^ 1/5 1/10
Anti IgG 1 1 1 1 • 1 ■ 15 10 "20 5 To 20
. 0 . 0 . 0 . 0 . 0 . 0
0 0 a 0 0 0
C.TBW 1/20 1/40
a Anti IgG = Goat antimouse IgG
b C.TBW = concentrated pooled day 48 convalescent TBW
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Plate 4 : Determination of the range of concentrations of pooled
day 61 convalescent sera and of goat anti-mouse IgA
used to precipitate IgA
Anti IgA dilutions 110 120 110 i20
. 0 
0
C.S. dilutions 1/5 1/10
Anti IgA dilutions 1
5
110 120 110 120
. 0 
0
C.S, dilutions 1/20 1/40
a Anti IgA = Goat anti- mouse IgA
b C.S. = pooled day 61 convalescent sera
r ? f
*T I "'
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Plate 5 : Determination of the range of concentrations of lOx
concentrated pooled day 48 convalescent TBW and of goat 
anti;-mou3e IgA used to precipitate IgA
Anti IgA
. 0 
0
. 0 
0
C. TBW Neat 1/2
Anti IgA 18 ■ 1 4
Ô . 0 
0 0
0 . 0
C.TBW 1/5 1/10
a Anti IgA = Goat anti-mouse IgA
b C.TBW= lOx concentrated pooled day 48 convalescent TBW
sc^T.'c^ciiS'et'
a W m w e B B M l È B e é J
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mixtures at 37°C for 1 h» The mixtures were then centrifuged at
10,000 rpm for 2,5 min in the microfuge. The supernates were 
removed and kept at 4°Co
Immunodiffusion of these supernates was next done against 
wells containing the corresponding antigen and antibody. Glass slides 
(10 X  50 mm) with 5 ml of barbitone agar were prepared as previously 
described, A row of 3 mm wells were cut with 1 cm between each.
Two troughs were cut with 1 cm between each, ie the twon troughs: were cut 
0,5 cm from either side of the wells. One trough was filled with 
pooled convalescent sera and the other with goat anti-mouse sera.
After 18 h at room temperature the slides were washed, stained, 
dried and inspected to determine which supernate failed to precipitate 
with either antigen or antibody. This was taken as the optimum 
proportion mixture. Appendix 13, 14, 15 and 16 contain the plates 
of each determination of optimal dilutions for the 4 groups given on 
Table 6.
4,5 Absorption of pooled sera with Phase I and Phase XV B, pertussis
The dose of fehase I B, pertussis 18-323 which removed all 
phase I agglutinins from pooled day 48 convalescent serum was 
determined. Doses of 5, 10, 25, 50 and 100 o.u. ml (Wardlaw, 1980) 
of 24 h BG grown B, pertussis 18-323 were suspended in 1 ml saline and 
centrifuged for 2,5 min at 10,000 rpm in a microfuge (Beckman, High
Wycombe, Bucks.), These pellets of live bacteria were resuspended
,fthoroughly in 0,5 ml pooled day 48 convalescent serum to give final 
concentration of 10, 20, 50, 100, 200 o,u, B, pertussis. The
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mixtures were left for 18 h at 4°C and microfuged again for 2.5 min at
10,000 rpm and the supernates removed. The concentration of bacteria 
which removed all B, pertussis Phase I agglutinins was found to be 
200 o.u, and this was termed the Standard Absorbing Concentration 
(S oAoC O) o
Aliquots of 0,5 ml of pooled day 48 convalescent sera were 
absorbed with 1 S.A.C, or 5 S.A.C. Phase I 18-323 or the same concen­
tration of B, pertussis Phase IV D30042, Pooled normal serum was 
absorbed with 1 S.A.C, B, pertussis Phase I, All of the above 
absorptions were done with live organisms and the final treated sera 
were diluted to 1/10 in saline and millipore filtered before use,
4,6 Bacterial agglutination
A modification of the method of Preston (1970) was used.
Saline (0,02 ml) was added to all wells except the first in each row 
in a Cooke Microtitre Tray (Sterilin Ltd., Sussex), Sample (0,02 ml) 
was added to the first 2 wells and doubling dilutions of the sample 
made, starting at the second well and using an automatic pipette 
with a fresh tip for each transfer. To each well, 0.02 ml of 30 o.u, 
live B, pertussis suspension prepared from 24 h growth on a BG plate 
was added.
Duplicate controls were prepared of (êO 0,02 ml of saline and
mixing. The trays were incubated for 30 min at 56^C, removed and
I
0.02 ml of 30 o.u, B. pertussis and (b) 0,02 ml of saline and 0.02 ml— ----------
of serum or TBW, Microtitre trays were then secured into a
IGallenkamp orbital shaker for 5 min at 180 rpm to ensure thorough
results read immediately and 2 h later. The agglutinin titre was the
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reciprocal of the last dilution showing definite clumping visible to 
the naked eye with the tray illuminated obliquely from below.
4.7 Anti-F-HA
This antibody was assayed by haemagglutination inhibition as 
follows: Saline (0.05 ml) was added to each well except the first
well in each row of a Cooke microtitre tray. Sample of serum or TBW 
being tested for antibody (0,05 ml) was added to the first two wells 
in each row and doubling dilutions made starting at the second well. 
Eight haemagglutinating units of culture supernate of B, pertussis 
strain 77/18319 grown in a modified Cohen and Wheeler Medium were 
added to each well and trays left at room temperature for 30 min.
To each well was then added 0,05 ml of 27. Horse RBC and the trays 
incubated for 1-2 h at 37°C, The reciprocal of the highest dilution 
of sample to show complete inhibition of haemagglutination was 
recorded as the haemagglutination inhibition titre (HAI titre),
4.8 Anti LPS
PBS (0.05 ml) was added to all wells except the first in each 
row in a Cooke Microtitre Tray (Sterilin Ltd., Sussex), Sample 
(0,05 ml) was added to the first 2 wells and doubling dilutions of 
the sample were made starting at the second well using an automatic 
pipette with a clean tip for each transfer. To each well, 0,05 ml 
of 27o HRBC previously coated with LPS (preparation in Appendix 5) 
was added.
Duplicate controls were prepared consisting of (a) 0,05 ml of
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veronal buffer and 0,05 ml of sample,(b) 0,05 ml of PBS buffer and 
0,05 ml of 2% coated HRBG, (c) 0,05 ml of PBS buffer and 0.05 ml of 
27o uncoated HRBG and (d) 0,05 ml of sample and 0,05% of untreated HRBG,
Mixtures were shaken and results read after 18 h at room 
temperature. The reciprocal of the highest dilution showing full 
agglutination of the LPS-coated HRBG was taken as the agglutination 
titre,
4.9 Anti-LPF in the convalescent mouse
B, pertussis-infected mice at various times after initiation of 
a pulmonary infection, and normal mice, all at approximately the same 
age, were injected intraperitoneally with 0,5 ml of three graded doses 
of Glasgow Standard Pertussis Vaccine (as In 4,1), Five days after 
inoculation, blood was removed for leucocyte count (as in 2,6), After 
the mice had recovered from anaesthesia, they were replaced in their 
cage and their histamine sensitivity was tested the following day,
4.10 Anti-HSF
4,10,1 In convalescent serum and TBW
Pooled sera and TBW were mixed with equal volumes containing 
either 10 or 20 HSD^^ of Glasgow Standard Pertussis Vaccine suspended 
in saline; after thorough mixing the samples were held for 18 h at 
4°G, Six to seven wk old HAM 1/CR mice of either sex were injected 
intraperitoneally in groups of 7 or 14 with 0,2 ml of mixture thereby 
giving each mouse 1 or 2 HSD^g (in the absence of neutralisation by 
antibody). Groups of 7 mice of 6»7 wk were injected intraperitoneally
79
with 0,2 ml of graded doses of vaccine sample alone to check the 
number of HSD^^ being used. Additional control mice were injected 
with saline. Five days later histamine sensitivity was measured as 
in 2 0 7,
4.10*2 In the convalescent mouse
B, pertussis infected mice at various stages of convalescence 
from pulmonary infection as in 4,9 with normal mice of the same ages 
as controls were examined for histamine sensitivity as in 2,7,
4.11 Anti-HLT
Anti-HLT was assayed by neutralization of haemorrhagic activity 
of B, pertussis cell-lysates in 4-day old suckling mice. For maximum 
sensitivity, the tests were done by mixing the HLT-containing lysate 
with an equal volume of serum or TBW so that the final mixture contained 
1 standard haemorrhagic dose (a dose which produced significant haemorr­
hage) in 0,05 ml. After 18 h at 4^C, each mixture was injected into 
a group of 2 or 3 suckling mice which were inspected 24 h later for 
haemorrhagic reaction,
4.12 Bactericidal activity
4 -1A dilution of 10 organisms ml was made from 24 h BG growth
of B, pertussis 18-323 suspended in CAA and 0,5 ml was added to 0,5 ml
of the serum or TBW samples, CAA (0,5 ml) was used as control to
determine the cfu of the organism added. Mixtures were shaken and
incubated at 37^0 for 90 min when samples were removed and duplicate
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0,025 ml portions spread on BG plates. These were incubated at 35°C 
for 5 days and the mean cfu were determined.
4.13 Crossed-over Immunoelectrophoresis
The composition of reagents is given in Appendix 4, The 
method of CuUliford (1964) was followed. Clean glass slides (75 mm x 
50 mm) were placed on a levelling tray and 12 ml of molten 0.757, 
barbitone agar were spread evenly onto the slides using a pipette.
The agar was allowed to solidify and left for 20 min at 4^C, Wells 
of 3 mm were cut in paired rows with 1 cm between the adjacent wells 
and 0,5 cm between the rows. Within each pair of rows samples were 
dispensed in the row placed nearest the anode and antigen preparation 
in the row opposite and put nearest the cathode on the electrophoresis 
chamber (Shandon type). Antigens, Phase I 18-323, Phase IV D30042 
and G Mode 18-334 were prepared by scraping 72 h growth on BG plate 
into CAA to give a thick suspension. They were sonicated (Ultrasonic 
Disintegrator, Measuring and Scientific Equipment Ltd., London) for 
6 X 20 sec until the suspension had become opaque. Wells were filled 
using an automatic pipette.
The slides were placed in the electrophoresis chamber with the 
antigen preparation of each paired row near the cathode and electro- 
phoresed for 30 min at 100 volts (Vokam power pack).
Slides were left in barbitone buffer and left overnight to 
remove unreacted protein. They were washed twice in distilled water
and stained for 10 rain in amino black saturated solution (E, Gurr 
Ltd,, Michrome Ltd., High Wycombe, Bucks), The gels were destained
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in 27, acetic acid for 24 h. The slide was then placed in 27, acetic 
acid/1% glycerol to prevent the dried gel flaking off the slide.
Slides were dried with a thick pad of tissues with a weight on top 
for approximately 30 min. Finally the slides were completely dried 
with a blow-drier.
4.14 Quantitative immunoelectrophoresis
This was done by the method of Hertz £t al^  (1979) in which the
- 2test samples were incorporated into the intermediate gel (40 |il cm ) 
using B, pertussis 18-334 sonicate reference antigen and rabbit 
antiserum (Hertz antiserum as in 4.2) in the back gel.
Antigen preparation was as follows: Phase I B. pertussis
18-334 grown on BG medium at 35^C for 72 h was suspended in modified 
Hornibrook medium containing 5 g NaCl 1 * to give X mode cells. The 
cells were incubated at 35^C for 72 h, then sonicated for 3 x 45 sec 
exposures, ice-cooled, at 20,000 Hz/sec using a Rapidis 300, 19 mm 
probe with a 9,5 ram tip. The sonicate was then centrifuged at
48,000 g for 60 min at 4°C and the supernatant was stored at -30°C.
The colloid concentration of supernatant used was 12,5 g l"^.
Rabbit antisera to the sonicate was prepared for the back 
gel as follows: Rabbits were immunized intradermally with sonicate
in Freund*s Incomplete Adjuvant, each animal receiving 100 pi of 
antigen per immunization. All rabbits were immunized for at least 
6 months,
Immunoelectrophoretic analysis of test samples was performed 
on 5 X 5 cm glass plates using 17, agarose (Indubiose A 37) in Tris-
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barbital buffer, pH = 8,6 ionic strength = 0,02,
First dimension electrophoresis of 2 pi of antigen were run 
o “2for 30 min at 12 G 10 volts cm , second dimension electrophoresis 
-2for 18 h, 2V cm . Test samples were in the intermediate gel and 
rabbit antisonicate (20 pi) in the second gel, Coomassie Brilliant 
Blue - R was used to stain the precipitates.
4,15 Sublethal intranasal passive protection activity
Pooled serum and TBW were titrated for ability to protect
53-4 wk old mice from SLIN challenge with approximately 1,25 x 10 cfu 
of 24 h BG grown B, pertussis 18;323 (P), Serial dilutions of 
samples were made and equal volumes of each mixed with the challenge 
suspension (SLIN/mix) (North, 1946), Controls included the same 
dose of cells mixed with 17, CAA. The mixtures were allowed to stand 
for 15 min and then administered to the mice in not more than 75 min 
thereafter. Each was instilled in 2 x 0,025 ml drops into ether- 
anaesthetized mice as in 2,2, To minimize bias mice were distributed 
between cages so that each cage contained animals representing each 
type of treatment.
Pooled day 48 convalescent serum (at 1/20 dilution) and TBW 
(at 1/2 dilution) were also intranasally instilled in 2 x 0,025 ml 
drops to each mouse at intervals of 48, 24 or 6 h before the mice were
5challenged with approximately 1,25 x 10 cfu each. This was to see 
if passive protection could be achieved by administering the serum 
or TBW before the challenge.
The mice were inspected daily for 14 d on which day they were 
autopsied as in 2,8, The difference between the results from control
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and test groups were tested for their statistical signficance by the
2 x 2  contingency tables of Finney ^  al (1963),
4.16 Intracerebral passive protective activity
Pooled serum and TBW were tested for their ability to protect
3-4 wk old mice against a lethal IC challenge of 3 x 10^ B, pertussis. 
Equal volumes of pooled serum and TBW were mixed with challenge 
suspension (IC/mix) and intracerebrally administered as in 2,3 (the 
"iC/mix" test of Dolby and Standfast, 1958). The mixtures stood 
for 20 min before inoculation, but not longer than .90 min before being 
inoculated. Mice were caged such that each cage contained animals 
representing each type of treatment.
Mouse deaths were recorded for 14 d after the inoculation.
Mice dying within 3 d of challenge were excluded from the final count, 
and not considered as "infection deaths". Mice moribund on day 14 
were counted as dead. Difference between the results from control 
and test groups were tested for their statistical significance by 
the 2 x 2  contingency tables of Finney £t al (1963),
SECTION V STATISTICAL ANALYSIS
5,1 Estimation of parameters
Counts of B, pertussis in the lungs of infected mice were 
summarized as the geometric mean as done by Dolby at al (1961), Varia- 
bility was expressed as the anti-logarithm of the standard deviation 
of the logarithm of the counts.
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Leucocyte counts in the blood of mice given pertussis vaccine 
or saline were summarized as the geometric mean and 95% CL since such 
counts are approximately log-normally distributed (Idigbe, 1979),
Lung pathology were summarized as the arithmetic mean and
95% CL,
5.2 Measure of association between two normal variables
The product-moment correlation coefficient (Campbell, 1974) 
was used to measure the association between (a) cfu in lungs and 
pathology score of those lungs, (b) infecting dose of B. pertussis and 
mortality rate and (c) reciprocal agglutinin titre in sera to 18-323 
and 18-334,
5.3 Assessment of significance of differences between experimental 
groups
5.3.1 The t-test
Results for the neutralization of LPF at each graded dose of 
vaccine in normal and infected mice were analysed by the t-test on 
the data expressed in logarithms to the base 10,
5.3.2 Mann-Whitney U-test
The Mann-Whitney U-test was employed to compare certain types 
of data where parametric tests seemed inappropriate, ég scores from 
lung pathology and lung culture from B, pertussis infected mice. The 
procedure was as described by Campbell (1974),
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5,3,3 Use of 2 X 2 contingency tables
For the comparison of data in the form of proportions (eg 
mortality ratios), 2 x 2  contingency tables were consulted (Finney 
et al) 1963), These were used to test the significance of differences 
in response for groups of mice given different treatments, eg passive 
protection afforded to groups of mice against an intracerebral or 
intranasal challenge with B, pertussis,
5,4 Estimation of in animal challenge experiments
For analysis of dose-response relationships (eg passive 
protection tests) where the response variable was a binomial proportion, 
the probit transformation was used. Data were processed by the probit 
method (Finney, 1971) using a computer programme developed in the 
Department of Epidemiology and Biometrics, School of Hygiene, University 
of Toronto, Canada, The University of Glasgow ICL2976 computer was 
used to run this programme which yielded PD^g values and the relative 
potencies compared with a standard, with 95% confidence limits.
RESULTS
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SECTION I SOME CHARACTERISTICS OF THE MURINE SUBLETHAL PULMONARY
INFECTION WITH B. PERTUSSIS
The main purpose of the investigation described in this thesis 
was to characterize the nature of the immune response of mice given a 
sublethal pulmonary infection with B. pertussis. Of particular 
interest was the comparison of acute-phase and convalescent sera and 
TBW, and it was therefore necessary to define the infection peak in 
the lungs of the experimental animals. Moreover, for monitoring 
passive protective activity of convalescent serum and TBW, it was 
necessary to have already determined the peak of infection so that 
observations in test animals could be made at that time,
1,1 Time course and infection peak
In two independent experiments, pulmonary infection was 
established in 3-4 week old HAM 1/CR mice of both sexes by the IN 
instillation of 4 x 10^ cfu (Expt 1) and 1 x 10^ cfu (Expt 2) of 
B, pertussis strain no, 18-323 (P), At suitable intervals after 
infection 3 or 4 mice were sacrificed and the thorax of each animal 
opened with sterile precautions. The lungs were examined for degree 
of consolidation and a pathology score assigned on a 0 to 4 scale 
(Fig 3b), The lungs were then excised, homogenized in sterile CAA 
and serially diluted for determination of cfu by surface colony 
counts on BG medium.
Figure 3a records the mean cfu of B, pertussis in the lungs 
during the 31 days (Expt 1) or 35 days (Expt 2) of observation. At
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Figure 3 : Development of murine pulmonary infections with
B. pertussis 18-323 (P) from an initial challenge of
5 5either 4 x 10 (Experiment 1) or 1 x 10 (Experiment 2)
cfu as determined by the mean^ cfu (A) and pathology
score (B) in the lungs. The error bars of A represent
1 SD,
Experiment 1 
Experiment 2
Each point is the mean of 3 or 4 mouse lungs.
ADay post-instillation
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day 4 and 5, the earliest post-instillation observation day for both 
experiments, the mean count was just over 10^ cfu per individual 
mouse lung mass. Thereafter the count increased further, reaching 
a peak of 10^ on day 11 in Expt 1, where the larger challenge had
7been given and 10 on day 14 in Expt 2, Subsequently, the counts
declined at a rate apparently not dissimilar from that at which they
had increased, but final clearance of all live bacteria had not been
achieved even at 31-35 days. For example, the 31 day mice in Expt 2
yielded 4,5 x 10^, 2.5 x 10^, 7.5 x 10^ and 10^ cfu from individual
5 4animals, and the 35 day mice from Expt i yielded 9,8 x 10 , 3,4 x 10 ,
2 2 2 ZL 10 and <. 10 cfu. The limit of detection was 10 cfu/lung mass.
In other experiments where pooled TBW was collected at 48 days
post"instillation and plated onto BG agar, no growth was obtained
showing that infection although persisting for 35 days had disappeared
by 48 days. For purposes of sacrificing mice at the peak of infection,
14 days post-instillation was taken as the standard time.
The parallelism of development of lung cfu and lung pathology
scores was investigated by the comparison afforded in Fig 3b,
Significant consolidation in the lungs was already visible in
Experiment 2 by day 4 (mean score 1,5) and in Experiment 1 by day 5
(mean score 1,6), Thereafter, the pathology scores increased, with
the larger infecting dose (4 x 10 ) of» Expt 1.yielding a higher mean
maximum score of 3,75 than the 2,5 of Expt 2, Fig 3b shows that the
pathology score reached plateaus rather than sharp peaks and that
this occurred between day 12 and 17, The difference in plateau
scores in the two expts was significantly different (P Z.5%) by the
Mann-Whitney U-test, By day 35 in experiment 1, the mean pathology
a
I
:|
I
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score was still at 3o25 (out of a maximum of 4*0) although the mean 
count at this time was nearly 10^ times lower than it had been at the 
peak. It was apparent therefore, that significant pulmonary 
consolidation persisted long after the infection peak had passed and 
long after the main burden of bacteria had been eliminated.
In other experiments, consolidation was found on day 42 after 
instillation but had disappeared by day 49, For details of pathology 
scores and bacterial counts in the individual mice in Fig 3a and 3b 
see Appendix fc,
1,2 Correlation between cfu and pathology score
In view of certain similarities in Figure 3 between mean
changes in bacterial count and in lung pathology, it was decided to
examine individual animals for the degree of correlation between
2these two variables. Where cfu were 10 an arbitrary value of 0 cfu 
was allocated and where cfu were uncountable because of confluent 
growth the value of 10^^ was allocated. From the two experiments, a 
total of 36 paired observations was available and these were plotted 
as a correlation diagram, which is not provided here but which showed 
no significant correlation between the two variables. The product- 
moment correlation coefficient 0,095 was statistically not significant 
(P 57o), Nevertheless it was noted that there appeared to be some 
correlation between pathology score and cfu in those mice which had 
been sacrificed before and including the infection peaks. Therefore 
the data were divided into two approximately equal groups, one
consisting of results that had been gathered up to day 11 in expt 1
and day 13 in expt 2, and those gathered thereafter.
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Two separate correlation diagrams were then plotted and are 
presented as Fig 4a and 4b, The product moment correlation coefficient 
of Fig 4a is 0,52 which is just a significant correlation (P at 5% 
level = 0,48) between pathology score and cfu during the time period 
before and including the infection peak. However after the infection 
peak the correlation coefficient in Fig 4b is 0,38 (P at 5% = 0,41) and 
thus does not quite reach the conventional level for a significant 
correlation score and cfu after infection. The main point to emerge 
is that significant correlation exists between pathology score and 
cfu while the organism is actively multiplying during the initial 
stage of infection (Fig 3a), However the correlation weakens as the 
infection passes its peak and the infection burden is in decline 
(Fig 3b),
1,3 Mortality rate in sublethal intranasal infections
To discuss mortality rate in B, pertussis infections which 
are described as "sublethal" may appear paradoxical, although there is 
precedence for this in the literature (Pittman, 1951), For purposes 
of the present investigations, "sublethal" is taken to mean "a mortality 
rate preferably below about 307, and certainly less than 50%",
The record of mortality observed in the large groups of mice 
that were infected so as to yield convalescent serum and TBW is set 
out in Table 7, In the course of the investigations extending over 
•3 years, a total of 924 mice was used in 8 separate experiments and the 
overall mortality rate was 22%, However this conceals sone notable 
variations in the source of the B, pertussis strain and in the sampling 
time. No mortality occurred in the normal mice.
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Figure 4, A. Correlation between lung pathology score and
c.f.u. before and including the infection peak,
B, Correlation between lung pathology score and 
c.f.u, after infection peak.
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Two different sources of strain 18-323 were used. The 
strain supplied by Dr, F, Sheffield (National Institute of Biological 
Standardization and Control, London) had a high IN virulence when 
first received and at this time it was used in expt 2 and 3, In 
both these experiments, significant pathological changes were 
recorded and B, pertussis was recovered from the lungs on day 14 
after instillation. Subsequently, however, a sharp drop in virulence 
of this strain occurred. Therefore strain 18-323 supplied by Dr,
Pittman (Bureau of Biologies, Bethesda) was used in all the other IN 
infection experiments described in this thesis. The virulence of 
this latter strain stayed at a high level, (Note however that the 
converse is true while in the IC infections with the strain supplied 
by Dr, F, Sheffield maintaining its virulence and Dr. Pittman's 
strain diminishing in IC virulence,)
In expt 3, pooled day 15 acute phase serum and TBW samples 
were obtained before any deaths due to infection had occurred. 
Nevertheless, there was evidence that this had been an infection with 
the expected level of virulence since there was abundant oozing of 
fluid from the incised trachea at the time of cannulation to obtain 
TBW, This suggested that the lungs were significantly congested.
In experiments 1, 2 and 4 to 8 the mortality rate was between 23-367, 
except in expt 1 which had a low mortality rate of 57, for no apparent 
reason.
Records of the day of death were kept for experiments 4 and 5 
which were terminated day 48 and day 34 post-ins filiation respectively 
(Fig 5). In experiment 4, deaths started around day 16 post-instillation 
with no more being recorded after day 41, In experiment 5, deaths
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Figure 5, Daily record of deaths in the infection experiments 4 and 
5 which were used to provide pooled sera and TBW from day 
48 and day 34 post-ins filiation. Each point represents 
one mouse.
bO 1
O  6
O   ^
Z  4
3
2
1
Experimenf 4 (Termination day4% post-instilla tion)
o o 
o o o
o o o o o o o  o o
o o o oo o o o o o o o
Experinnen5 (Termination day34 post-instlU ion)
oo
o oo
o oo o
o o o o o o
o o o o o o
o o o oo o o
o o o o o o  o o o
!____ 1____ 1____L5 10 15 20 25 30 35 40 45
Days post-instillation
:a
:
*
■Ia #
95
Figure 6, Correlation between the cfu in the infecting dose and
the subsequent % mortality of the recipient mice. 
Numbers in parenthesis are the days on which the 
experiment was terminated.
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commenced on day 9 post-instillation and continued until termination 
day 34, In both experiments the daily peak no of deaths were on 
day 23 and deaths were recorded until day 42 of experiment 4 and 
day 33, the day before termination, of experiment 3,
The question of correlation between the mortality rate and 
the cfu in the infecting dose is investigated in Fig 6, In short 
there was no correlation (product-moment correlation coefficient = 0,29), 
But it should be noted that the 2-fold dose range was very small 
compared with what is customary in a bacterial virulence titration,
1.4 Lysozyme concentrations in pooled TBW and serum
Lysozyme determinations were made on pooled TBW from infected
mice in experiments 1-8 as a measure of the non-specific inflammatory
response to infection (Fig 7). Normal, uninfected animals of the
same age were used as controls. The latter animals had a mean
lysozyme level of 8 pg ml However lysozyme concentrations of
50 pg ml  ^in pooled day 15 acute phase TBW was 6 times that of normal
pooled TBW, This coincided with the presence of heavy congestion in
the lungs at this time, Lysozyme concentrations had returned to
normal levels by day 61 post-instillation with pooled day 61
-1convalescent TBW having 8 pg ml of lysozyme.
The pooled TBW gave no idea of the variation in lysozyme 
concentrations between individual animals. This question was explored 
by sampling 10 individual TBW from normal mice at 3 wk and 12 wk old
5and mice which had been infected with 1,0 x 10 cfu B. pertussis at 
3 wk of age and then sampled 14 day and 61 day post-instillation
97
Figure 7, Lysozyme concentrations in pooled TBW and sera from
normal and B, pertussis infected mice at different 
times post-instillation.
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(Table 8)« The range of lysozyme concentrations were similar in 
normal mice at 3 wk and 12 wk of age and also at day 61 post- 
instillation of infected miceo The mean lysozyme concentrations for 
these groups were 7*2, 6<, 1 and 8 „ 1 p.g ml  ^respectively^ Lysozyme 
concentrations in individual TBW did not alter with age and in 
individual infected mice at day 61 post-instillation had nearly all 
returned to normal levels*
Individual TBW sampled on day 14 post-instillation (infection 
peak) had a wider range of lysozyme concentrations and the mean value 
(25 M-g ml )^, lower than found in pooled day 15 acute phase TBW, was 
significantly elevated from either the normal or mice at day 61 
post-instillation of infection.
Individual lung homogenates from the normal mice at 3 and 
12 wk and infected mice 61 days post-instillation also had a similar 
range with a mean lysozyme content of 27*5, 18*25 and 21 (xg/mouse 
lung mass respectively (Table 9)* Therefore 1/4 - 1/5 of the 
lysozyme content of the lungs from either normal or mice 61 days 
after infection was in the lung washings. Individual lung homogenates 
from mice at day 15 of a pulmonary challenge had a mean value of 
63,6 jxg/mouse lung mass, ie nearly 1/3 of the lysozyme content, 
slightly more than in normal or convalescent mice was recovered by 
lavage from mice at the infection peak* A slightly higher proportion 
of lysozyme is in the secretions at infection peak than in the tissues,
1,5 Protein concentration of pooled TBW
Protein determinations were made on pooled TBW from normal and
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Table 10 ; Protein concentrations of pooled TBW from normal and
Bo pertussis infected mice obtained at different times 
post-instillation
SourceofTBW
Day post­instillation 
when TBW obtained
No. of mice contributing 
to TBW pool
ExptNOo Proteinconcentration
mg/ml
Normal - 90 1 0.46 )
) ra=0 .;Normal - 80 2 0.25 )
Infected 15 90 2 1.5
Infected 42 114 1 0.93
Infected 49 93 2 0.38
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sî
A
B. pertussis infected mice in Expt 1 and 2, firstly to determine 
the protein ratio of TBW in relation to serum for immunological 
comparison, and secondly to see how protein concentration varied
B. pertussis strain no 18-323 was determined by analysis of pooled 
convalescent sera and TBW by various vitro and vivo assays with 
pooled normal and acute phase samples included for comparison. The 
U.S. Standard Antipertussis Serum was used in all tests as a reference
I
during infection (Table 10)o With normal mice there was nearly a 
two fold difference in the protein level in TBW in experiments 1 and 
2, This was not due to any technical error in the protein estimation 
because the two samples were run strictly in parallel. Pooled day 15 
acute phase TBW showed a 4-fold increase over the mean normal protein 
concentration and coincided with the massive congestion in the lungs 
on this day. Pooled day 42 and 49 convalescent TBW had protein
■-concentrations which although elevated from that of pooled normal TBW 
seemed to be returning to normal. The ratio of protein concentration 
between serum in relation to pooled normal TBW was 100:lgbut was
reduced to 50:1 in pooled day 42 and day 49 convalescent TBW.
'
SECTION II IMMUNOLOGICAL INVESTIGATIONS OF POOLED ACUTE PHASE 
AND CONVALESCENT SERA AND TBW
The immune response to the murine pulmonary infection with
i"
I
serum available to other investigators.
i
2.1 Agglutination Tests
Because agglutinins have been the most extensively studied
10 3
serological response of both mice and humans to B. pertussis infection, 
it was convenient to measure them at an early stage of the present 
investigation. It was also of interest to measure agglutinin not 
only against the 18-323 strain used for infection but also against 
other strains of B. pertussis. For this purpose strain 18-334, 
standard Phase I vaccine strain, was used both as X-mode and C-mode 
suspensions. Thus the pooled sera and TBW from infected mice were 
titrated for agglutinins against 18-323, 18-334 X-mode and C-mode.
Normal pooled sera and TBW were also assayed, as was the U.S. Standard 
Antipertussis serum (Figure 8).
Taking the last-mentioned first, it had a reciprocal 
agglutination titre of 16,000 towards both X-mode strains 18-323 and 
18-334 but only had a titre of 512 towards 18-334 G-mode.
Pooled convalescent day 34 serum had a reciprocal titre of 
32 towards both of the X-mode strains and 8 towards 18-334 G-mode.
This titre for X-mode organisms persisted unchanged in pooled day 61 
convalescent serum. However agglutinins were not present at this 
stage towards 18-334 C-mode,
An unexpected result was that normal serum obtained from two 
different batches of mice both had a reciprocal titre of 8 towards the 
X-mode strains, as did pooled day 15 acute phase serum. However 
neither pooled normal or day 15 acute phase sera had any agglutinins 
to 18-334 C-mode, Neither pooled TBW from normal nor from infected 
mice contained demonstrable agglutinins.
The unexpected observation that pooled normal mouse serum 
contained agglutinins to B. pertussis and that the reciprocal agglutinin 
titre of infected mice was not increased greatly, led to a study of
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Figure 8, Reciprocal agglutination titres of pooled sera from normal 
and B. pertussis infected mice at different times post- 
instillation. The sera were tested for agglutinins 
against 18-323 (P), 18-334 X-mode and 18-334 C-mode 
strains. The U.S. Standard Antipertussis Serum was used 
as a reference.
16,000
4,000
1,000
256
64
CU 16C- 4
-4—
C= 16,000O 4P00
-4— 1,000C?c 256
•4— 64
ID 16
" o i 4c n
CJ 16,000
1 5 4P00w 1,000Oc~ 256C L 64
w 16
CU
q : 4
X
X
1»JL
4k
18-323
X
X
X
X
X
X
X
X
X
X
X
-k
X
X
X
-2t
18-334 X-mode
18-334 C-mode
HLb ±
X
<X
X
X
XXX
X
X
4k
4k1 2 ""“ is  34 40 42 47 40 49 61 61 "  US 
Normal (2) (5) (6) II) (6) (4) (2) (7) (8) STD
Days post-i nsti llQtion“
' (Experiment’ number) 
a Note this is not a linear scale
105
sera from individual normal mice. Normal animals were bled at 3 wk 
and 12 wk of age and individual infected mice after 2 wk and 9 wk 
post-instillation. All these individual sera were titrated to 
determine the consistency of reciprocal agglutinin titre within each 
group (Table 11). Individual normal sera from both 3 wk and 12 wk 
old mice had a reciprocal agglutinin titre for both 18-323 and 18-334 
ranging from 0 to 32. There was no significant difference in the 
reciprocal titre for the two strains of B. pertussis or between the 
two age groups of mice. There therefore appeared to be a low titre 
B. pertussis agglutinin in the serum of normal HAM 1/GR mice. 
Individual day 15 acute phase sera also had a reciprocal agglutinin 
titre for both 18-323 and 18-334 ranging from 0 to 32 with no 
significant difference in the reciprocal titre for the two strains 
of B. pertussis. It is noteworthy that infection did not seem to 
act as a booster stimulus in what might be presumed to be primed 
animals.
Twelve wk old mice at day 61 of infection had a significantly 
elevated agglutinin titre towards both the B, pertussis strains. 
However since paired sera samples were not obtained for individual 
mice, it is not known if each mouse had an increase in agglutinin 
titre after infection as a few infected mice gave sera with agglutinin 
titres within the normal range.
Possibilities of correlation between the reciprocal agglutin­
ation titres for the 2 strains of B. pertussis with sera from the 4 
types of mice (as tabulated in Table 11) is investigated in Fig 9.
The correlation coefficients of Fig 6a-d were 0.47, -0.03, 0,65 and 
0,36, respectively, of which only the third mentioned was significant.
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Figure 9, Correlation of reciprocal agglutination titres for
18-323 and 18-334 in the individual groups of table 11, 
(X-mode of both strains were used,)
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From statistical tables the critical values of P at the 57» level are 
0.66 for Fig 6a and 0,632 for the others. Overall there was no 
significant correlation in reciprocal agglutination titres for the 
two strains of B. pertussis*
2,2 Immune response to LPS
Since LPS is a prominent surface antigen (Aprile and Wardlaw,
1973) of B, pertussis, a possible immune response to this component 
in the pooled serum and TBW samples was investigated. This was done 
by determining the ability of these fluids to agglutinate horse RBC 
which had been coated with B, pertussis LPS (Figure 10).
The U.S. Standard Antipertussis serum which was included as 
a reference had a reciprocal titre of 4000, a lower titre than found 
in the agglutination test (16,000) with whole bacteria. Pooled 
convalescent sera had no demonstrable (<.1/1) anti LPS at any of the 
sampling times despite having a bacterial reciprocal agglutination 
titre of 40-60 and having 50-100 times more protein than TBW,
Pooled normal and acute phase sera had no detectable anti LPS,
Pooled day 34 convalescent TBW had a reciprocal anti LPS 
titre of between 32-64 which persisted to around day 47 post-instillation. 
By day 61 post-instillation the reciprocal titre in pooled TBW had 
dropped to 4, For unexplained reasons pooled day 48 convalescent TBW 
had no demonstrable antibody to LPS, However, this could indicate 
an inconsistent response to LPS during the sublethal pulmonary 
infection. Pooled normal and day 15 acute phase TBW lacked demon­
strable antibody to LPS,
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Figure 10, Reciprocal anti-LPS titres of pooled TBW from normal 
and B, pertussis infected mice obtained at different 
times post-instillation. The U*S« Standard 
Antipertussis Serum was used as a reference.
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2 0 3 Immune response to F-HA
F-HA is another prominent surface component of Bo pertussis 
(Sato, 1979)o Therefore it might be expected to induce an immune 
response during a pulmonary infection. In this investigation, the 
anti-F-HA titre was determined in the pooled serum and TBW from normal 
and B. pertussis infected mice, with the U*So Standard Antipertussis 
serum used as a references
The latter, as shown in Figure 11, had a reciprocal anti-F-HA 
titre of 8o Pooled day 34 convalescent serum had a reciprocal anti 
F-HA titre of 32 which by day 49 had dropped to 8, Thus whereas in 
the bacterial agglutination tests, the reciprocal titre of the U.S. 
Standard Antipertussis serum was 300 fold greater than pooled 
convalescent serum, it was 4 fold lower than pooled day 34 convalescent 
serum and equal to pooled day 49 convalescent serum. Pooled 
convalescent TBW had no detectable anti-F-HA but it must be 
remembered that this fluid is highly diluted in its protein content 
compared with serum.
Pooled normal sera had a reciprocal anti-F-HA titre of 2 as 
did the pooled day 15 acute phase serum. Again, pooled normal sera 
appeared to have a natural antibody which reacted with a surface 
component of B. pertussis and did not exhibit a booster response after 
infection, since pooled day 15 acute phase serum showed no rise.
Pooled normal and acute phase TBW had no detectable anti-F-HA.
2„4 Immune response to HLT
Anti-HLT antibodies do not develop in human whooping cough
■I
Ill
Figure 11. Reciprocal anti-F-HA titres of pooled sera from normal 
t^id B. pertussis infected mice obtained at different times 
post-instillation. The U.S. Standard Antipertussis Serum 
was used as a reference.
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and Maitland,
(Evans/C 1939) and Standfast (1951) was unable to establish a virulence 
role for HLT in the murine lethal pulmonary infectiouo However, the 
possible development of anti-HLT after a sublethal pulmonary infection 
in mice does not appear to have been investigated.
As shown in Table 12 the U.S. Standard Antipertussis serum, 
even undiluted, did not show the slightest sign of neutralising the 
test dose of HLT for 6 out of 6 suckling mice developed haemorrhagic 
oedema, the same as in the toxin-alone group. However there was 
available in the department a known active anti-HLT containing rabbit 
hyperimmune serum which had been prepared by intensive immunization 
as described in Materials and Methods, This serum was designated 
loLo and had an anti-HLT titre of 120 units ml This antitoxin
was able to neutralise the test dose of HLT with none of the six 
suckling mice developing haemorrhagic oedema.
Pooled convalescent serum showed no detectable anti-HLT 
action and neither did pooled convalescent TBW (Table 12). Pooled 
normal and acute phase serum also had no detectable anti-HLT and 
similarly neither did pooled normal and acute phase TBW. Thus if 
any anti-HLT had been produced it was below the level of detection by 
the system used.
2.5 Crossed-Qver immunoprécipitation
Immunoprécipitation is one of the procedures recommended for 
serological diagnosis of pertussis in children (Aftandelians and 
Connor, 1973). This technique also offers the possibility of 
detecting immune responses to additional antigens in the bacteria
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Table 12 : Anti-HLT in pooled sera and TBW from normal and B, pertussis 
infected mice obtained at different times post-instillation7 The U.S. Standard Antipertussis Serum and rabbit hyperimmune antiserum with 120 antitoxin units ml”  ^were used as references
Type of Mouse and (Date of Sampling)
Expt.
No,
Anti-HLT
TBW
_. . . bactivity in
Sera
Toxin alone 
controls
N* 1 4/4 3/3 6/6
N 2 4/4 3/3 2/2
I*(15) 2 3/3 3/4 6/6
I (34) 5 2/3 3/3 6/6
I (40) 6 2/2 3/3 6/6
I (42) 1 3/3 3/4 6/6
I (47) 6 3/4 3/4 6/6
I (48) 4 3/3 3/4 6/6
I (49) 2 4/4 4/4 6/6
I (61) 7 N,T.* 2/2 2/2
U.S. Standard 
Antipertussis Serum 6/6 6/6
Rabbit hyperimmuneantiserum with
120 antitoxin units ml 0/6 6/6
I
N = Normal; I = Infected; N.T, Not tested
b Results are expressed as No. of suckling mice with haemorrhagic area/ total No, challenged.
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B, pertussis reference antigen run against corresponding "Hertz"
which might not be exposed on the cell surface. This particular method 
of immunoprécipitation was chosen because of its sensitivity. Two 
different sonicated B. pertussis antigen preparations were used;
18-323 X mode and 18-334 C mode, to see if the antibodies responsible 
for the precipitation were directed against X mode specific virulence 
factors o
As shown in Plate 6, the H.S. Standard Antipertussis serum 
gave at least Q, strong lines against both X and C mode organisms.
Pooled convalescent serum sampled from day 40 onwards gave single
"iflines against X and C mode organisms. Thus the immune response 
detected by this method was not directed against exclusively X mode 
specific virulence factors.
Pooled day 34 convalescent serum gave no precipitin lines,
-against either antigen. No pooled convalescent TBW gave any 
precipitin lines against the antigen preparation. Pooled normal and
■•f'fday 15 acute phase serum also gave a negative result against both
-::4antigens as did pooled normal and day 15 acute phase TBW.
2.6 Quantitative Immunoelectrophoresis
This method also was used to investigate the immune response
in pooled samples of serum and TBW to antigens in sonicated B, pertussis,
■It has the advantage of being more sensitive than crossed-over 
Immunoelectrophoresis and gives a "profile" of the immune response 
rather than a single precipitin line. j
The crossed immunoelectrophoretic pattern of sonicated
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Plate 6 : Crossed-over immunoprécipitation o£ pooled sera and TBW from normal and B. pertussis infected mice obtained at 
different times post-instillation. The U.S. Standard Antipertussis Serum was used as a reference. Sonicated B. pertussis strains 18-323 and 18-334 were employed as the antigens
N N D15 D15 D34 D34 D40 D40 D42 D42 USTBW SERA TBW SERA TBW SERA TBW SERA TBW SERA STD
Row 1 18-323
X-Mode
18-334C-Mode
D47 D47 D48 D48 D49 D49 D61 D61 D61 D61 US
TBW SERA TBW SERA TBW SERA TBW SERA TBW SERA STD
18-323
X-Mode
18-334C-Mode
a : N = Normal ; D = Day
b ; U.S.STD = U.S. Standard Antipertussis Serum
Rows 1 and 2: Have the same pooled serum or TBW in the top wells
Rows 3 and 4: Have the same pooled serum or TBW in the top wellswhich are different from rows 1 and 2
Rows 1 and 3; Have 18-323 X-mode sonicate in the bottom wells
Rows 2 and 4; Have 18-334 C-mode sonicate in the bottom wells.
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Plate 7 : Crossed Immunoelectrophoresis of sonicated B. pertussis
reference antigen run against corresponding rabbit 
antiserum in the second dimension gel with the intermediate 
gel containing diluent, U.S. Standard Antipertussis serum, 
or pooled normal, acute or pooled day 49 convalescent serum,
a = NaCl in intermediate gel
b = U.S. Standard Antipertussis serum
c = pooled day 49 convalescent sera
d = pooled acute phase sera
e = pooled normal sera
a. b.
c.
e.
d.
firrcuNS mdl'icôtfi. by pooLtdi dôy convalescent Scrum. #poo Le. d acijte, pr pooUd InormaL seroV jt\ twc ir\t£rtvyedi&i£- ge-L .
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Plate 8 : Crossed Immunoelectrophoresis of sonicated B, pertussis
reference antigen run against corresponding rabbit 
antiserum in the second dimension gel with the intermediate 
gel containing diluent, U.S, Standard Antipertussis serum, or 
pooled normal, acute or pooled day 49 convalescent TBW,
a = NaCI in intermediate gel 
b = U.S. Standard Antipertussis serum
c = pooled day 49 convalescent TBW
d = pooled acute phase TBW
e = pooled normal TBW
a. b.
I
c. d.
e.
ftrrôios if\dicat5^  pc.&b bvj pooüecl day W  coAVôLÊScervt T£k3
pûûLed ûLcude, pkôse TGü îa tKc üv\W"A\^ diodb2. ^eL .
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rabbit antiserum (see Materials and Methods) in the second dimension 
gel was obtained when NaCl was placed in the intermediate gel (Plate 
7a), A complex pattern of peaks was found in the intermediate gel 
when the U,S„ Standard Antipertussis was incorporated in it (Plate 7b).
Four precipitin lines were formed when pooled day 49 
convalescent sera was incorporated in the intermediate gel (Plate 7c) 
and two precipitin lines were formed in the intermediate gel with 
pooled acute phase sera incorporated (Plate 7d), Pooled normal sera formed 
1 precipitin line(Plate 7e).No precipitin line was formed in the 
crossed immunoelectrophoresis of pooled normal and acute phase
The crossed immunoelectrophoretic pattern of sonicated 
Bo pertussis reference antigen run against rabbit antiserum in the 
second dimension gel with NaCl and U.S* Standard Antipertussis serum 
in the intermediate gel are presented again in Plates 8a and 8b 
respectively. When pooled day 49 convalescent TBW was incorporated 
into the intermediate gel, three precipitin lines were formed (Plate 8c), 
Two precipitin lines were formed by pooled acute phase TBW (Plate 8d) 
were undetected in crossed over immunoelectrophoresis. Pooled normal 
TBW did not precipitate any lines when incorporated into the inter­
mediate gel (Plate 8e).
As well as quantitating the number of immune responses present 
to sonicated B. pertussis reference antigen, this immunoelectrophoresis 
was more sensitive than crossed over immunoelectrophoresis which was 
unable to detect antibodies in pooled normal and acute phase sera.
It was also able to detect an immune response in pooled acute and 
convalescent phase TBW where neither agglutination, haemagglutination 
inhibition test or crossed-over immunoprécipitation did.
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2.7 Bactericidal activity
The possible bactericidal activity of mouse serum and TBW was 
investigated primarily because it might adversely affect the results 
of passive protective tests done by the "intranasal mix" method 
(North, 1946), . Involved in this method is the preparation
of mixtures of pooled serum and TBW with live B. pertussis which are 
then held for up to 1 h at room temperature in the course of 
administering the challenge. During this time, the bacteria might 
die. To explore this question and also to increase the chance of 
demonstrating bactericidal activity, mixtures of serum or TBW with 
lis strain 18-32 3 were incubated for 90 min at 37^C and
viable counts made.
The results of Table 13 show that the mean dose inoculated 
into each sample was 33 cfu per sample volume (0*05 ml) and that after 
90 min incubation at 37°C all the mixtures, in fact, yielded an 
increase in viable count. This indicated that the bacteria far from 
being killed in the mixtures were able to multiply. It was therefore 
concluded that no reduction in viability of challenge would occur 
over the time scale and under the conditions in which mixtures of sera 
and TBW with B, pertussis were held while performing the intranasal 
challenge.
2,8 Passive protective activity towards sublethal intranasal 
infections of B, pertussis
All of the above described immunological assays on the pooled 
convalescent sera and TBW had been done vitro and therefore did not
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provide direct information on protective activity against infection*
It therefore seemed appropriate at this stage in the investigation 
to study serum and TBW for protective activity against SLIN challenge* 
For this purpose the protection was assessed by both lung pathology 
and culture score at day 14 (infection peak) post-instillation of 
challenge*
A quantitative comparison between SLIN passive protective 
activity of pooled sera and TBW was made expressing both in terms of 
U.So Standard Antipertussis serum* The passive protective activity 
of the pooled samples was also assessed by the IC infection route.
This allowed the comparison between the passive protective potency 
of pooled samples against the SLIN and IC infections.
An initial experiment was carried out by the SLIN/mix method 
to determine if in fact pooled convalescent sera and TBW were 
passively protective and, if so, if heating for 30 min at 56°C to 
remove complement reduced this passive protective activity*
Table 14a records the individual lung pathology and culture 
score for each mouse and also the significance by the Mann-Whitney 
U-test of each group result compared to that of the relevant lung 
pathology or culture score of the challenge alone group* Table 14b 
records the proportion of the responses ^ 2  and also the significance 
of each group compared to the challenge alone lung pathology or 
culture by the 2 x 2  contingency tables by Finney e_t a_l (1963)* 
Appendix 7 gives and values for Table 14a* Pooled day 49 
convalescent serum significantly reduced lung pathology and culture 
score by the Mann-Whitney test and highly significantly by the 2 x 2  
contingency tables of Finney et al (1963), when compared to challenge
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protective activity since heated convalescent pooled day 49 serum 
still give the same degree of significant reduction of lung pathology 
and culture by both analyses.
Pooled day 49 convalescent TBW also significantly reduced 
lung pathology and culture score by the Mann-Whitney test and highly 
significantly by the 2 x 2  contingency tables when compared to
gchallenge alone groupo Heating for 30 min at 56°C again had no
effect on passive protective activity as measured either by lung 
pathology or culture score of mice when compared to challenge alone. 
Pooled normal serum did not reduce lung pathology and culture 
from that found in the challenge alone by either the Mann-Whitney test
or the 2 x 2  contingency tables. This was also true for pooled 
normal TBW»
This passive protective activity of pooled day 49 convalescent 
sera and TBW appears to be independent of complement since heating 
for 30 min at 56°C had no effect.
Referring to the two alternative methods of statistical 
analysis, it may be stated that, in general they yielded similar 
conclusions, ie where the difference was significant by the Mann- 
Whitney U test it was also significant by the 2 x 2  contingency tables* 
The same was true where the result was insignificant. However in
a few instances where the group size was small, the Mann-Whitney 
U-test seemed less sensitive than the 2 x 2  contingency tables in 
detecting a significant difference* Table 15 gives such an example* 
In light of the above, the results of subsequent SLIN passive 
protection tests were presented as proportions of ^  2 score and
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analysed by the 2 x 2  contingency tables* For completeness of record 
however, the corresponding individual mouse scores are tabulated in 
the Appendix and analysed by the Mann-Whitney U-test*
2*8*1 Sublethal intranasal passive protective activity development
in pooled sera and TBW !
To identify quantitative trends in the development of SLIN i
passive protective activity of the pooled sera and TBW obtained in I
Expt 1-8, SLIN passive protective activity was titrated using both i
reduction in significant lung pathology and culture score as criteria* \
Appendix 8a-d gives the results of the individual titration of the |
pooled samples for both lung pathology and culture score* From each |
-1titration, the ml and 95% C*L* were obtained using the U*S* I
Standard Antipertussis serum as the reference serum of relative |
potency 1*0 (Figure 12)* - I
IThe U.S. Standard Antipertussis serum had an SLIN passive !
protective activity by the lung pathology criterion of 570,000 PDy^ ml"^; I
.'■M
by lung culture the value was 440,000. Pooled day 34 convalescent sera j
had developed SLIN passive protective activity of 6,666 PBy^ ml"^ by I
-1 =lung pathology and 5,000 PLy^ ml by lung culture. By day 61 activity 1
culture*
Pooled day 34 convalescent TBW had also developed SLIN passive 
protective activity and prevented development of lung pathology 
(PD^q ml  ^= 125) and lung culture (PDy^ ml  ^= 100), This again 
increased by day 61 where pooled convalescent TBW had between 222-1000
had increased to between 13,500-33,000 PBy^ ml  ^as determined by |
lung pathology and 40,000-50,000 PDu_ ml  ^as determined by lung |
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Figure 12 : Development of sublethal intranasal passive protective 
activity in serum and TBW of B. pertussis intranasal1y 
infected mice. Note that the abscissa, as on other 
Figures, is not a linear scale and the diagram 
summarises data from several independent experiments.
The U.S. Standard Antipertussis Serum was used as the 
reference preparation for calculating 95% C.L.________
Q  = U.S. Standard Antipertussis serum 
# —#  = pooled convalescent sera
0-0 = pooled convalescent TBW
^  = pooled normal and acute phase serum and TBW
The individual mouse data on which this figure is based are recorded
in Appendices 8a-d.
%
a.i
Pathology
L J
Culture
oun
Q
Q _
Normal it  (5) (6) (1) (6) (4) (2) (7) (ft)
Days post-instillation
(Experiment number) 
a This is not a linear scale
STD
a
1
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ml  ^as determined by lung pathology and 666-2,000 PD^^ ml ^
activity in preventing lung pathology and lung culture, ie ^  20 PD 
-1ml , the limit of detectioUo By day 15 post-instillation there
50
as determined by lung cultures
Pooled normal serum had no detectable passive protective
»
S
was still no detectable SLIN passive protective activity^ A similar 
absence of detectable passive protective activity was found in pooled 
normal and day 15 acute phase TBWo
Thus mice which were convalescent from a sublethal infection 
had developed SLIN passive protective activity at least by day 34 of 
infection in both the sera and TBW. This development continued 
until at least day 61 post-instillatioHo Pooled convalescent sera 
were approx 40 times more potent than pooled convalescent TBW and the 
LF.So Standard Antipertussis serum was, in turn, 20 times more potent 
than pooled day 61 convalescent serum both in reducing lung pathology 
and culturea
2.9 Passive protective activity towards intracerebral infections 
of B. pertussis
Since convalescent serum and TBW had easily detected passive
.protective activity by the SLIN/mix test, it was obviously of interest 
to see if the same specimens would also protect mice against IC 
challenge. Moreover, it may be noted that the number of cfu in the
challenge dose of strain 18-323 is quite similar in both infection
5routes. However 10 cfu by the IN route is approximately 1 LDUr 
5whereas 10 cfu by the IC route is y 100 LCy^. So the IC/mix
Î
129
passive protection test is a more severe trial of antibody protective 
activity than the SLIN/mix passive protection test.
In these IC passive protection tests the samples were given 
as a 1 in 2 dilution with challenge organisms which were the IC 
virulent 18-323 strain supplied by Dr. F„ Sheffield except when pooled 
samples were tested from expt 1 (Table 17) where the 18-323 strain 
supplied by Dr. Pittman was used. From this experiment it was 
obvious that the IC virulence of this strain was falling since in the 
challenge alone group given a dose which should have been 100 LD^^ 
finished with only 7 out of 10 dead.
Intracerebral passive protective activity of the U.S, Standard
-1Antipertussis serum was titrated and found to contain 1650 PD^^ ml 
againC ^100 LD^^ (Table 16), This was a 300-fold smaller value 
than against 1 1^2^ in. the SLIN infection. Turning to the results 
with pooled convalescent sera and TBW (Table 17), it will be seen 
that no IC-passive-protective activity was detected in any of the 
experimental samples. Even when only 1 LOy^ was given with pooled 
day 42 convalescent sera and TBW, 7 out of 10 and 8 out of 10 mice 
died respectively. Therefore no passive protective activity was 
detected for pooled day 42 convalescent samples against a challenge 
equivalent to 3 LDg^ of the SLIN challenge. However these were the 
only samples receiving 1 LDy^. The other pooled convalescent samples 
received ^ 100 LDy^ challenge.
Pooled normal and acute phase samples also had no detectable 
passive protective activity against IC challenge of 1 LDy^ o r 100 LD^^,
130
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Table 16 : Intracerebral passive protective activity of U.S. Standard 
Antipertussis Serum
“1Passive protective activity Dilutions PD^^ml Challenge Dose
/  Deaths \ (LD )Total Challenged
Neat 1/20 1/200 1/2000 1/a
0/10 5/10 9/10 10/10 10/10 1650 >  100 LD^^ ^ 50
131
Table 17 : Intracerebral passive protective activity of pooled sera
and TBW from normal and B„ pertussis infected mice obtained 
at different times post-instillation
Type of mouse^ and 
(Day of sampling)
Expt 
No,
Passive protective activity (Deaths/Total challenged)
TBW Serum (Undiluted) (Undiluted)
Challenge
alone
N 1 8/10 6/10 7/10
N 2 8/8 8/8 8/8
I (15) 2 7/8 8/8 8/8
I (34) 5 8/8 8/8 7/8
I (40) 6 8/8 7/8 7/8
I (42) 1 8/10 7/10 7/10
I (47) 6 7/8 6/8 7/8
I (48) 4 7/8 7/8 7/8
I (49) 2 7/8 8/8 8/8
I (61) 7 10/10 10/10 10/10
I (61) 8 10/10 10/10 10/10
a N = Normal ; I = Infected,
The of challenge used to test pooled sera and TBW collected
in Expt 1 was 2 while in all the other tests it was greater
than 100 Nevertheless in the challenge doses the c.f.u. was
always around 1x10^ c.f.u.
■I
:■41
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2.10 Absorption of pooled sera with Phase I and Phase IV B. pertussis
Since the SLIN passive protective activity developed in the 
sera of mice convalescent from a pulmonary infection, it was of 
interest to see if this activity was directed against surface virulence 
component(s) specific to Phase I B. pertussis or towards surface components 
found also on Phase IV avirulent organisms.
The criterion used to determine the minimal dose of B, pertussis 
with which to absorb pooled convalescent sera was that dose of 
Phase I 18-323 which absorbed all agglutinins. This was determined 
by absorbing I ml aliquots of a pooled convalescent serum with a 
range of doses from 10 o,u. to 200 o.u. Phase I B, pertussis and then 
titrating the agglutination titre in the absorbed samples (TablelS),
Absorption with 200 o.u. Phase I B, pertussis per ml of serum 
removed all agglutinins to both agglutinating strains (18-323 and 
18-334). With smaller absorption doses, the residual reciprocal 
agglutination titre showed less decline with both agglutinating 
stra.ins. The pooled serum absorbed with 10 o.u. Phase I B, pertussis
ml  ^had a reciprocal agglutination titre of 16 for both 18-323 and 
18-334 agglutinating strains which was only a factor of 2 less than 
unabsorbed pooled convalescent sera which had a reciprocal agglutin­
ation titre of 32 towards both agglutinating strains.
Plate 9 shows crossed-over immunoelectrophoresis of the 
absorbed sera using the antigenic preparations of B, pertussis Phase I 
18-323 (Row 1 and 2) and Phase IV D30042 (Row 3 and 4), Precipitin 
lines were absent between pooled convalescent sera absorbed with 
200 o.u. to both antigenic preparations of B, pertussis (well A of
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Table 18 Reciprocal agglutination titre of pooled day 48 
convalescent sera either unabsorbed or absorbed with 
Phase I B. pertussis at various doses. Agglutinins were
strains 18-323 and 18-334tested with
Absorption treatment (ml 
of sera (with B. pertussis Reciprocal agglutinating titre^ with strain18-323)
(o.u.) 18-323 18-334
Nil (unabsorbed) 32 32
10 16 16
20 16 16
50 4 8
100 4 4
200 ^  1 2:1
a All titrations were done in duplicate on the same day. 
Consistent results for each value were obtained.
"Ï
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Plate 9 : Crossed-over immunoelectrophoresis of pooled sera from mice at 
day 48 of a pulmonary infection of B. pertussis strain 18-323 
and the same absorbed with either various doses of Phase I or two different doses of Phase IV B . pertussis. The antigen preparations used were B. pertussis Phase I 18-323 and Phase IV D30042
Antigen 
preparation Phase I sonicate
Antigen preparation Phase IV sonicate
Antisera in rows 2 and 4
A = 200 o.u. Absorbed sera 
B = 100 o.u. " "
C = 50 o.u. " "
D = 20 o.u. " "
E = 10 o.u,
F = U.S. Standard Antipertussis 
Serum.
Antisera in 
rows 1 and 3
A 200 o.u. Phase I absorbed sera 
B 1000 o.u, " " "
C 200 o.u. Phase IV absorbed sera 
D 1000 o.u. " " "
E Normal sera
F U.S. Standard Antipertussis 
Serum.
a Antigenic preparations were made by scraping the growth of a 
24 h puddle plate to make a thick suspension in C.A.A. then 
sonicating for 6 x 20 sec. .
o o 5’
c:#»
O .  O
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rows 2 and 4). However precipitin lines were found between pooled 
convalescent serum absorbed with 100 o.u. B. pertussis Phase I 18-323 
and both antigenic preparations of B. pertussis. The minimum dose of 
B. pertussis Phase I 18-323 or Phase IV D30042 used to absorb each ml 
of pooled convalescent serum was therefore 200 o,u. To ensure the 
removal of phase specific antibodies, aliquots of serum were absorbed |
(per ml) with 1000 OoU, of either B, pertussis Phase I 18-323 or ■
Phase IV D30042. (Wells A to D of rows 1 and 3 confirm these I
absorptions with both Phase I and IV B. pertussis completely removing Ii
precipitinso) !
iSublethal intranasal passive protective activity of the 
unabsorbed and absorbed pooled convalescent sera (all at 1/10 diln) |
were determined in two separate experiments. Normal serum was I
absorbed with 200 o.u. Phase I B, pertussis to see if absorption j
augmented the virulence of challenge. The results of both experiments |
are given as the proportion of significant lung pathology and culture score ;
(Table 19) and the individual lung pathology and culture scores analysed jI
by the Mann-Whitney U-test are in Appendix 9, |
I
Unabsorbed pooled convalescent■serum produced at least a I
Isignificant reduction in pathology and culture score. However this \
Ipooled convalescent serum absorbed with either 200 o.u, or 1000 o.u, i
IPhase I B, pertussis was not passively protective and there was no 
difference between both pathology and culture results found in mice 
given infection alone and those treated with pooled convalescent serum 
absorbed with both doses of Phase I B. pertussis.
Pooled convalescent serum absorbed with both doses of Phase IV 
remained passively protective, since it produced at least a significant
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infection alone group. Pooled normal serum absorbed with 200 o.u,
2,11 Passive protective activity of pooled convalescent sera and 
TBW given intranasally before challenge
I
5
.S'
reduction in pathology and culture score compared to those found in the
Phase I B. pertussis did not augment the virulence of the infection 
and mice treated with pooled normal absorbed serum did not give
significantly different pathology or culture score from the infection 
alone.
To confirm that absorption with Phase I B, pertussis did remove 
SLIN passive protective activity from pooled convalescent sera and 
Phase IV B. pertussis did not, the absorption procedure was repeated 
and SLIN passive protective activity determined on two separate 
experiments (Table 20), Individual pathology and culture score 
analysed by the Mann-Whitney U-test are given in Appendix 10,
These results confirm that absorption of pooled convalescent 
sera with either 200 o.u, or 1000 o,u. B, pertussis Phase I removes 
SLIN passive protective activity as determined by both pathology and 
culture score. Whereas B. pertussis Phase IV absorption with either
200 o,u, or 1000 o,u, of pooled convalescent sera had no effect on the 
SLIN passive protective activity in that Phase IV absorbed sera 
remained passively protective by the SLIN route. Thus SLIN passive
protective activity seems to be directed against Phase I specific 
surface antigens since even the 1000 o.u. dose of Phase IV did not 
remove SLIN/mix passive protective activity from pooled day 48 
convalescent serum.
North (1946) demonstrated mouse convalescent serum to be
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passively protective when administered intranasally up to 48 hours 
before a SLIN challenge* In terms of modern immunology this could be 
interpreted as indicating a possible role of IgE in SLIN passive 
protective activity of mouse convalescent serum if one accepts that 
homocytotrophic IgE would be the only immunoglobulin to persist on 
pulmonary epithelium over a 48 hour period* It was therefore of 
interest to establish if the pooled convalescent sera and also TBW 
obtained in the present investigation had this ability to protect 
passively when given intranasally up to 48 hours before a SLIN 
challenge*
In the first experiment (Table 21) when pooled convalescent 
sera at 1/20 dilution was given intranasally 48, 24 and 6 h before 
challenge, it was found to be as passively protective against pathology 
development as both dilutions. 1/20 and 1/200 given intranasally as a 
mixture with challenge* The individual lung pathology and culture 
scores are in Appendix 11* There was a highly significant reduction 
in pathology of all groups given pooled convalescent serum compared to 
the pathology of challenge alone by the 2 x 2  contingency tables of 
Finney ^  ^  (1963)* However since no culture results were obtained 
(because of mould contamination) the experiment was repeated*
The pathology results in the second experiment were similar 
to the first with convalescent serum given 48 h before challenge 
significantly reducing pathology score* Convalescent serum (1/20) 
mixed with challenge produced a highly significant reduction in both 
pathology and culture and at a 1/200 dilution mixed with challenge 
there was a significant reduction in both pathology and culture*
However the culture scores of mice given convalescent serum 48 h
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before challenge disagreed with the pathology results and were not 
significantly reduced.
This implied that the antibody which persisted for 48 h 
prevented pathological change induced by B. pertussis but was not 
involved in clearance of the organisms, since they were still present 
after 14 days* However when the experiment was again repeated, 
pooled convalescent serum given 48 hours before challenge reduced in a 
highly significantly fashion both the lung pathology and culture 
scoreso Mice treated with 1/20 and 1/200 dilution of pooled conval­
escent serum mixed with challenge did not significantly reduce either 
lung pathology or culture in experiment 3 for reasons unknown. In 
all experiments mice given anaesthetic alone two days before challenge 
were no less susceptible to infection as the challenge alone mice.
The same procedure was followed with pooled day 48 convalescent 
TBW which had been xlO concentrated (Table 22), The individual lung 
pathology and culture scores are in Appendix 12, In the first 
experiment, pooled convalescent TBW at a 1/2 dilution did not 
significantly reduce pathology score when given 48 h before challenge. 
However when given 24 or 6 h before challenge it did highly significantly 
prevent pathology development. Mice given a 1/2 or 1/20 dilution of 
pooled convalescent TBW mixed with challenge had a highly significant 
reduction in lung pathology. The experiment was repeated to obtain 
culture results.
Pooled day 48 convalescent TBW given 48 h before challenge in 
experiment 2 produced a highly significant reduction in pathology and 
a significant reduction in culture. However pooled convalescent TBW
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given 24 h before challenge did not significantly reduce either lung 
pathology or cultures No passive protective activity was demonstrated 
by lung pathology or culture by either 1/2 or 1/20 dilution of pooled 
convalescent TBW mixed with challenge. This was peculiar since these 
dilutions were previously protective.
Pooled convalescent serum was passively protective given 
intranasally 48 h before challenge and prevented the development of 
pathology and culture as efficiently as when it was given as a mixture. 
Pooled convalescent TBW was able to passively protect by preventing 
pathology and culture on one experiment if given intranasally, 48 h 
before challenge. However the inconsistency of the pooled convalescent 
TBW might reflect the lower potency compared to pooled convalescent 
serum. The overall conclusion was that convalescent serum and TBW 
could be given intranasally separately from the challenge and up to 
48 h beforehand and still exhibit impressive protective activity,
2.12 Ability of pooled sera and TBW to neutralise the HSF activity 
of pertussis vaccine
As yet there has been no report on the development of antibodies 
to the biological activities associated with pertussigen after a murine 
pulmonary infection. It seemed relevant to establish if an immune 
response to pertussigen took place during such an infection since what 
may be taken as this component (under a different name) has been 
proposed by Sato £t ^  (1980) as the protective antigen in both the IC 
and SLIN murine infections.
Pooled sera and TBW were therefore examined for ability to
for 6 or 7 out of 7 mice were still sensitive to histamine compared to 
7 out of 7 sensitive in the vaccine alone group (Table 24), They were 
still unable to neutralize 1,5 HSD^^ from the observation that 5 or 7
144 ■:%
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neutralize the HSF activity of B. pertussis vaccine. To ensure 
maximum chance of detecting antibodies, low doses of vaccine, 1,5 and 
3 HSD^q , were mixed with pooled undiluted convalescent sera and TBW. 
The mixtures were injected, after 18 h incubation at 4^G, into 7 wk
old mice and the induction of histamine sensitivity tested by histamine 
challenge 5 days later.
As shown in Table 23 pooled convalescent sera did not 
neutralize 3,0 HSD^^ of pertussis vaccine, since between 5 to 7 out of 
7 mice became sensitive to histamine. In the vaccine-alone group, 7 
out of 7 mice died when the lower vaccine dose of 1,5 HSD^g of pertussis 
vaccine was used, day 49 and day 61 pooled convalescent sera reduced 
the number of deaths (2 out of 7) and (5 out of 14) respectively.
However these were not significantly different compared to vaccine 
alone when analysed by 2 x 2 contingency tables of Finney e^ ^  (1963), 
The U.S. Standard Antipertussis serum did however significantly reduce 
histamine sensitivity with no mice dying after histamine challenge.
Pooled normal and acute phase sera were unable to neutralise
either 1,5 or 3 HSUy^ of pertussis vaccine: there were 7 out of 7
mice dead for both sera mixed with either dose of vaccine.
Pooled convalescent TBW was unable to neutralise 3,0 HSUy^
Iout of 7 and 10 or 14 out of 14 sensitive to histamine compared 
with 5 out of 7 sensitive in the vaccine alone group.
Pooled normal TBW was unable to neutralise 1,5 or 3 HSUy^ I
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pertussis vaccine since 6 out of 7 mice died given either dose of 
pertussis vaccine. Pooled acute phase TBW was also unable to 
neutralize HSF since 7 out of 7 mice died at both doses of vaccine.
Pooled day 49 and day 61 convalescent sera were the only 
pooled samples which were able to reduce the histamine sensitising 
activity of pertussis vaccineo However the difference between these 
and the vaccine alone was not significant when analysed by the 2 x 2  
contingency tables. Only H.S. Standard Antipertussis Serum signifi­
cantly reduced histamine sensitivity,
SECTION III;HSF AND LPF RESPONSIVENESS OF CONVALESCENT ANIMALS
The foregoing showed that convalescent sera and TBW were not 
detectably able to neutralise histamine-sensitizing activity of 
pertussis vaccine. However, there remained the possibility that the 
fully-recovered mice themselves might be somewhat resistant to 
induction of histamine sensitization as tested by injection of vaccine 
and subsequent challenge. This was therefore done at 53 and 61 days 
post-instillation. The same animals were also tested for possible 
refractoriness to induction of leucocytosis by the vaccine. Thus on 
the 4th day after Ip, administration of the vaccine the animals were 
blood-sampled for leucocyte count and then on the 5th day histamine 
challenged.
3.1 Leucocyte count in vaccinated normal and convalescent mice
Some of the mice which had been infected to raise day 49
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convalescent sera and TBW In Experiment 3 were used to see if they 
were unresponsive to the LPF in 1.33 and 4.00 o.u. pertussis vaccine 
given ioPo (Table 25). The mean leucocyte count on day 53 convales-
-3cent mice receiving no vaccine (6456 mm ) was similar to that
of normal unvaccinated mice (6767 mm  ^ However no reduction
in the mean leucocyte count in day 53 convalescent mice was found at 
either vaccine dose. Of mice given 1,33 o.u. vaccine day 53 
convalescent mice had a mean leucocyte count of 10790 ram  ^compared to 
11,324 mm  ^in normal mice. No difference was found in the mean 
leucocyte count of mice treated with 4 o.u. pertussis vaccine with 
day 53 convalescent mice having 16,710 ram  ^normal mice having a count 
of 15136 ram
The next experiments into the possible neutralisation of LPF 
were done on day 65 convalescent mice reserved from sampling experi­
ments 4 to 7. Four groups of day 65 convalescent mice were 
investigated independently using low doses of vaccine to ensure 
maximum chance of detecting neutralisation. These 4 experiments 
were totalled and analysed by comparing the mean leucocyte count of 
convalescent and normal mice at each vaccine dose by the t-test on 
the geometric mean.
Again the mean leucocyte count (mm of day 66 convalescent
(9044) and normal mice (9115) receiving no vaccine were not significantly 
different. In mice given 0,44 o.u. pertussis vaccine the mean 
leucocyte count of convalescent mice (10,767 ram )^ less than normal
-3mice (12,957 mm ) but the difference was not significant by the 
t-test. Of mice given 1.33 o.u. pertussis vaccine the mean leucocyte 
count of day 65 convalescent mice (11,290 mm' )^ was significantly less
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Figure 13, Leucocyte count in the normal and B, pertussis day 65
convalescent mice given various doses of B, pertussis vaccine, 
The geometric mean ( ^ 1 S.D, ) are given. The numbers in 
parenthesis are the number of mice tested.
G----O Normal control mice
Q  (H Convalescent mice.
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than that of normal mice (17,488 mm )^o
Figure 13 shows the mean leucocyte count of normal and de^  63 
convalescent mice in E4-7 plotted against vaccine dose* Normal mice 
gave a good dose-response curve to 0.44 and 1*33 o„Uo ml B. pertussis 
vaccine. However day 65 convalescent mice gave a flattened dose- 
response curve with both 0*44 and 1,33 OoUo ml Bo pertussis vaccine 
having had the leucocyte promoting activity neutralised,
3,2 Histamine sensitivity in vaccinated normal and convalescent mice
On the day after the leucocyte counts of the above mice were 
recorded, their histamine sensitivity was determined by i,p, challenge 
with histamine (Table 26)o No reduction in refractoriness towards 
histamine sensitization was found in day 54 convalescent mice given 
either 1,33 o,u« or 4,00 OoUo pertussis vaccine* Of mice given 
1*33 o.u,, 7 out of 10 convalescent mice were still sensitive to 
histamine compared to 7 out of 7 normal mice* Four o*u* pertussis 
vaccine sensitized 10 out of 11 convalescent mice and 7 out of 10 
normal mice* However the convalescent mice without pre-treatment 
with vaccine were somewhat sensitive to histamine, presumably as a 
result of the pulmonary infection with 7 out of 12 convalescent mice 
histamine sensitive*
These results indicate that the histamine sensitising effect 
of a murine pulmonary infection of B* pertussis is longer lasting than 
that of leucocytosis promoting effect*
Histamine sensitization results of day 66 convalescent mice 
of Experiments 4-7 were totalled and analysed by the 2 x 2  contingency
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tables of Finney £t ^  (1963) by comparing the histamine sensitivity 
of the convalescent and normal mice of the same age and sex at each 
vaccine dose* Histamine sensitivity of day 66 convalescent mice had 
returned to norma1^only 3 out of 57 showing sensitivity compared to 
1 out of 56 sensitive in the normal mice. In mice given 0.44 o.u* 
pertussis vaccine day 66 convalescent mice, were significantly less 
sensitive to histamine (18 out of 62) than normal mice (30 out of 54)* 
Mice given 1,33 OoU* pertussis vaccine day 66 convalescent mice were 
less sensitive (41 out of 52) than normal mice (50 out of 54) but 
the difference between the two groups was not significant by the 2 x 2 
contingency tables*
The neutralisation of leucocyte promoting activity is more 
pronounced at the higher dose of vaccine (1,33 o,u,) which is the 
opposite result found in the neutralisation of histamine sensitizing 
activity where neutralisation was more pronounced at the lower dose 
(0*44 OoU,), This might be indicative of the sensitivity of the 
assays, ie it might require less pertussigen to induce histamine 
sensitivity than leucocytosis,
SECTION IV; NATURE OF IMMUNOGLOBULINS IN CONVALESCENT TWB AND SERA
Geller and Pittman (1973) examined the development of 
B. pertussis specific immunoglobulins in sera and TBW after a sublethal 
murine pulmonary infection. However the target antigens of the 
developing Igs was not investigated. In the present study, IgM, IgG, 
IgA and IgE were removed from pooled convalescent sera and TBW after
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which agglutination and passive protective activity were assayed. 
Pooled day 61 convalescent sera was used since it had the
with Ig classes selectively removed
Since agglutination tests were one of the main serological 
assays in analysing convalescent serum in this study, it was decided
particular class of immunoglobulin (Table 27),
Untreated pooled day 61 convalescent sera was tested at a
highest SLIN passive protective activity and the agglutinin response 
of all pooled convalescent sera were similar. Pooled day 48 
convalescent TBW was used because of availability. It was concentrated 
xlO to increase SLIN passive protective activity*
Details of the procedures used to remove the immunoglobulins
are given in Materials and Methods*
4,5 Agglutination tests on pooled day 61 convalescent sera and lOx 
concentrated pooled day 48 convalescent TBW either untreated or
to determine if the agglutinins at day 61 of infection came from a
1/5 dilution since this was the dilution of sera at which immunoglobulins 
were selectively removed. Untreated pooled normal sera was also 
titrated at this dilution.
Untreated pooled day 61 convalescent sera has a reciprocal 
titre of 8 for both agglutinating strains of B. pertussis 18-323 and 
18-334* The removal of IgG from pooled day 61 convalescent sera 
completely removed the agglutinins for both 18-323 and 18-334 strains 
of B, pertussis, whereas the removal of IgM, IgA and IgE from pooled 
day 61 convalescent sera did little to change the reciprocal
'.I
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Table 27 : Reciprocal agglucination titre on pooled day 61 convalescent
sera and the same sera with the immunoglobulin classes IgM, 
IgG, IgA and IgE selectively removed. All sera were at a 
1/5 dilution and agglutinins against both B. pertussis 18-323 
and 18-334 strains were investigated
Treatment
of Reciprocal titre^
Daybl sera
(1/5 din) 18-323 18-334
None 8 8
IgM removed 8 4
IgG removed "■ -
IgA removed 8 4
IgE removed 8 4
Untreated 
pooled normal 
sera(1/5 Din)
- «
a The reciprocal titres shown were obtained on two independent 
occasions.
-a.
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agglutination titre with the 3 sera having reciprocal titres of 8 
and 4 for B, pertussis 18-323 and 18-334 strains respectively*
Untreated pooled normal sera at 1/5 dilution did not agglutinate 
either strain* The major agglutinating immunoglobulin in sera at 
day 61 of a pulmonary infection was therefore IgG*
Concentrated pooled convalescent TBW without any Ig class 
removed still gave no agglutination with either B. pertussis strain 
as did the unconcentrated pooled TBW* So removal of IgG classes had 
no observable effect on the agglutinin titre*
4*6 Sublethal intranasal passive protection tests on pooled day 61
convalescent sera and lOx concentrated pooled day 48 convalescent 
TBW either untreated or with Ig classes selectively removed
The class(es) of immunoglobulins responsible for the SLIN 
passive protective activity found in both pooled convalescent sera 
and TBW was investigated to see which immunoglobulin(s) contributed to 
SLIN passive protective activity in pooled convalescent sera and TBW, 
However although it was pooled day 61 convalescent sera and lOx 
concentrated pooled day 48 TBW that were used, the passive protective 
Ig(s) on these days might be completely different to those at day 34 
post-insfiliation.
Sublethal intranasal passive protective activity of pooled 
convalescent sera and TBW, either untreated or with Ig classes 
selectively removed, was titrated twice and the ml  ^and 95% G,L*
calculated for both the lung pathology and culture results from the 
cumulative tôtals of both titrations (Table 28)* Untreated pooled 
convalescent serum and TBW were the reference standard from which the
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Table 28 : Sublethal intranasal passive protective activity of pooled 
day 61 convalescent sera and the same sera with the 
immunoglobulin classes IgM, IgG, IgA and IgE selectively 
removed and assessed by lung pathology and culture________
Treatment
ofsera
Untreated
Passive protective activity as determined by
Lung pathology 
P D 5 0  m l - l
(95% CL)
20,000
Lung culture 
P D 5 0  m l ' l
(95% CL)
13,320
IgM removed
IgG removed
IgA removed
IgE removed
20,000
(8,680-40,000)
8,000
(3,060-20,000)
8,000
(4,000-25,000)
13,320
(8,000-57,140)
20,000
(8,000-133,320)
10,000
(3,620-26,660)
10,000
(3,620-26,660)
10,000
(3,320-25,000)
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95% CqLo were calculated* The proportion of significant scores for 
both lung pathology and culture in the titrations are tabulated in the 
Appendix 17 (pooled serum) and Appendix 18 (pooled lOx concentrated 
TBW)*
” 1The ml of untreated serum was 20,000 as determined
by lung pathology results and 13,320 by lung culture results (Table 27),
This correlates with previous titrations of this pooled serum*
Pooled day 61 convalescent serum #ith IgM removed also had a PD^^ ml ^
of 20,000 determined by both lung pathology and culture results* It
would seem that the IgM in this serum was not involved in SLIN/mix
passive protective activity*
The removal of IgG reduced the SLIN passive protective
activity significantly when determined by lung pathology results with
PD^Q ml  ^= 8,000 and upper confidence limit of 20,000* However the
reduction was not significant when determined by lung culture results
where PD^^ ml  ^was 10,000 but the upper confidence limit of 26,660
-1was greater than the PD^^ ml of untreated serum*
Although IgA removal produced a reduction in PD^^ ml”  ^by both
lung pathology (8 ,000) and lung culture (10,000), the upper confidence
limits of both the lung pathology (25,000) and lung culture (26,660)
were both greater than the ml  ^of untreated serum* The
reduction was therefore not significant*
A similar result was found with IgE removal in that the 
-1PD^q ml by both lung pathology (13,320) and lung culture (10,000) 
were reduced, the upper confidence limits (57,140 and 25,000) 
respectively were both greater than the mean of untreated serum.
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Therefore although removal of IgG, IgA or IgE each reduced 
SLIN passive protective activity, IgG lung pathology results were the 
only case where the difference was significant*
When a similar investigation was done on lOx concentrated 
pooled day 48 TBW, the untreated fluid had a ml  ^of 1320 by
both lung pathology and lung culture results* Titration of the 
5^0PDcn nil  ^of this TBW with IgM removed produced dissimilar results by
lung pathology and lung culture* The PBy^ ml  ^ (and upper confidence 
limit) determined by lung pathology was 1000 (66,600) and by lung 
culture was 200 (not defined)* Therefore by lung pathology results 
IgM seemed to have no involvement in SLIN passive protective activity, 
but by the culture results it appeared as if it was involved.
However unlike the pathology results, which were based on two experi­
ments the culture scores were only determined once, and it would be 
difficult to draw conclusions without repeating*
IgG removal from convalescent TBW significantly reduced the
50
_1PD(-^  ml of TBW to 60 by lung pathology results since the upper
confidence limit was 320, The PBy^ ml  ^for the lung culture results 
was also reduced to 38 but the upper confidence limits were undefined* 
However although the ml  ^of TBW with IgA removed (580) and IgE
removed (500), the reduction was not significant since the upper 
confidence limits (4,000 and 2,840 respectively) overlapped with the 
PD^q ml  ^of untreated TBW* The lung culture results did> noitallow 
the PL^q ml  ^ to be determined for either the titration of TBW with 
IgA or IgE removed*
IgG seems to have a more marked involvement in the SLIN
1.60
Table 29 : Sublethal intranasal passive protective activity of lOx
concentrated pooled day 48 convalescent TBW and the same TBW 
with the immunoglobulin classes IgM, IgG, IgA and IgE 
selectively removed and assessed by lung pathology and culture
Treatment
of
TBW
Passive protective activity as determined by
Lung pathology
PD50 ml-l
(95% CL)
Lung culture
PD30 ml-l 
(95% CL)
Untreated 1320 1320
IgM removed 1000 200
(160 66,660) (N.D.*)
IgG removed 60 38
( N.H., 320) (N.D.)
IgA removed 580 N.D.
(60 4000)
IgE removed 500 N.D.
(40 2840)
a N.D, = Non defined since computer was unable to calculate this 
value due to poor data.
1 61
passive protective activity of TBW than in serum* Although in both 
TBW and serum it is the only immunoglobulin which when removed leads 
to a significant reduction in this activity* IgA and IgE appear to 
have a less significant degree of involvement in SLIN passive 
protective activity of serum and TBW* IgM plays no demonstrable 
role in the serum activity and the question of its role in SLIN 
passive protective activity remains unanswered*
DISCUSSION
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SECTION I PATHOPHYSIOLOGY OF Bo PERTUSSIS INFECTIONS IN THE HUMAN 
AND OTHER SPECIES
Several important aspects of the disease process in pertussis,
'ilI
such as the basis of the paroxysmal cough, are still unexplained* 
However since direct experiments on humans are not possible, many 
attempts have been made to establish animal models which would mimic 
the main features of the disease* So far, no fully satisfactory 
model has been demonstrated although the one described in this thesis 
is believed to have many worthwhile features*
Primates, of which the Taiwan monkey (Macaca cvclopsis) has 
emerged as the best species for production of paroxysmal cough, have 
been proposed as animal model of pertussis (Lin, 1958; Huang ^  al, 
1962; Stanbridge and Preston, 1974)* However, reports tend to be
I
1few and not widely confirmed* Nevertheless the Taiwan monkey, when 
infected with B* pertussis developed a disease with several patho­
physiological features similar to human pertussis: in particular, the
incubation period, time-cpurse, leucocytosis and duration of paroxysmal 
coughing were similar. So are the immunological responses of
I
opsonocytophagic index and induction of active immunity by vaccination
or by infection and recovery (Lin, 1958; Huang et al, 1962)*
The marmoset species which exhibits serotype shift during 
.infection, as in human pertussis, but does not cough, has been much 
studied by Stanbridge and Preston (1974)* These authors have focused 
attention on responses to the agglutinogens, largely to the exclusion 
of other pathophysiologically or immunologically significant components
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of the bacillus* From a practical viewpoint however, primates are 
too rare and expensive for widespread adoption as animal models of 
pertussis, since such a model, ideally would be sufficiently available 
to permit the routine potency and safety testing of vaccines*
Various other animal species have been investigated (dogs, 
ferrets, rats) but none, apart from the mouse, in any detailed fashion* 
Thus while the rabbit can undergo respiratory tract infection with 
B* pertussis, it does not cough, although serotype shift during the 
infection has been noted (Preston, 1980)* This leads to consideration 
of the mouse as the prime candidate for a pertussis model, and one 
of the main objects of the present work was to explore further the 
suitability of this species*
There have been extensive studies on three main types of 
experimental B, pertussis infection in the mouse, notably (a) the 
intracerebral infection which is used as part of the standard mouse 
protection test for vaccine potency but is highly artificial; (b) 
the lethal intranasal infection, which kills mice within 1-2 weeks 
through overwhelming growth of the bacteria in the lungs; and (c) 
the sublethal intranasal infection which has been studied here. This 
last-mentioned has a similar time-course of physiological and immuno­
logical changes to those in human pertussis and also is prevented by 
a heat-labile antigen of the bacillus (Fisher, 1955), Indeed it has 
been proposed by Pittman ef al^  (1980) as a worthwhile animal model for 
studying the disease* The main imperfection of the intranasally 
sub-lethally infected mouse is that it does not appear to cough; on 
this score however, detailed enquiry has failed to uncover any agent 
which induces coughing in mice (Wardlaw, personal comm.) and it may be 
that the cough reflex is absent in this species.
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The positive features of this mouse model are highlighted in 
Table 29 which makes comparisons with human pertussis. It will be 
noted that the mouse model resembles the human disease in 8 out of 
10 listed characteristics* Both infections have age-related severity. 
This was established in mice very soon after this species was subject 
to respiratory tract infection (Culotta £t al, 1938) and confirmed in 
later studies, eg Standfast (1951) and Pittman ^  ^  (1980)* The 
age-related severity of pertussis in man has been amply documented and 
further reinforced by experience in recent epidemics in the United 
Kingdom (Miller nt al, 1982)*
Mouse lung lesions (Burnet and Timmins, 1937) after SLIM 
infection with B* pertussis show several similarities in pathology 
with the human disease (Mallory and Horner, 1912)* Multiplication of 
the organisms was localized in the mucus lining the bronchial tubes; 
there was degeneration of cilia-bearing epithelial cells and inter­
stitial pneumonia*
Adhesion has been proposed as the first step in the pathogenesis 
of pertussis (Olson, 1975; Pittman, 1979) but is obviously difficult 
to study directly in humans. However various experimental systems 
for studying adhesion of B. pertussis have been developed (Holt, 1972; 
Muse^ 1977; Burns, 1982), The last-mentioned author, who worked
in this department, developed an adhesion assay in which B, pertussis
fresh isolates which were IN virulent, were shown to be more adhesive 
to mouse lungs than were C-mode or Phase IV strains* This observation 
of a relation between adherence and virulence should now be more 
extensively studied to determine its general validity.
The challenge doses used to establish a murine sublethal
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Table 30 : Comparison of the murine sublethal pulmonary infection of 
B. pertussis and human whooping cough
Characteristics Murine sublethal Pulmonary Infection
Human
Whooping
Cough
Age-related severity + +
Lack of invasiveness +
Multiplication and organism disappearance around Day 30 + 4*
Histamine sensitization +
Leucocytosis or lymphocytes + +
Hypoglycaemia +
Hyperinsulinaemia •f NI^
Attenuation of adrenaline- mediated hyperglycaemia +
Paroxysmal cough - •h
Transmission between individuals in close contact +
a NI = Not Investigated.
However pertussis vaccine produces a transient hyperinsulinaemia in 
the child. (Hannik and Cohen, 1979),
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3pulmonary infection have been between 2 x 10 cfu B. pertussis 
(Andersen, 1953b; Dolby e_t al, 1961) and 3 x 10 cfu B, pertussis 
(Pittman et al, 1980)* These are between 10 and 2000 times greater 
than the dose used by Macdonald and Macdonald (1933) to infect 
successfully two of their unimmunised children* In 7-day old mice 
Pittman e_t ^  (1980) found the LD^^ was 1000 times less than in 3-4 
wk old animals*
In the present investigation, the infection peak of murine 
sublethal pulmonary infection occurred between days 11 to 14 post- 
instillation* At the peak of infection, around 10^ to 10^ cfu 
B. pertussis could be recovered from the lungs of individual mice. 
Thereafter the count declined but viable bacteria could still be 
recovered on day 31 and 35 when these experiments were terminated*
This time-course pattern is similar to that reported by other investi­
gators using other strains of B* pertussis and other breeds of mice 
(Proom, 1947; Andersen, 1953b; Dolby et al, 1961)* The last-
mentioned authors emphasised that the number of bacteria in the SLIN
7dose should not exceed 10 cfu otherwise a lethal infection was likely* 
Proom (1947) recovered B. pertussis from the lungs as late as 56 days 
after SLIN Infection and Andersen (1953l>)as late as the 59th day post­
instillation* These times are much longer than those found in man, but 
it must be remembered that Isolation of B« pertussis from the human is 
not done by culturing portions of lung tissue. Indeed the possibility 
can not be dismissed that the bacteria may persist in the human lung 
for some time after they can be recovered from cough plates or nas- 
pharyngeal swabs (Olson, 1975)*
The gross pathological changes which occurred during the murine
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sublethal pulmonary Infection also peaked between days 14 and 18 and 
had scarcely declined at day 35, by which time most of the live 
Bo pertussis had been eliminated* This indicated that the clearance 
mechanisms for removing live bacteria were more rapidly acting than 
those involved in resolving the damage caused by the infection* 
Comparable data for man are unavailable for obvious reasons*
Leucocytosis, hypoglycaemia and histamine sensitivity, which 
are pathophysiological features of both human pertussis and murine 
infection, persist until at least day 33 in the latter (Pittman et al, 
1980) and until well into the paroxysmal stage in the former 
(Lagergren, 1963; Regan and Tolstoouhov, 1936; Sanyal, 19bO)* 
Therefore the mouse model supports the hypothesis of Pittman (1979) 
that pertussis should be regarded as an exotoxin disease in which a 
non-invasive bacillus excretes a toxin with long-lasting effects - in 
this case the diverse pharmacological alterations produced by 
pertussigen.
As already emphasised, the major difference between human 
pertussis and the murine sublethal pulmonary infection is that the mice 
do not appear to cough* However, Pittman (1951) suggested that there 
was some significance in the parallelism between the time course of 
histamine sensitivity during the murine infection and the duration of 
the paroxysmal coughing in the child* This led to the further 
proposal that there might be similar underlying pharmacological 
reactions taking place but with different outward manifestations in 
humans and mice* This might be analogous to the species differences 
in systemic anaphylaxis where the target organs differ in different
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species, eg the lungs in man and guinea pig and the liver in the dog.
Lack of serotype shift in the murine infection was considered 
by Carter and Preston (1981) to detract from its value as a pertussis model. 
However in the studies which they reported, a majority of their mice died 
during the infection which could hardly therefore be described as 
’sublethal*. Contrary to Carter and Preston's conclusions, their actual 
data show that the few surviving mice did actually exhibit serotype 
shift of the infecting B, pertussis from type 1 to type 1,3,
Pertussis is far from being alone in lacking a perfect animal 
model, for relatively few bacterial respiratory tract infections of 
man have a fully satisfactory model in a convenient laboratory species.
For example, experimental rat pulmonary Haemophilus influenzae infection 
leads to bacteraemia and meningitis; however a lower incidence of 
meningitis is found in bacteraemic rats than in infants (Moxon et al,
1974). Pseudomonas aeruginosa, an opportunistic pathogen in cystic 
fibrosis, will only grow in the respiratory tract of rats or other 
experimental animals when instilled with an agar plug (Cash £t al,
1979), The pulmonary infection of the Syrian hamster with Mycoplasma 
pneumoniae does, however, seem to be fairly satisfactory as a model, in 
that the organisms remain localized in the ciliated epithelium of the 
upper respiratory tract, as in man, and similar pathological changes 
occur in both species (Dajani e^ 1965).
SECTION II IMMUNE RESPONSES TO B. PERTUSSIS INFECTIONS.IN MOUSE AND MAN
2,1 Protection against infection
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The high incidence of severe pertussis in infants, particularly 
those below 6 months of age, has been attributed to the lack of transfer 
of maternal protection (JoGoVoI,, 1977). However Preston ^  _al (1974) 
found some infants had type 1 and type 2 but not type 3 agglutinins at 
low levels, which could be explained by the half-life of the IgG of 
maternal origin. He suggested that maternal antibodies might be 
transferred but that they might not be directed against important 
virulence factors, notably agglutinogen 3* Agglutinogen 3 might be 
absent from the mother if her infection had been a long time in the 
past when the 1,2 serotype was prevalent*
In an early report, protection of children against B. pertussis 
infection.by passive immunization was done with convalescent children's 
serum (Debre, 1923) and hyperimmune serum (McGuiness et al, 1944). This 
appeared to be successful if done during the incubation period; 
however higher doses of hyperimmune serum were necessary to demonstrate 
the therapeutic value of immune serum and it is not now used in the 
U.K* although it still finds favour in continental Europe (F* Sheffield, 
per. comm.). Convalescent childrens' serum was active in mice. When 
given by either i.p. or IN route it protected mice from both lethal 
(Winter, 1953) and sublethal pulmonary infections (North ct al, 1939).
The same is true of mouse convalescent serum taken from animals that 
had recovered from SLIN infection (North, 1946; this investigation).
Normal children's and normal mouse sera were non-protective in these
,
systems (Winter, 1953; North et al, 1939).
iThe present investigation not only confirmed the development of 
SLIN passive protective activity in serum during a murine sublethal
pulmonary infection but also, apparently for the first time, showed that
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such activity could also be demonstrated in tracheobronchial 
washings (TBW), Both pooled sera and TBW from sublethally infected 
mice had passive protective activity by day 34 post-instillation and 
their activity had increased 10 fold by day 61. The ratio of passive 
protective activity between mouse convalescent sera to mouse 
convalescent TBW was usually approx 50:1 which is the same as the 
protein ratio of the convalescent sera and TBW* Normal and acute- 
phase (15-day) sera and TBW had no such activity* The U.S* Standard 
Antipertussis serum was at least 20 fold more active than day 61 
mouse convalescent sera*
An. attempt was made to determine the nature of the bacterial 
components against which the passively protective antibodies in mouse 
sera were directed* To be definitive, this would have to be done 
either with monoclonal antibodies administered passively or with 
purified virulence factors which could be used as absorbents for the 
convalescent sera. Since neither was available, the effect of 
absorbing the convalescent sera with different virulence types of 
B* pertussis cells was done* Phase I cells were shown to absorb the 
passive protective activity of convalescent serum completely, whereas 
Phase IV B. pertussis did not* This indicated that the antigens 
against which the passively protective antibodies were directed were 
present on the surface of Phase I B. pertussis but not on the surface 
of Phase IV*
Andersen (1953b)investigated the occurrence of active SLIN 
immunity by infecting mice by this route 70 days after a previous 
pulmonary infection with B. pertussis from which the mice had by then 
recovered* She found that the convalescent mice were able to clear
a
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B. pertussis from the lungs 4-8 days after re-infection which was much 
faster than during the primary infection* However since no normal 
controls of old mice were used, this might have been due to the age 
effect associated with B. pertussis infections in mice (Standfast, 1951) 
rather than being due to acquired immunity*
In the child, it is generally accepted that recovery from 
pertussis confers solid immunity of at least several years duration, 
(Pittman, 1970)*
Active immunization against the human pulmonary infection 
reduces the H*E*A*R* by between 65-80%. This parameter correlates 
strongly with the vaccine potency as measured by the mouse protection 
test where IC challenge was administered to mice 14 days after i.p, 
vaccination* However comparison between human and murine vaccine 
efficacy against pulmonary challenges is difficult. Mice at 5 weeks 
of age, ie 2 weeks after i*p* vaccination, are much less susceptible 
to a pulmonary challenge due apparently to an age associated resist­
ance to pulmonary infections (Standfast, 1951; Pittman et al, 1980).
Turning now to the IC infection of mice with B. pertussis, no 
development of antibodies in sera from children between 1-12 wk after 
infection was found by Dolby and Stephens (1973); however in 3 
uninfected children, exposed to active cases 2 out of 3 developed 
mouse IC passive protective activity. Perhaps the exposure provided 
a booster stimulus to pre-existing priming immunity*
Cooper (1952) found mice after day 30 of a sublethal pulmonary 
infection were able to resist IC challenges of between 1-5 LD^^,
However, until the present study, the development of IC passive 
protective activity during a murine sublethal pulmonary infection has 
not been investigated. The results were clear cut; the convalescent
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of 1-6 months also contain low àgglutinin titre to B, pertussis (Dolby
I7-
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sera and TBW from the sublethal intranasally-infected mice had no 
protective activity against either 1 or 100 LD^^ of strain 18-323 
given intracerebrally in a "mix" test. The U*S* Standard Anti 
pertussis serum was however passively protective by this challenge
route but 300 fold less active than by the SLIN/mix test* However 
if the same ratio between potency of the latter and mouse convales­
cent serum exists in the IC challenge as exists in the SLIN challenge,
any IC passive protective activity present in mouse convalescent
serum would remain undetected,
-
The existence of two distinct protective antigens by the IC 
and IN infection routes was demonstrated by Dolby and Standfast (1961)* 
The "IG antigen" was heat-labile (100°C) and the "IN antigen" heat- 
stable (100°). However, it should be noted that the "IN antigen" 
refers to the lethal IN infection. Fisher's earlier work was in
agreement with these findings but made the further significant 
observation that the protective antigen in the SLIN test was heat-
labile (100°G) and thus different from the protective antigen in the 
lethal IN system.
2.2 Serology
Human convalescent sera has long been known to contain 
Bo pertussis agglutinins (Bordet and Gengou, 1906). However 99% of 
sera from healthy adults and non-vaccinated, non-infected infants
i
and Stephfens, 1973). The authors found this agglutinin was removed 
from all baby sera by absorption with B, pertussis strain which had
Î
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only agglutinogen 1 and from. 76 out of 93 adult sera by absorption 
with agglutinogen 1.
In the present study, a low reciprocal agglutinin titre was 
found in pooled normal and acute phase mouse sera, both of which had 
a titre of 8 * This agglutinin had no SLIN passive protective 
activity. When this was investigated further, 19 out of 20 
individual sera samples contained this agglutinin with reciprocal 
titres ranging from 2-32* This agglutinin in pooled normal and acute
phase sera was X mode B. pertussis specific and had not previously been
reported* However this might be due to undilution of normal mouse 
sera not receiving attention* Cooper (1952) using a 1/5 dilution of 
individual normal mouse sera did not find agglutinins to formalized 
B. pertussis nor did Andersen (1953b) using a 1/10 dilution of pooled 
serum. Possibly these authors started their titrations at 1/5 and 
1/10 dilution to avoid the normal agglutinin* This agglutinin in 
normal serum is unlikely to be due to previous priming of animals with 
B. pertussis as a booster effect would have occurred by day 15 post­
instillation, in acute phase sera and this was not seen* Possible 
intercurrent Bordetella bronchiseptica infection is also considered 
unlikely since no pathological changes were evident in normal mouse 
lungs* At no time were B. pertussis or other bacteria ever isolated
on BoGo plated with lungs from normal mice*
The frequent absence of agglutinin development after a pertussis 
infection has been noted (Dolby and Stephens, 1973; Macaulay, 1979; 
Aftandelians and Conndr, 1973) and also in the murine pulmonary 
infection (Andersen, 1953b), However where agglutinins did develop in
I?
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the last-mentioned article it was around day 35 and 42 post-instillation 
and the maximum reciprocal titre recorded in pooled serum was 80, 
Development of B* pertussis 18-323 and 18-334 X mode and 18-334 C mode 
agglutinins, in this study, reached respective peaks of 64, 128 and 8 
agglutinating units by day 40-49 of a murine pulmonary infection, with 
a slight decrease to 32 in X mode titre and disappearance of C mode 
agglutinin on day 61* The more rapid disappearance of C mode 
agglutinins compared to the X mode specific agglutinins suggests that 
a different immunoglobulin class may be involved in the agglutination 
of G mode organisms.
The UoSo Standard Antipertussis Serum again showed a more 
marked immunological response than pooled convalescent mouse sera with 
a reciprocal titre of 16,000 to both X mode B. pertussis strains 18-323 
and 18-334, and a reciprocal titre of 512 to C mode B. pertussis strain 
18-334. The presence of C mode agglutinins in both the U.S. Standard 
Antipertussis serum and pooled day 40-49 mouse convalescent sera are 
obviously directed toward surface antigens not involved in the 
virulence of the organism but are common to X and C mode B. pertussis.
No agglutinin development was detected in pooled TBW at any 
stage of the infection. The absence of this immune response from 
the secretory surfaces is peculiar since it is thought to be involved 
in the clearance of organisms from the lung (Olson, 1975), However 
the inability to detect this immune response need not indicate that 
it does not exist but might be explained by the high dilution effect 
when sampling TBW.
The decrease in agglutinins to X mode B. pertussis on day 61
•i1
175
as well as the apparent absence in agglutinins in convalescent TBW 
prevented the correlation of reciprocal agglutination titre with SLIN
by the convalescence stage, 4 precipitin lines to B. pertussis sonicates
f
passive protective activity. However absorption of 1 ml of pooled
convalescent day 48 serum with 0.5 ml of 100 o.u. Phase I B. pertussis 
removed both the SLIN/mix passive protective activity and agglutin­
ating activity. This together with the fact that U.S. Standard 
Antipertussis serum had correspondingly high SLIN/mix passive 
protective activity and reciprocal agglutination titre suggests there 
is a relationship between these two activities.
Immunoprécipitation as another means of serological identifi­
cation of human pertussis has also been investigated, and precipitins 
to B. pertussis sonicates developed in 86% of paired sera from 
bacteriologically confirmed cases of pertussis (Aftandelians and Connor, 
1973), Some sera sampled during the acute phase of infection had 
multiple bands which intensified then diminished during convalescence. 
Until the present study, there had been no report of development of 
precipitins during a murine infection; however this study showed that 
pooled convalescent sera but not pooled TBW did contain precipitins 
to B. pertussis sonicates. The U.S, Standard Antipertussis serum 
produced at least â, lines compared to only 1 faint line in pooled 
convalescent sera.
By analysis of these pooled sera and TBW by qualitative 
immunoelectrophoresis, a more detailed precipitin profile was obtained.
S
positive reaction in that one precipitin line was observed. However
■ t'-"K
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had developed. Pooled normal TBW did not contain any response to 
these sonicates but by day 15 one line had developed and by day 49 
post-instillation 2 lines were present.
The U.S. Standard Antipertussis serum presented a much more 
complex pattern and obviously contained a variety of antibody 
specificities.
It would be interesting to find out towards which components 
of B. pertussis these immune responses were directed since the immuno­
logical response in pooled convalescent TBW, which gave two lines, 
might be directed against different components than those 4 immune 
responses found in pooled convalescent serum.
This would be evidence as to which immune responses are 
necessary in the secretory surfaces to prevent infection becoming 
established, eg anti LPS^and similarly which are important in the serum 
to prevent pharmacological changes associated with pertussis, eg 
anti pertussigen.
2,3 Immune responses towards individual virulence factors
Although it is not yet possible to say which of the B. pertussis 
virulence factor(s) is involved in producing the SLIN passive protective 
activity or the precipitin lines in qualitative immunoelectrophoresis, 
it was possible to investigate the immune responses to these active 
components of B, pertussis. These will be discussed in the sequence 
in which the components are thought to be involved in pathogenesis 
with the exception of the agglutinogens which have already been 
discussed.
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Attachment of B. pertussis to the ciliated epithelium is thought 
to be due to F-HA. There have been conflicting reports on anti-HA 
development during the human infection with Winter (1953) finding 
only 7-14% of convalescent children with this antibody but Dolby and 
Stephens (1973) found all sera from infected children had anti-HA,
B. pertussis has two components with haemagglutinating 
activities: the LPF-HA (pertussigen) and the F-HA, with the purified
form of the latter being 7 fold more active. As yet the development 
of an immune response to purified F-HA in the human or murine 
pulmonary infection has not been reported. However purified F-HA 
produced active protection in mice (Munoz jet al, 1981) and i.p, anti- 
F-HA was passively protective in mice by the SLIN infection route 
(Sato et al, 1981),
In this investigation pooled sera from normal and B, pertussis 
mice contained antibodies to purified F-HA with the former having a 
reciprocal titre of 2 and the latter having a reciprocal titre of 32 
on day 34 but returning to a reciprocal titre of 8 by day 49 post- 
instillation. Since anti-F-HA decreases in late convalescence as SLIN 
passive protective activity is increasing, there is no correlation 
between the two activities at this stage. However this does not mean 
that anti-F-HA is not involved in SLIN passive protective activity in 
pooled sera taken from early convalescence.
As with the agglutination test, the low anti-F-HA reciprocal 
titre in pooled normal sera was most probably not due to previous 
experience of B. pertussis and B, bronchiseptica, since no booster 
effect was detected in pooled day 15 acute phase serum. This anti­
body did not give rise to any SLIN passive protective activity.
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The proposed role of F-HA, as stated previously, in patho­
genesis is one of attachment of B. pertussis to the ciliated epithelium 
of the respiratory tract since Sato (1981) found anti-F-HA prevented 
attachment to such epithelium, Sato ^  a_l (1979) also demonstrated 
anti-F-HA bound to the pili-like appendages. This was not confirmed 
by Ashworth £t ^  (1982) who in fact showed agglutinin 2 bound 
specifically to the appendages and not anti-F-HA. The involvement of 
agglutinogen 2 in attachment has yet to be determined.
The disappearance of anti-F-HA agrees with the hypothesis by 
Pittman (1979) who proposed that F-HA is responsible for a short-term 
immunity which moreover would be needed at the secretory surfaces. 
However pooled TBW never developed detectable anti-F-HA which again, 
as with agglutinin development, may be explained by the high dilution 
of the secretions when washing out the lungs* Also non-development 
does not mean it would not be protective if it had developed.
After B» pertussis has attached to the ciliated epithelium, 
the organism multiplies and would be expected to synthesise the toxic 
components; HLT, LPS and pertussigen. The lack of anti-HLT in 
convalescent children's sera has been demonstrated (Anderson and 
North, 1943; Evans and Maitland, 1939) and has raised questions about 
its role in pathogenesis of the disease. However anti-HLT was 
passively protective in a murine pulmonary infection if the antiserum 
was administered as a mixture with challenge. In this investigation 
the anti-HLT response in pooled normal and infected sera and TBW was 
insufficient to neutralise a standard haemorrhagic dose of HLT. The 
absence of anti-HLT in convalescent TBW seems peculiar if this 
component plays an important role in virulence except that its low
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itnmunogenicity may be responsible.
Turning now to the anti-LPS response, Ackers and Dolby (1972) 
found when determining the bactericidal activity of children's 
convalescent sera, an assay which is dependent on anti-LPS and 
complement, the bactericidal activity was variable. The latter assay 
cannot be compared to the one used in this study where no anti-LPS 
activity was found in pooled normal or infected mouse serum since the 
assay used here did not have an added source of bactericidal complement. 
Pooled day 40 convalescent TBW had an anti-LPS reciprocal titre of 64 
by haemagglutination of LPS coated erythrocytes which diminished to a 
reciprocal titre of 4 by day 61. This response might play an important 
role in opsonization of B, pertussis thereby aiding phagocytosis and 
therefore clearance of organisms. Since anti-LPS decreased in late 
convalescence, the response does not correlate with SLIN 
passive protective development. However it could be responsible for 
SLIN/mix activity in early convalescence.
The magnitude of the anti-LPS response in convalescent TBW is 
doubly surprising since it was not detected in convalescent sera 
considering how dilute pooled TBW is in respect to pooled sera. It 
was therefore a local immune response, and Se-rgmsn,
The last toxin to be discussed is pertussigen (Munoz^ 1979)&L sLareferred to as LPF-HA by Sato\(1981), has been proposed as the IC mouseoind BcQm&njprotective antigen (Munoz^ 1979) and also as an SLIN protective 
antigen (U.S. Workshop, 1982). Accumulated evidence (Parker and 
Morse, 1973; Ortez, 1977) indicates that pertussigen alters the' 
responsiveness of different cells to adrenergic and other agents, and 
interferes with cAMP metabolism. The proposed molecular mechanisms
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sera and TBW were not able to neutralise 1 or 2 HSD^q of pertussis
No neutralisation of HSF or LPF in 4 or 1,33 o,u, ml of 
pertussis vaccine occurred in day 49 convalescent mice. However day
by which pertussigen achieves these changes are by increasing 
activation of adenylate cyclase (Katada and Ui, 1982a, b ; Katada 
et al, 1982, ),
Pittman (1979), who referred to the component as Pertussis 
Toxin, proposed this antigen was responsible for the longer-lasting 
immunity associated with pertussis vaccines in the child. However
l b "
development of an immune response to this component during either the
human or the murine pulmonary infection has not previously been 
investigated. In this study 0,1 ml of pooled normal and infected
vaccine. However since this assay might have been insufficiently 
sensitive, convalescent mice themselves were examined for their ability 
to neutralise both LPF and HSF in pertussis vaccine.
Î
63 convalescent mice were able to neutralise both activities in 1.33 
and 0,44 o,u, ml (the HSD^^ was usually around 0.44 o.u, ml) of 
pertussis vaccine although the neutralisation of histamine sensitizing 
activity in 1,33 o.u, ml was less demonstrable than leucocytosis 
promoting activity. This might be related to the sensitivity of the 
assay, ie less pertussigen is required to stimulate histamine 
sensitivity than is required to promote leucocytosis.
None of the immune responses to the individual components
.correlate with the development of SLIN passive protective activity
either in convalescent sera or TBW, This could well mean that SLIN 
passive protective activity in convalescent serum or TBW might be the 
resultant of several independent antibody specificities and actually 
reflects a combination of immune responses.
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2.4 Immunity in secretions and sera
2,5 Ig Glass
The non-specific inflammatory response has previously been
,measured by recording lung weight as an index of lung oedema (Andersen, 
1953a,). In this author's work the response peaked around day 14 post- 
instillation of challenge but was still maximum in some mice on day 21 
(last recording day). In the present investigation lysozyme, as an 
index of leucocyte infiltration, was assayed in pooled TBW and in serum 
for comparison. This enzyme is contained in polymorphs and macrophages 
and is released into secretions when these cells lyse. Its peak 
concentration coincided with infection peak, day 15 post-instillation, 
and had returned to normal by day 63 when few, if any, organisms 
remained in the lungs. Not surprisingly this non-specific response 
was found only in pooled TBW and not in pooled sera.
Identification of the Ig class responsible for immunological 
responses in children has been limited to serum agglutination tests 
where the 19S and 9S Ig fractions were equally active (Dolby and 
Stephens, 1973), In this study IgG removal reduced agglutinin titres 
in day 61 convalescent serum. Murine B» pertussis specific Ig response 
to a sublethal pulmonary infection has been examined in both pooled 
serum and TBW (Geller and Pittman, 1973), Serum IgA started to 
increase on day 30 of infection and Pittman (1976) demonstrated 
parallelism between the time course of development of this murine 
serum IgA response and the development of LIN passive protective 
activity of sera from pertussis cases. In this investigation the Is
SECTION III FURTHER PERSPECTIVES
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preliminary evidence obtained was that antibodies belonging to the 
IgG, IgA and IgE classes might all be involved in the SLIN passive
protective activity of pooled day 61 convalescent serum of these, the
1IgG seemed to be about twice as active as the other two classes* The 
lack of IgM involvement was not surprising since after primary
:stimulation with other antigens IgM usually disappears after 30 days 
(Bauer et al, 1963)* An additional method of showing serum IgE 
involvement in SLIN passive protection made use of the ability of 
this homocytotrophic antibody to remain bound to tissue for up to 48 
hours* North (1946) demonstrated the ability of SLIN passively 
protective sera to remain active if given up to 48 h before a murine 
challenge* This result was verified for pooled day 61 convalescent 
serum in this study* Serum IgE elevation in other secretory surface 
diseases, ie gonorrhoea and syphilis have been reported (Green £t al,
1976).
I
The direction of subsequent investigations could profitably 
be towards those areas where hitherto there has been a limitation in 
either stuiable equipment or purified preparations from B, pertussis. 
The murine sublethal pulmonary infection, as a model, falls 
short in its initiation of human pertussis since the typical 
characteristic cough of the latter infection does not occur*
However perhaps adequate physiological instruments would permit 
detection of changes in murine respiratory function associated with 
the infection* The appearance of the mouse lungs at autopsy make it
difficult to believe that a normal physiological profile would be 
present since they are so heavily consolidated during the infection*
Immunological investigations should be in the following areas* 
Firstly the cell-mediated immune response has received little 
attention (Dolby and Stephens, 1973) although Cheers and Gray (1969) 
found intracellular survival of B* pertussis even with enhanced intra­
cellular killing ability during a murine sublethal pulmonary infection. 
Secondly, the nature of the mouse immune response to purified 
Bo pertussis components would be more accurately described if detected 
by the sensitive enzyme linked immunoabsorbent assay* Once these 
purified components, such as F-HA, pertussigen etc, become freely 
available, monoclonal antibodies could be prepared and would reveal 
which Ig class(es) are involved in the immune response to each 
component* Also the monoclonal antibodies could be used in passive 
protection tests to determine which antibodies give protection and 
therefore which antigens are protective* The important protective 
antigen combinations in mice, would then provide a rational choice of 
protective components for investigation in man*
|:I
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Appendix I
lû Preparation of Media
1*1 1% CAA solution
Materials grams
CAA (Difco technical) 10,0
MgCl^oôH^O 0*1
CaClg 0.016
NaCl 5*0
The above ingredients were dissolved in 1 1 of distilled water and 
the pH adjusted to 7*6 with lN*NaOH* The CAA solution was then 
autoelaved.
1*2 B.G* plates
The BG agar (10 g) was dissolved in 250 ml 4% (v/v) glycerol, 
autoclaved at 121°C for 15 min and allowed to cool to 45°C* The 
defibrinated horse blood (50 ml) previously heated to 37°C was 
added aseptically, mixed gently with agar base and poured in either 
20 ml volume onto 90 mm or 10 ml volume onto 45 mm triple vent plastic 
petri dishes. Bubbles were removed by flaming and plates were stored 
in plastic bags and used within two wek.
1,3 Modified Cohen and Wheeler Medium (Sato et al, 1973)
Materials grams
Casamino Acids (Difco technical) 50
CaCl„ (anhydrous) 0,05
A2
Materials
GuSO,.5H„0 4 Z
cysteine
FeSO,,7H„0 *4 2
Glutamic Acid 
Glutathione *
KH^PO^
MgCl^.ôH^O
Nicotinamide (BDH, Poole, England) 
NaCl
Soluble starch (BDH, Poole, England) 
Tris (hydroxymethyl) aminomethane
grams
0.0038
0*15
0*05
1
0.05
2*5
2
0*15
12*5
7*5
30.4
All the components of the media except those labelled * were dissolved 
in 4.5 1 of distilled water and the pH adjusted to 7.2* The components 
labelled * were dissolved in 100 ml of water, filter sterilized 
(Millipore) and then added just before use* The starch was dissolved 
in boiling water before adding it to the bulk of the medium* The 
volume was then made up to 5 litres and sterilized*
1.4 Modified Hornibrook medium
This medium is a modification of the recipe of Hornibrook 
(1940) as described by Parton and Wardlaw (1975) and consists of the 
following ingredients
Materials
(i) Casamino Acids (Difco Technical)
(ii) CaCl^ (anhydrous)
per 10 1
100 g
0*02 g
:i
1
S
3|
-â
S
..i
a:
1Sï
I
îr
4
sA3
Materials per 10 I
(iii) NaCl 50 g
(iv) KcCl 2 g
Nicotinamide (BDH, Poole, England)
(v) 0 ol% (w/v) solution 10 ml
(vi) MgCl^.dH^jO, 1% (w/v) solution 25 ml
i
(vii) K^HPO^, 10% (w/v) solution 25 ml
(viii) Soluble Starch (BDH, Poole, England) 10 g
(ix) Glutathione (Sigma Chemical Company,
St. Louis, Mo, USA) 0.1% (w/v) solution 100 ml 
The ingredients (i)-(ii^  were dissolved in 800 ml of distilled water 
and the freshly prepared solutions v, vi and vii added. The starch 
was suspended in 25 ml of distilled water and this added, with 
immediate mixing to 175 ml of boiling distilled water. This mixture
was brought back to the boil and added to the rest of the medium.
The volume was made up to 1 1 and the pH adjusted to 7.0 with 
approximately 0.45 g of Na^CO^. This 10 times concentrate was 
dispensed in 100 ml amounts in screw cap bottles, sterilized by 
autoclaving at 121°C (15 psi) for 15 min, cooled and stored at 4°C.
Prior to use 100 ml of concentrate was added to 890 ml of 
distilled water in a 2 1 dimpled conical flask and autoclaved at I21^G
(15 psi) for 15 min. Immediately before use 10 ml of Seitz filter 
sterilized glutathione solution (0.1% (w/v)) was asceptically added to 4
give Hornibrook X-raedium.
A4
Appendix 2
Protein determinations of tracheobronchial washings.
Reagent A
2% (w/v) Na^CO^ in distilled water 
Reagent B
1% (w/v) CuSO^oSH^O in distilled water
2% (w/v) aqueous solution of sodium potassium tartrate.
Equal volumes of the above two solutions were mixed and the precipitate 
allowed to settle before using the supernatant.
Reagent G
To 50 ml of reagent A add 2 ml of reagent B, This reagent 
was prepared immediately before use and discarded after one day.
Reagent D
Folin and Giocalteau phenol reagent (BDH, Poole, England), 
Reagent E
Protein Standard 1 mg/ml  ^bovine serum albumin (Sigma 
Chemical Co,, St, Louis, U,S,A,),
A5
Appendix 3
Preparation of lysoplates
One gram of agarose (BDH Ltd», Poole, England) and 1% NaCl 
were dispensed into a bottle containing 90 ml of O0O6M sodium phosphate 
buffer (pH 6*4) (Appendix 4)« The pH was re-adjusted to 6o4 with 40% 
(w/v) sodium hydroxide where necessary* The bottle was then auto- 
claved (121°C/15 min) cooled to 60°C and 60 mg freeze-dried M, luteus 
suspended in 10 ml buffer by treatment with ultrasound for 15 sec, 
added to each bottle with mixing* Aliquots of 5 ml were dispensed 
into 5 cm diameter petri dishes. When the agarose had set 3,4 ran 
diameter wells were cut in each with a No, 1 cork borer (Gallenkamp 
Ltd,, London) and the plugs removed by suction.
Ï
I
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Appendix 4
Preparation of barbitone buffer pH 8,3
This was a saturated solution of Amino Black (E, Gurr Ltd 
Michrome Ltd.) in 2% Acetic Acid,
o Ï
I
I
In approximately 450 ml distilled water 8,5 g barbitone sodium 
(BDH, Poole, England) was dissolved. The pH was adjusted to 8*3 
using IN HCl and made up to 500 ml with distilled water.
lonagar
lonagar (0,75 g) (Oxoid L28, Oxoid Ltd,, Basingstoke, Hants) 
was dissolved in barbitone buffer.
"I!,Stain
4
A7
Appendix 5
Preparation of sensitized Horse Red Blood Cells (HoRoBoCq)
Defibrinated horse blood was centrifuged, the RoBoC, washed 
three times in saline by centrifugation, and a 2,5% suspension was 
made in PBS buffer. The H,R,B,C. suspension was mixed with an equal 
volume of 0,1 mg/ml LPS (provided by Dr, A, Robinson, Centre for 
Applied Microbiology Research, Porton) which had been previously 
activated (Neter, 1950) by incubation for 18 h at 37^C in O.OlN NaOH 
in saline, and adjusted to pH 7 with dilute HCl, The mixture was 
incubated 1 h at 37°C, centrifuged, and washed 3 times in PBS buffer. 
The sensitized erythrocytes were resuspended in PBS buffer to make a 
2% suspension for use in haemagglutination tests.
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Appendix 13 : Determination by immunodiffusion of optimal concentrations
to precipitate out IgG from pooled day 61 convalescent
sera using goat antimouse IgG
1 2 3 4 5 6 Anti IgG 1/10a0 0 0 0 0 0 Wells 1-6^ containing various absorbed seraC,So I/IOQC
Anti IgG = Goat antimouse IgG
Wells 1-6 contained pooled day 61 convalescent sera at a 1/50 
dilution which had been absorbed with the following 
dilutions of goat antimouse IgG:
Well 1 1/10 dilution of goat antimouse IgG
Well 2 1/20
Well 3 1/40
Well 4 1/80
Well 5 1/160
Well 6 1/320
II II II II II
II II II II II
II II II II II
II II II II II
It It It It II
c CS = Pooled day 61 convalescent sera
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Appendix 14 : Determination by immunodiffusion of optimal concentra­
tions to precipitate out IgA from pooled day 61
convalescent sera using goat antimouse IgA
Anti IgA 1/2 dilution
Wells 1-6^ containing various 
absorbed sera 
CoSo^ 1/8 dilution
Anti IgA = Goat antimouse IgA
Wells 1-6 contained pooled day 61 convalescent sera at a 1/5
dilution which had been absorbed with the following 
dilution of Goat antimouse IgA
Well 1 1/2 dilution of Goat antimouse IgA
Well 2 1/4 II II II
Well 3 1/8 II II II
Well 4 1/16 " II It II
Well 5 1/32 " " II II II
Well 6 1/64 " " II II II
c C.Sp = Pooled day 61 convalescent sera
H
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Appendix 15 ; Determination by immunodiffusion of optimal concen­
trations to precipitate out IgG from lOx 
concentrated pooled day 48 convalescent TBW 
using goat antimouse IgG
Anti IgG* 1/20
Wells 1-6^ containing various absorbed TBW 
C.TBW^ 1/20
Anti IgG = Goat antimouse IgG
ylOxWells 1-6 contained/concentrated pooled day 48 convalescent TBW at a 
1/10 dilution which had been absorbed with the 
following dilutions of Goat anti IgG
Well 1 1/2 dilution of Goat anti mouse IgG
Well 2 1/4 II II II II II It
Well 3 1/8 II II It II II II
Well 4 1/16 II II tr II II II
Well 5 1/32 II II II II II
Well 6 1/64 II II It II II
c C.TBW = concentrated pooled day 48 convalescent TBW
M
A21
Appendix 16 Determination by immunodiffusion of optional concen­
trations to precipitate out IgA from lOx concen­
trated pooled day 48 convalescent TBW using goat 
antimouse IgA
0 0 0 0 0 0 IgA.* 1/2 dilution
1 2  3 4 5 6 Wells 1-6^ containing various absorbed TBW
C.TBW^ Neat
a Anti IgA = Goat anti mouse IgA
lOxb Wells 1-6 contained/concentrated pooled day 48 convalescent TBW 
neat which had been absorbed with the following 
dilutions of Goat anti IgA 
Well 1 Neat Goat anti mouse IgA
Well 2 1/2 dilution of Goat anti mouse IgA
Well 3 1/4 " " "
Well 4 1/8
Well 5 1/16 " " "
Well 6 1/32 "
c CoTBW = concentrated pooled day 48 convalescent TBW
TET:
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